OnCo · weekly issue
OnCo weekly, 2026-11-04
1221 changelog entries, 1 regulatory event, 398 corrections. Generated from the corpus; every item links to its page and, through it, to the primary source. Not medical advice.
What changed this week
New pages, new data and fixes, from the changelog.
- 4 November 2026: 268 cancer institutions measured against the IRS and Charity Commission registers, AACI, the Children's Oncology Group, Japan's designated cancer hospitals, India's National Cancer Grid and UICC, including the American Cancer Society itself
- 4 November 2026: Accuracy round two checks every figure on the country pages and the 60 most-linked cancer pages against its source: 365 corrections, 37 dead DOIs replaced, and NICE's October reversal on trastuzumab deruxtecan for HER2-low breast cancer
- 4 November 2026: Drugs now link what they bind rather than what they act on downstream, an investor and a trials group are no longer credited as makers, and stale company histories are corrected from registry and SEC records
- 4 November 2026: National cancer societies: 27 UICC members from Denmark, Norway, Finland, Belgium, New Zealand, South Africa, Singapore, Hong Kong, Japan, Korea, the Philippines, Egypt and Latin America, the registered names of fourteen centres the corpus held, and the institution lists described in the data sources
- 4 November 2026: The British Thoracic Oncology Group is held as a nonprofit company beside the other groups, and new charity records drop a tag that had no description
- 4 November 2026: New centres keep their own trials: sponsor names for Loyola, Mass General Brigham, Mott, UCSF Benioff, UPMC Children's and St. Jude India resolve to their records, and UICC links the American Cancer Society itself
- 4 November 2026: UK cancer charities and Japan's designated cancer hospitals: 46 charities from the Charity Commission register and Maggie's, 39 prefectural hub and genomic medicine core hospitals from the health ministry's lists with their own English names, and the UICC member directory as a list
- 4 November 2026: Nineteen RNA tests, every radiotherapy machine line dated from its FDA record with scalp cooling, cryocompression and infusion chairs, Invictus Therapeutics and Invictus Oncology, and a daily check that the live search finds every record
- 4 November 2026: Cancer charities and paediatric centres: 45 US charities from the IRS register including the American Cancer Society and Blood Cancer United, 44 Children's Oncology Group member programmes and 36 National Cancer Grid members in India, each linked from the cancer, network or parent record it belongs to
- 4 November 2026: Invictus: the two cancer companies of that name, Invictus Therapeutics in Sydney and Invictus Oncology in Delhi
- 4 November 2026: Radiotherapy machines, chemotherapy chairs and scalp cooling: every model line dated from its FDA record, five roadmaps of how each machine family developed, and four improvement ideas
- 4 November 2026: A daily search health check: records missing from the live index, how far the site is behind main, and every typed name ranked by the site's own search
- 4 November 2026: AACI member centres: 25 academic cancer centres and the association itself, five large US cancer centres from the IRS list, and the legal names of eleven centres the corpus already held; the Jaime Leandro Foundation's record now carries its IRS filing, how its vaccine process works and who it is named for
- 4 November 2026: RNA tests: nineteen tests that read tumour RNA in tissue, urine and blood, a liquid RNA technology, and the proposal to read tumour RNA beside tumour DNA in one residual disease blood draw
- 4 November 2026: The command-line tool is onco-cc, since the npm name onco belongs to someone else, and four EU approvals read from EMA's register
- 4 November 2026: The CLI is published as onco-cc, because the npm name onco belongs to an unrelated package and npx onco would run it
- 4 November 2026: Institution coverage: a proper name at the start of a longer name counts, a description at its end does not
- 4 November 2026: Institution universe lists: US cancer charities (IRS), UK cancer charities (Charity Commission), AACI, Children's Oncology Group and National Cancer Grid members, with a coverage script
- 4 November 2026: EU authorisation rows for elinzanetant, Lumeblue, gallium-68 edotreotide and epoetin beta, read from the EMA pages, with epoetin beta quoting its cancer indication
- 4 November 2026: The subclone residual disease record now says the 57 mutations came from exome sequencing, and states the design cut-off and molecule counts that limit naming a subclone
- 4 November 2026: GLOBOCAN 2024 across the site: every figure from IARC's 2024 estimates, the edition named from the data, and a map legend for every 2024 data-method code
- 4 November 2026: Ultra-sensitive residual disease: eight more MRD assays including China's, the methods that read clones and phenotype from blood, TROP2 PET tracers, eleven trials and the limit on telling subclones apart; and 47 portfolio companies the monitors found
- 4 November 2026: Three new MRD trials are linked from their assay, drug and technology records
- 4 November 2026: Residual disease tests with their stated detection limits, the subclone attribution bottleneck, TROP2 PET tracers and the trials that act on a breast cancer blood result
- 4 November 2026: Electra Therapeutics and ipsoprubart are one record each, and the papers-snapshot gauge counts the drugs and targets added this week
- 4 November 2026: 83 oncology companies and 68 products found by the startup monitors in SEC filings, FDA and EMA orphan designations and NCI small-business grants, and GLOBOCAN 2024 waiting at /admin/
- 4 November 2026: Curadel and CPI-008 rest on the EMA designation and the trial registry only, since the company site refuses automated reads
- 4 November 2026: 47 oncology companies from investor and accelerator portfolios, with 32 pipeline products and 41 registry trials
- 4 November 2026: 83 oncology companies and 68 products found by the startup monitors in SEC filings, FDA and EMA orphan designations and NCI small-business awards
- 4 November 2026: 282 pipeline products for 156 companies and 14 new targets now that the engine pages are lighter, 130 unsupported links removed, survival calculators linked for issue 43, and the NHS Cancer Alliances list read from ONS
- 4 November 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE) (#348)
- 4 November 2026: chore: refresh preprint tracker from Europe PMC (#347)
- 4 November 2026: chore: check regional approvals against the EMA register (#346)
- 4 November 2026: chore: refresh FDA approvals feed (OCE notifications, openFDA drugsfda) (#345)
- 4 November 2026: chore: draft change proposals that need review (#344)
- 3 November 2026: Add sourced RGCC International evidence coverage
- 3 November 2026: Alleanza Contro il Cancro keeps its own sponsor name rather than pointing at a consortium record, as the one-home rule for cooperative groups requires
- 3 November 2026: Pipeline products keep a cancer link only where a registered trial, approval or paper supports it: ten trials gain the cancers their ClinicalTrials.gov conditions or titles name, 130 unsupported product-cancer links from the company pipeline fill are removed, four trials drop cancers their registry entries never name, and MDS answers to its singular name
- 3 November 2026: Eleven pipeline products name the protein they are linked to as their sources do (TROP2, FCGR2B, CD3 for CLSP-1025, PIK3CG, BCMA from the KLN-1010 registry title, MYH9, MET, MEK1/2, BCR::ABL1); CBX-250 loses a CD3 link no source states
- 3 November 2026: Paper identifier snapshot covers the 43 PubMed ids added with the country pages; every one resolves to the paper its record describes, DOI and year agreeing
- 3 November 2026: PRODUCT (needs owner approval): the engine's interleukin-15 pattern matches IL-15 as a word, not inside the product alias cytoTIL15
- 3 November 2026: PRODUCT (needs owner approval): the eligibility pattern for androgen receptor pathway inhibitors matches enzalutamide as a word, and deutenzalutamide by name rather than inside it
- 3 November 2026: Trials sponsored by the Uganda Cancer Institute's UCI-Fred Hutch centre count for the Kampala institute, and Alleanza Contro il Cancro's English name no longer resolves to the US Alliance group
- 3 November 2026: Members test follows the tests fill: BostonGene Tumor Portrait and FoundationOne Heme rows now resolve to their own records
- 3 November 2026: Remove a duplicated companies key on AVZO-103 left by a merge; both copies named Avenzo
- 3 November 2026: Prognosis calculators from Memorial Sloan Kettering and the National Cancer Institute are listed on /software/ as link-outs with their validation papers, and the NHS Cancer Alliance list is read from the ONS geography after NHS England's page began refusing scripts
- 3 November 2026: A trial-linked TROP2 record listed its company twice, which TypeScript rejects; the duplicate key is removed
- 3 November 2026: The ten new country pages quote GLOBOCAN 2024 beside the 2024 table, and France's gap with GLOBOCAN is no longer explained by skin cancer
- 3 November 2026: GLOBOCAN's all-cancers figure includes non-melanoma skin cancer: the UK and Israel pages and the default label say so
- 3 November 2026: Pages read the GLOBOCAN edition from the data file instead of naming 2022, and the cancer map explains every 2024 data-method code in IARC's words
- 3 November 2026: Maintenance scripts name the GLOBOCAN edition they read rather than 2022
- 3 November 2026: Research-ranking rates for France, Canada, Italy, the Netherlands, Korea, Australia, Spain, Brazil, Sweden and Switzerland move to GLOBOCAN 2024
- 3 November 2026: Cancer figures move to GLOBOCAN 2024: IARC's new edition is fetched for 186 countries, and every burden line, country card, research-ranking rate and geography layer that cited GLOBOCAN 2022 or 2020 is re-read from it
- 3 November 2026: Accuracy round two checks every figure on the country pages and the 60 most-linked cancer pages against its source: 365 corrections, 37 dead DOIs replaced, and NICE's October reversal on trastuzumab deruxtecan for HER2-low breast cancer
- 3 November 2026: Drugs now link what they bind rather than what they act on downstream, an investor and a trials group are no longer credited as makers, and stale company histories are corrected from registry and SEC records
- 3 November 2026: Every figure on the country pages and the 60 most-read cancer pages read against its source: 23 per cent needed a fix, and four checks now stop the commonest faults coming back
- 3 November 2026: Review-list judgements from labels, registries and filings: drugs link the receptor they bind, an investor and a trials group no longer pose as makers, sponsors resolve to their own centres, ten company pages corrected, and two duplicate products cross-referenced with a merge plan
- 3 November 2026: Accuracy round one fixes wrong paper ids, trials and side-effect figures; 28 FDA companion diagnostics and 11 tumour tests, FDA, EMA and WHO coverage lists, about 270 wrong links corrected, and deals and regimens linked to their records
- 3 November 2026: Readout pages keep tests and medicines apart: devices name their readouts, test cancer links rest on coverage, trials or papers, and three devices are credited to their FDA applicants
- 3 November 2026: The ten new country pages were checked against their sources, with 151 faulty claims fixed and every funding row corrected
- 3 November 2026: The open drug engine pages carry the same look in short classes, so the small-molecule page drops from 468,848 to 411,819 bytes of markup
- 3 November 2026: Fourteen proteins named by new pipeline medicines now have target pages, including PLK4, HPK1, PARG, LSD1, CDC7 and KIF18A, and sixteen small molecules move from Not placed into the engine grid
- 3 November 2026: Every drug side-effect rate now names its source: the last 143 unsourced rows read against FDA labels and trial papers, and the count held at zero
- 3 November 2026: Company pages that showed no products now list them: 282 pipeline products from 156 biotech and cell-therapy companies, each confirmed on the company's own pipeline page, filing or the registry, with 273 registry trials; thirteen existing products gain the company that discovered or co-develops them
- 3 November 2026: Keep GC012F and AZD0120 as separate records for now: merging them adds a site redirect, which waits for the owner
- 3 November 2026: Seven regulator and knowledge-base universe lists, FDA oncology approvals since 2020 as dated events, the missing FDA companion diagnostic rows, and nine medicines the EMA, FDA and WHO lists hold
- 3 November 2026: A link-sense audit finds links that resolve but mislead: myeloma loses a prostate vaccine and three imaging agents, 76 bowel cancer trials stop reading "bevacizumab (glioblastoma use)", and sponsor names stop matching by fragment
- 3 November 2026: TL;DRs for the OncoMate test and Promega spell out microsatellite instability, and TruSight Oncology 500 reads as a test kit
- 3 November 2026: Deals, regimens, isotopes, sponsors, software and open-source rows now link the records they name, with twelve deal parties and ten deal assets given sourced records
- 3 November 2026: A read-only gap audit ranks what reader pages leave out, and page sections gathered from the corpus wait at /admin/ for approval
- 3 November 2026: Tumour profiling tests and companion diagnostic devices get their own pages: FoundationOne Heme, Caris MI Profile, OncoExTra, OmniSeq INSIGHT, Tumor Portrait, Altera, TruSight Oncology 500, Strata Select, Tempus xE, NeoGenomics Neo Comprehensive and PanTracer, and 28 FDA companion diagnostic devices
- 3 November 2026: The first measured accuracy sample: 182 claims read against their sources, the errors fixed, and guards for the patterns found
- 3 November 2026: The Signatera merge test follows the readout record, which no longer lists the assay row
- 3 November 2026: Readout, technology and company sections gather their members from the corpus by a stated rule, one item per product
- 3 November 2026: A read-only gap audit lists what reader pages leave out, ranked by pages affected
- 3 November 2026: Every Medicare-covered MRD blood test now has its own page, including Foundation Medicine's FoundationOne MRD and Personalis NeXT Personal, with Oncodetect, Guardant Reveal and RaDaR corrected from their sources
- 3 November 2026: Eight more ctDNA residual disease tests get sourced records (FoundationOne MRD, NeXT Personal, Haystack MRD, NavDx, Labcorp Plasma Detect, Precise MRD, TrueMRD, Tempus xM), and Oncodetect, Guardant Reveal and RaDaR ST are re-sourced
- 3 November 2026: Ten country deep dives wait at /admin/ for approval, and the proposal script records its preview address
- 3 November 2026: Weekly watch for new oncology startups across fifteen sources and for landmark cancer papers, the Nature lung Treg interception paper, and the GLOBOCAN all-cancers note corrected to include non-melanoma skin cancer
- 3 November 2026: GLOBOCAN's all-cancers figures include non-melanoma skin cancer; say so
- 3 November 2026: Country deep dives for Australia, Spain, Brazil, Sweden and Switzerland, each read from its own registry, payer and regulator
- 3 November 2026: A weekly landmark-paper watch proposes new oncology papers for review, and the Nature regulatory T cell interception paper is added
- 3 November 2026: Startup monitors read portfolios, SEC filings, HKEX 18A, orphan designations and NCI small-business awards into the freshness issue
- 3 November 2026: 36 multi-cancer early detection tests, the Prometheus gaps filled, rare lymphomas linked to their trials, sixteen companies brought up to date and imaging agents given approval rows
- 3 November 2026: France, Canada, Italy, the Netherlands and South Korea, each read from its own national sources
- 3 November 2026: Add Selvana and Jiyu Bio, freshen sixteen large companies, name nine drugs' targets and give imaging agents regional approval rows
- 3 November 2026: Lymphoma: trials and papers for the entity pages the taxonomy added, and two corrections
- 3 November 2026: OpenOnco joins the open-source catalogue (PR 290), and the Open Medical Registry stays listed while its repository is private
- 3 November 2026: Fill the second round of Prometheus gaps: nine technologies, two drugs, eighteen companies, two facilities, the tumour atlas network and cDC1 cross-presentation
- 3 November 2026: Extend the multi-cancer test census to China, Taiwan and India, and add two new US Breakthrough designations
- 3 November 2026: chore: weekly maintenance (logos, structures, trial links, acronyms, orphan links) (#339)
- 3 November 2026: Pathway diagrams draw clean right-angle routes with rounded corners: no line runs through a box and every label is shown in full
- 3 November 2026: chore: refresh literature snapshot from Europe PMC (#338)
- 3 November 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE) (#337)
- 3 November 2026: chore: draft change proposals that need review (#335)
- 3 November 2026: chore: EU regional rows read from the EMA register pages (#334)
- 2 November 2026: Draw pathway diagrams with routed, rounded edges that avoid boxes
- 2 November 2026: The weekly refresh reads Even One's new page again and opens an issue when a source goes stale or a portfolio company is missing
- 2 November 2026: Cover brain-to-cancer neural circuit research
- 2 November 2026: chore: render this week's issue to public/newsletter/ (#333)
- 2 November 2026: chore: weekly fact check, audit, and provenance refresh (#332)
- 2 November 2026: chore: refresh public/votes.json from Discussions reactions (#331)
- 2 November 2026: chore: refresh trial counts from ClinicalTrials.gov (#330)
- 2 November 2026: chore: draft change proposals that need review (#329)
- 2 November 2026: chore: EU regional rows read from the EMA register pages (#328)
- 1 November 2026: The weekly universe refresh reads Even One's new page, and opens an issue for stale sources and portfolio companies OnCo lacks
- 1 November 2026: To-do: country deep dives, wave 2
- 1 November 2026: To-dos: Selvana, every source for new oncology startups, and a weekly watch for landmark cancer papers
- 1 November 2026: chore: monthly identifier enrichment (HGNC, Wikidata) (#327)
- 1 November 2026: chore: refresh HTA decisions and survival snapshots (#326)
- 1 November 2026: chore: draft change proposals that need review (#325)
- 1 November 2026: chore: EU regional rows read from the EMA register pages (#324)
- 31 October 2026: chore: draft change proposals that need review (#323)
- 31 October 2026: chore: EU regional rows read from the EMA register pages (#322)
- 30 October 2026: Tests, imaging agents and devices are called what they are, and 83 of them stop claiming to kill cancer cells
- 30 October 2026: Tests, imaging agents and devices are no longer called drugs or treatments
- 30 October 2026: Logos for 218 of the 262 new oncology companies, from each company's own site icon
- 30 October 2026: Preserve PostHog ingestion token and anonymous profile flag
- 30 October 2026: Fix consented Google tag commands and prepare private PostHog page counts
- 30 October 2026: chore: draft change proposals that need review (#320)
- 30 October 2026: chore: EU regional rows read from the EMA register pages (#319)
- 29 October 2026: 262 oncology companies new to OnCo, and 82 existing ones brought up to date with this year's acquisitions, approvals and listings
- 29 October 2026: Exact Sciences records the completed Abbott purchase, with Abbott's own release
- 29 October 2026: 262 oncology companies from 2024 to 2026 added, and 82 existing companies brought up to date with their acquisitions, approvals and closures
- 29 October 2026: Every multi-cancer early detection test we could verify, 27 of them worldwide, with their real performance, regulatory status and an honest grade
- 29 October 2026: Every multi-cancer early detection test we could find: 27 tests, 13 new companies, 57 registered studies and 26 papers
- 29 October 2026: Organisations without a logo show OnCo's own initials tile instead of a stock icon, and a profile for Dr Melissa Taylor at UCSF
- 29 October 2026: Organisations without a logo show OnCo's own initials tile instead of a stock icon from Google's favicon service
- 29 October 2026: A profile for Dr Melissa Taylor, breast medical oncologist at UCSF
- 29 October 2026: Eleven people stop showing a stranger's photo, 28 gain a properly licensed portrait, and 77 logos get sharp
- 29 October 2026: Portraits: 28 added, 11 wrong faces removed; logos: 77 sharper files
- 29 October 2026: Portrait and logo fetchers: stricter identity checks, ORCID matching, site icons
- 29 October 2026: 108 records that nothing linked to now appear on the pages they belong on, and six genes stop being called HER2 amplicon neighbours
- 29 October 2026: Six genes from other chromosomes stop being listed as HER2 amplicon neighbours
- 29 October 2026: The immune and microenvironment pages now show the trials acting on them: 88 for T-cell exhaustion, 28 for macrophages, 22 for adenosine
- 29 October 2026: Give 108 orphan records a way in from the records they belong to
- 29 October 2026: Alligator Bioscience's page stops claiming a single-arm trial showed longer survival
- 29 October 2026: Connect the immune and microenvironment mechanisms to the agents and trials acting on them
- 29 October 2026: To-do: a profile for Melissa Taylor, once the owner confirms which one
- 29 October 2026: chore: refresh pulse, abstract and citation snapshots (#318)
- 29 October 2026: chore: weekly roadmap registry check (public/roadmap-watch.json)
- 29 October 2026: chore: refresh institution research output from OpenAlex (#317)
- 29 October 2026: chore: draft change proposals that need review (#316)
- 29 October 2026: chore: EU regional rows read from the EMA register pages (#315)
- 28 October 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE) (#314)
- 28 October 2026: chore: refresh preprint tracker from Europe PMC (#313)
- 28 October 2026: chore: check regional approvals against the EMA register (#312)
- 28 October 2026: chore: refresh FDA approvals feed (OCE notifications, openFDA drugsfda) (#311)
- 28 October 2026: chore: draft change proposals that need review (#310)
- 28 October 2026: chore: EU regional rows read from the EMA register pages (#307)
- 27 October 2026: chore: weekly maintenance (logos, structures, trial links, acronyms, orphan links) (#309)
- 27 October 2026: chore: draft change proposals that need review (#308)
- 26 October 2026: Performance ceilings lowered to what the live site measures after round two
- 26 October 2026: Pages stop freezing on phones: the home page's blocking time falls from two seconds to almost nothing, and it downloads a third as much
- 26 October 2026: Record pages on a wide screen stop downloading themselves a second time
- 26 October 2026: Home and drug pages stop blocking the phone for two to three seconds, and the home page halves in size
- 26 October 2026: Seven duplicate ideas become one each, a proton paper stops being listed twice, and a cohort study is no longer called a randomised trial
- 26 October 2026: Eight Sleep's Hot Flash Mode, graded honestly: one preprint by company staff in menopausal women, nothing yet in cancer
- 26 October 2026: Record the Ask recall measurement for the 26 October merges
- 26 October 2026: One proton RBE review and six care ideas each had two pages; they are merged, and a lung cancer study is no longer called a randomised trial
- 26 October 2026: chore: weekly fact check, audit, and provenance refresh (#306)
- 26 October 2026: chore: render this week's issue to public/newsletter/ (#305)
- 26 October 2026: chore: refresh public/votes.json from Discussions reactions (#304)
- 26 October 2026: chore: refresh trial counts from ClinicalTrials.gov (#303)
- 26 October 2026: chore: draft change proposals that need review (#302)
- 26 October 2026: chore: EU regional rows read from the EMA register pages (#301)
- 25 October 2026: chore: draft change proposals that need review (#300)
- 25 October 2026: chore: EU regional rows read from the EMA register pages (#299)
- 24 October 2026: chore: draft change proposals that need review (#298)
- 24 October 2026: chore: EU regional rows read from the EMA register pages (#297)
- 23 October 2026: chore: draft change proposals that need review (#296)
- 23 October 2026: chore: EU regional rows read from the EMA register pages (#295)
- 22 October 2026: A measured performance budget: Lighthouse on seven page types under real throttling, with a ratchet
- 22 October 2026: Pages load faster: first visits stop loading twice, the cancer map stops downloading the whole corpus, and drawings wait until the page has settled
- 22 October 2026: chore: weekly roadmap registry check (public/roadmap-watch.json)
- 22 October 2026: chore: refresh pulse, abstract and citation snapshots (#294)
- 22 October 2026: chore: refresh institution research output from OpenAlex (#293)
- 22 October 2026: chore: draft change proposals that need review (#292)
- 22 October 2026: chore: EU regional rows read from the EMA register pages (#291)
- 21 October 2026: The ship chain retries once when Vercel refuses a deploy without creating one
- 21 October 2026: How precise cancer care is: a sourced page test by test, beam by beam and dose by dose, and 37 protocol upgrades that could improve care now
- 21 October 2026: chore: refresh preprint tracker from Europe PMC (#289)
- 21 October 2026: chore: check regional approvals against the EMA register (#288)
- 21 October 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE) (#287)
- 21 October 2026: chore: refresh FDA approvals feed (OCE notifications, openFDA drugsfda) (#286)
- 21 October 2026: chore: draft change proposals that need review (#285)
- 21 October 2026: chore: EU regional rows read from the EMA register pages (#284)
- 20 October 2026: Twenty-two cheap, evidence-backed changes to everyday cancer care are graded by how proven and how widely used they are, and two pages stop saying symptom tracking makes people live longer
- 20 October 2026: Two dosing rows marked as oversold carry their evidence grade
- 20 October 2026: Five precision rows marked as oversold now carry the evidence grade that says how far
- 20 October 2026: How precise a cancer drug dose is today: ten matrix rows and four records on blood levels, genes and kidney function
- 20 October 2026: Pegulicianine says what its trial showed, and the PD-L1 calibration idea cites the assay comparison it names
- 20 October 2026: Fifteen ways to deliver radiotherapy and surgery better, from letting patients see their own breath-hold to four weeks of clot prevention after bowel surgery
- 20 October 2026: Fifteen precision rows for blood tests and genomic matching say how precise each test is today and what acting on it has been shown to buy
- 20 October 2026: Radiotherapy precision rows: margins, contouring, image and surface guidance, breath-hold, motion, MRI-guided adaptation, radiosurgery, proton range, FLASH and dose painting
- 20 October 2026: A page for how precise cancer care is, test by test and dose by dose, with a roadmap and a check that every row is sourced
- 20 October 2026: Precision matrix for surgery, imaging and pathology: thirteen sourced rows on margins, sentinel nodes, robots, PSMA PET, lung screening and slide scoring, and a record for checking breast margins during the operation
- 20 October 2026: Skeleton for the precision and protocol-upgrades run: matrix types, one file per facet, registrations and tags
- 20 October 2026: chore: weekly maintenance (logos, structures, trial links, acronyms, orphan links) (#283)
- 20 October 2026: chore: refresh literature snapshot from Europe PMC (#282)
- 20 October 2026: chore: draft change proposals that need review (#281)
- 20 October 2026: chore: EU regional rows read from the EMA register pages (#280)
- 20 October 2026: Exclude navigation pages before CLI and MCP search limits
- 19 October 2026: 252 lung cancer trials stop being filed under small-cell, and six radioligand trials stop being called FAP-2286
- 19 October 2026: The sidebar stops reprinting the Connected section, and ordinary words like why and infection stop linking to unrelated glossary pages
- 19 October 2026: Trials that have closed stop saying they are recruiting, in English, plain language and Chinese
- 19 October 2026: The audit contradictions it took a day to clear can no longer come back unnoticed
- 19 October 2026: Ten cancer pages now say what the failed trials they cite actually found
- 19 October 2026: A de-escalation trial reads as one, and a product approved in 1990 stops hiding it
- 19 October 2026: An offline API copy in a folder with a space in its name is read correctly by the CLI and the MCP server
- 19 October 2026: chore: weekly fact check, audit, and provenance refresh (#277)
- 19 October 2026: chore: render this week's issue to public/newsletter/ (#276)
- 19 October 2026: chore: refresh public/votes.json from Discussions reactions (#275)
- 19 October 2026: chore: refresh trial counts from ClinicalTrials.gov (#274)
- 19 October 2026: chore: draft change proposals that need review (#273)
- 19 October 2026: chore: EU regional rows read from the EMA register pages (#272)
- 18 October 2026: chore: draft change proposals that need review (#271)
- 18 October 2026: chore: EU regional rows read from the EMA register pages (#270)
- 18 October 2026: Fix offline API file URL decoding
- 17 October 2026: chore: draft change proposals that need review (#266)
- 17 October 2026: chore: EU regional rows read from the EMA register pages (#267)
- 16 October 2026: The weekly literature refresh stops discarding its own work, and stops recording throttled replies as zero papers
- 16 October 2026: Nineteen immune markers get a page, and the microenvironment records link to the agents aimed at them
- 16 October 2026: chore: EU regional rows read from the EMA register pages (#265)
- 15 October 2026: chore: refresh pulse, abstract and citation snapshots (#264)
- 15 October 2026: chore: weekly roadmap registry check (public/roadmap-watch.json)
- 15 October 2026: chore: refresh institution research output from OpenAlex (#263)
- 15 October 2026: chore: EU regional rows read from the EMA register pages (#262)
- 14 October 2026: The command palette stops showing results for a query you have cleared
- 14 October 2026: Concept search recovers after a blip, a stale feed stops claiming it is fresh, and the chain keeps what landed while it worked
- 14 October 2026: Concept search recovers after a blip, and a stale feed stops claiming it is fresh
- 14 October 2026: chore: refresh preprint tracker from Europe PMC (#261)
- 14 October 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE) (#260)
- 14 October 2026: chore: check regional approvals against the EMA register (#259)
- 14 October 2026: chore: EU regional rows read from the EMA register pages (#258)
- 13 October 2026: chore: weekly maintenance (logos, structures, trial links, acronyms, orphan links) (#257)
- 13 October 2026: chore: draft change proposals that need review
- 13 October 2026: chore: EU regional rows read from the EMA register pages (#255)
- 12 October 2026: Fifty-eight UCSF breast studies we were missing, and the PARP breast gaps closed
- 12 October 2026: chore: render this week's issue to public/newsletter/ (#254)
- 12 October 2026: chore: weekly fact check, audit, and provenance refresh (#253)
- 12 October 2026: chore: refresh public/votes.json from Discussions reactions (#252)
- 12 October 2026: chore: refresh trial counts from ClinicalTrials.gov (#251)
- 12 October 2026: chore: draft change proposals that need review
- 12 October 2026: chore: EU regional rows read from the EMA register pages (#250)
- 11 October 2026: chore: EU regional rows read from the EMA register pages (#249)
- 10 October 2026: Complete UCSF adult female breast-study coverage with 58 registry records
- 10 October 2026: Connect PARP evidence records and preserve supportive approval scope
- 10 October 2026: Fill PARP breast trial and evidence gaps with scoped eligibility
- 10 October 2026: chore: EU regional rows read from the EMA register pages (#243)
- 9 October 2026: Correct the prevalence figures in the cBioPortal roadmap note
- 9 October 2026: Seven contributor changes: table filters stop colliding, dossiers say where you are and fold, prevalence opens as a list
- 9 October 2026: The bot's proposal list, and cBioPortal ingestion scoped on the roadmap
- 9 October 2026: chore: draft change proposals that need review
- 9 October 2026: chore: EU regional rows read from the EMA register pages (#241)
- 8 October 2026: Weekly idea votes from Discussions, and the bot's proposal list
- 8 October 2026: The new trials page gets a measured weight ceiling, pinned because its table is paged
- 8 October 2026: A page for finding a trial you could still join, filtered by cancer, country and who it is open to
- 8 October 2026: An unreviewed page says so in three words at the foot, not five sentences in the margin
- 8 October 2026: A trial page now says who can join and where, and a page has one way to correct it
- 8 October 2026: The site no longer loads unstyled after a deploy
- 8 October 2026: The site loaded unstyled after a deploy, and the star count comes back
- 8 October 2026: Land dossier jumps again when a table pages in rows mid-scroll
- 8 October 2026: Refit other columns while a column is being resized
- 8 October 2026: The TROPION-Breast01 record says what the FDA actually did
- 8 October 2026: Link dossier navigation only to sections the target has
- 8 October 2026: chore: refresh pulse, abstract and citation snapshots (#240)
- 8 October 2026: chore: weekly roadmap registry check (public/roadmap-watch.json)
- 8 October 2026: chore: refresh institution research output from OpenAlex (#239)
- 8 October 2026: chore: draft change proposals that need review
- 8 October 2026: chore: EU regional rows read from the EMA register pages (#238)
- 7 October 2026: Keep open header tips from widening table columns
- 7 October 2026: Respect row content minimums when sizing table columns
- 7 October 2026: Include the visible mobile language label in its accessible name
- 7 October 2026: Cover similar page ranking and lazy export behavior
- 7 October 2026: Compute similar pages per record during rendering
- 7 October 2026: Keep review images outside the repository
- 7 October 2026: Refresh resize review screenshots after accessibility fixes
- 7 October 2026: Provide initial accessible column resize values
- 7 October 2026: Show column resize dividers on hover and focus
- 7 October 2026: Fit and resize shared table columns with visual comparisons
- 7 October 2026: Require side-by-side screenshots in product pull requests
- 7 October 2026: Follow React lint rules in disclosure rendering tests
- 7 October 2026: Make dossier sections collapsible with prevalence closed initially
- 7 October 2026: Highlight the current section in dossier navigation
- 7 October 2026: Run CI gates and static export in parallel without weakening checks
- 7 October 2026: Align CI render gates and avoid duplicate page checks
- 7 October 2026: Fix table filter names and badge accessibility
- 7 October 2026: Expire fact-check cache entries and record source retrieval dates
- 7 October 2026: Thirteen contributed fixes: nine fetchers that keep what they already had, four that let search recover
- 7 October 2026: Revert "Expire older-day OpenAlex work caches before dating research snapshots (#213)"
- 7 October 2026: Eleven contributed TROP2 and PARP pull requests, and the trials they brought
- 7 October 2026: AGENTS.md: never resolve a contributor's pull request by union
- 7 October 2026: Eleven contributed records land, and the trials they brought get an inbound edge
- 7 October 2026: The page-weight ratchet counts the right thing now
- 7 October 2026: chore: refresh preprint tracker from Europe PMC (#230)
- 7 October 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE) (#229)
- 7 October 2026: chore: check regional approvals against the EMA register (#228)
- 7 October 2026: chore: refresh FDA approvals feed (OCE notifications, openFDA drugsfda) (#227)
- 7 October 2026: chore: EU regional rows read from the EMA register pages (#226)
- 7 October 2026: Expire older-day OpenAlex work response caches
- 7 October 2026: Retain survival snapshots when a source site fails
- 7 October 2026: Retain institution research after required request failures
- 7 October 2026: Preserve congress abstract snapshots after failed pages
- 7 October 2026: Release saved import capacity before growing lists
- 7 October 2026: Preserve saved lists when an import cannot persist
- 7 October 2026: Type the preprint request test cases consistently
- 7 October 2026: Retain preprints when search responses are incomplete
- 7 October 2026: Keep citation snapshot when an OpenAlex batch fails
- 7 October 2026: Retain pulse items when a source returns a non-feed response
- 7 October 2026: Restore the page origin after closing keyboard shortcuts
- 7 October 2026: Scope recovery assertions to lexical search errors
- 7 October 2026: Preserve paper snapshots after malformed search responses
- 7 October 2026: Restore command palette opener focus on dismissal
- 7 October 2026: Retry concept search after temporary index failures
- 7 October 2026: Require verified rows before advancing the EMA check stamp
- 7 October 2026: fix: retry browser Ask index after temporary failures
- 7 October 2026: Recover search results and inline answers after index failures
- 7 October 2026: Reject malformed browser record envelopes before caching
- 7 October 2026: fix: retain EMA snapshots after unreadable refresh input
- 7 October 2026: Report browser record failures and permit Ask retries
- 7 October 2026: fix: scope modality table URL state
- 7 October 2026: Preserve FDA snapshots until both sources finish completely
- 6 October 2026: Deepen PARP1 programmes, biomarker evidence and clinical trial states
- 6 October 2026: Clarify current US PARP labels and withdrawn ovarian treatment
- 6 October 2026: Expand TROP2 clinical and historical programmes from primary registries
- 6 October 2026: Reconcile TROP2 regulatory labels and FDA trial outcomes
- 6 October 2026: Refresh TROP2 trial landscape from current registry records
- 6 October 2026: Expand TROP2 clinical programs and early evidence
- 6 October 2026: Add primary-sourced preclinical TROP2 ADC programs
- 6 October 2026: Add cited KH815 and ASP2998 TROP2 dual-payload programs
- 6 October 2026: Seven trims to the top of a record page, and a review card that says what is true
- 6 October 2026: Cite breast ADC labels for the TROP2 testing statement
- 6 October 2026: About 19,500 pages stop opening with the least useful true thing they could say
- 6 October 2026: Correct LCB84 modality and cite its phase 1/2 registry record
- 6 October 2026: Separate TROP2 copy-number amplification from IHC expression
- 6 October 2026: Update TROP2 biomarker with current US breast indications
- 6 October 2026: Correct TROPION-Breast01 approval statement and cite final survival results
- 6 October 2026: Seven things leave the top of a record page
- 6 October 2026: Three more things leave the top of a record page
- 6 October 2026: Four things leave the top of a record page
- 6 October 2026: Reopen retained search queries from the keyboard
- 6 October 2026: Recover search box queries after index load failures
- 6 October 2026: Keep trial feed stale when a snapshot date is invalid
- 6 October 2026: fix(factcheck): count unresolved helper record identities
- 6 October 2026: Read explicit marker results before bare sign fallback
- 6 October 2026: fix(factcheck): reject ambiguous ids across data files
- 6 October 2026: Share marker suffix parsing across trial criteria and profiles
- 6 October 2026: Keep protocol identity separate from title context
- 6 October 2026: Expose retained trial dates in modality and feed status views
- 6 October 2026: Require complete marker predicates before applying trial exclusions
- 6 October 2026: Filter semantic candidates before score allocation
- 6 October 2026: Preserve complete trial titles and identifier boundaries
- 6 October 2026: Disclose retained snapshot dates in trial aggregates
- 6 October 2026: Keep ambiguous eligibility marker clauses unresolved
- 6 October 2026: Require trial-specific identity before registry patches
- 6 October 2026: fix(mcp): retain hidden values in field comparisons
- 6 October 2026: chore: weekly maintenance (logos, structures, trial links, acronyms, orphan links)
- 6 October 2026: chore: EU regional rows read from the EMA register pages (#154)
- 5 October 2026: chore: render this week's issue to public/newsletter/ (#153)
- 5 October 2026: chore: weekly fact check, audit, and provenance refresh (#152)
- 5 October 2026: chore: refresh public/votes.json from Discussions reactions
- 5 October 2026: chore: refresh trial counts from ClinicalTrials.gov (#149)
- 5 October 2026: chore: EU regional rows read from the EMA register pages (#128)
- 5 October 2026: fix(mcp): compare complete field values instead of summaries
- 5 October 2026: Propagate Ask record retrieval failures in CLI and MCP
- 5 October 2026: Preserve qualified biomarker names when matching trials
- 5 October 2026: Keep trial biomarker polarity scoped to each result
- 5 October 2026: Hold trial fact-check patches until registry identity is resolved
- 5 October 2026: Preserve trial index entries across failed refresh requests
- 5 October 2026: fix(search): filter record kinds before limiting retrieval
- 5 October 2026: Patch only direct literal fields in fact-check corrections
- 5 October 2026: fix(cli): resolve record URLs with query strings and anchors
- 4 October 2026: The sources come off the sidebar and go to the foot of the page
- 4 October 2026: Arrow keys reach the results, and a brand name finds its drug
- 4 October 2026: Arrow keys reach the results, a brand name finds its drug, and a prefix finds what starts with it
- 3 October 2026: chore: EU regional rows read from the EMA register pages (#127)
- 2 October 2026: How recovery is measured, and who is reached by it
- 2 October 2026: Name the England quality of life survey as a gap rather than describe it
- 2 October 2026: How recovery is measured, and who is actually reached by it
- 2 October 2026: The recovery front gets its hub, its history and its open problems
- 2 October 2026: Recovery: the front's hub rewritten, the history of survivorship, and the research agenda
- 2 October 2026: Rehabilitation, reconstruction, and a matrix of what comes back
- 2 October 2026: What comes back after treatment: a sourced recovery matrix, treatment by treatment
- 2 October 2026: Cancer rehabilitation and reconstruction: the services that put function back, and the gap between them and what people are offered
- 2 October 2026: Recovery: transplant, second cancers, the mind, and the markdown nobody was rendering
- 2 October 2026: Graft-versus-host disease, late effects after transplant, and the immune system afterwards
- 2 October 2026: Fear of recurrence, mood, body image, work, money and sleep after cancer
- 2 October 2026: Second cancers after treatment, and the screening that follows
- 2 October 2026: Childhood and young adult survivorship: the cohorts that made the field
- 2 October 2026: Childhood, adolescent and young adult survivorship: the cohorts, the burden, and the follow-up that governs care
- 2 October 2026: Six summaries that described the page instead of the thing
- 2 October 2026: Six TL;DRs were talking about the page instead of the subject
- 2 October 2026: Recovery and rejuvenation: a new front, and the hair spike the owner asked for
- 2 October 2026: Biological ageing after cancer treatment, and what is sold against it
- 2 October 2026: Recovery and rejuvenation: the body, system by system
- 2 October 2026: AGENTS.md learns the five days since it was written
- 2 October 2026: The home page stops drawing a flow the corpus does not have
- 2 October 2026: Hair: the number for your own regimen, and an honest grade for everything sold for regrowth
- 2 October 2026: The home page stops drawing a flow the corpus does not have, and two labels come off
- 2 October 2026: A twentieth front: Recovery and Rejuvenation
- 2 October 2026: Lymphoma, and a home page with less above the grid
- 2 October 2026: The hero stops promising a plain-English TL;DR
- 2 October 2026: The home page loses the record count, the JSON chip and the body pill above the grid
- 2 October 2026: chore: EU regional rows read from the EMA register pages (#125)
- 1 October 2026: Lymphoma: the biology of the germinal centre, and what a person actually decides
- 1 October 2026: Lymphoma: the UK and NHS pathway, and the world geography layer
- 1 October 2026: Lymphoma evidence: 29 trials, 42 papers, a roadmap and eight open questions, each resolved against a registry or Europe PMC
- 1 October 2026: Nineteen lymphoma entity pages, a rewritten non-Hodgkin hub, and both 2022 classifications quoted where they disagree
- 1 October 2026: The oldest three DLBCL rows retire, because the record now says the same thing three times
- 1 October 2026: Lymphoma molecular layer: the antigens and what they cost, the lesions, the classifications, resistance and the tests
- 1 October 2026: Lymphoma, the person: six decisions, six red cards, three first-sixty-days lists
- 1 October 2026: The weekly check now fails when a page grows past what a reader downloaded last week
- 1 October 2026: A ceiling on what a reader actually downloads, measured on the live site
- 1 October 2026: Lirafugratinib is approved, not phase 2, and the bot stops proposing one combination's approval for another
- 1 October 2026: chore: monthly identifier enrichment (HGNC, Wikidata) (#124)
- 1 October 2026: chore: refresh HTA decisions and survival snapshots (#123)
- 1 October 2026: chore: refresh pulse, abstract and citation snapshots (#122)
- 1 October 2026: chore: weekly roadmap registry check (public/roadmap-watch.json)
- 1 October 2026: chore: refresh institution research output from OpenAlex (#121)
- 1 October 2026: chore: draft change proposals that need review
- 30 September 2026: A name typed in full comes first, and people have faces in the search
- 30 September 2026: /prevalence/ opens on a list, because the grid is 95 per cent empty
- 30 September 2026: Four verified approval rows from the proposals queue, and two structure keys that stopped the build
- 30 September 2026: Page titles, second attempt: a noun phrase naming the thing and the dimension that orders it
- 30 September 2026: The unattended gates run the tests the way the ship chain does, so a weekly data refresh can merge itself again
- 30 September 2026: The sources come off the sidebar and go to the foot of the page, grouped by who published them
- 30 September 2026: chore: refresh preprint tracker from Europe PMC
- 30 September 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE)
- 30 September 2026: chore: check regional approvals against the EMA register
- 30 September 2026: chore: weekly citation link check
- 30 September 2026: chore: refresh FDA approvals feed (OCE notifications, openFDA drugsfda)
- 30 September 2026: chore: draft change proposals that need review
- 29 September 2026: Lymphoma treatment rows, and red cards that no longer name a drug the reader is not taking
- 29 September 2026: Lymphoma treatment: 70 standard-of-care rows across 21 diseases, each citing its trial
- 29 September 2026: The software of oncology, and the top of a record page
- 29 September 2026: chore: weekly maintenance (logos, structures, trial links, acronyms, orphan links)
- 28 September 2026: Every cancer-page section named for what is in it, in nine languages
- 28 September 2026: The block inside Symptoms and diagnosis is not called that too, and four pill labels follow the new names
- 28 September 2026: The page that shows what is waiting, with the queue read from the open pull requests
- 28 September 2026: A command for a person to type is not a change to the product
- 28 September 2026: The queue is a rendering of the open pull requests, refreshed on every ship
- 28 September 2026: The admin page waiting in its own queue
- 28 September 2026: The page that shows what is waiting, and says plainly what it is not
- 28 September 2026: The record page top waiting in the queue
- 28 September 2026: The top of a record page is the record again: a family strip of six, two paragraphs of summary, the clinic names readable, the model panel last
- 28 September 2026: The software map waiting in the queue
- 28 September 2026: The map a product proposal belongs in: 136 pieces of oncology software, each row saying whether anything outside the company backs it up
- 28 September 2026: The title review waiting in the queue
- 28 September 2026: Thirty page titles that named a format, could belong to any site, or needed a term first
- 28 September 2026: Product changes now wait for the owner, and the plan for the cancer page is written
- 28 September 2026: The approval mechanism belongs on main; the renames stay in the queue
- 28 September 2026: The cancer page measured before it is redesigned, and a plan the owner can approve part by part
- 28 September 2026: The first product change waiting in the queue
- 28 September 2026: Product changes wait for the owner; data ships
- 28 September 2026: Each section of a cancer page is now named for what is inside it, and the years index says which years it holds
- 28 September 2026: The front page links to 140 sections and shows almost none of them
- 28 September 2026: The prevalence matrix: 23 columns wide and growing with the corpus
- 28 September 2026: Visual first, and the measurement that would be misleading if taken naively
- 28 September 2026: Every page title, with the count of how many are one or two words
- 28 September 2026: The machine links, and the admission that seven patches are not a design
- 28 September 2026: The years index title, and the question of how it differs from the timeline
- 28 September 2026: The section names and the wall of links, with what each section holds and how many links a page carries
- 28 September 2026: The section called Evidence is called Trials and papers, which is what is in it
- 28 September 2026: Three more record-page asks on the roadmap, with what the print control actually does
- 28 September 2026: The fourth ask: the also-known-as line is the smallest type on the page
- 28 September 2026: Three owner asks on the roadmap: what a reader meets first on a record page
- 28 September 2026: Five weekly runs merged, the agent rules written down with the scripts they point at, and a card that can name no record no longer counts as one that lost one
- 28 September 2026: A card that can name no record is not a card that lost one
- 28 September 2026: Provenance regenerated with the private name redacted after the weekly run reintroduced it
- 28 September 2026: A locally installed skill directory is not part of this project
- 28 September 2026: The rules an agent needs, in the file every agent reads, with the scripts they point at now in the repository
- 28 September 2026: chore: render this week's issue to public/newsletter/
- 28 September 2026: chore: weekly fact check, audit, and provenance refresh
- 28 September 2026: chore: refresh public/votes.json from Discussions reactions
- 28 September 2026: chore: refresh trial counts from ClinicalTrials.gov
- 28 September 2026: chore: draft change proposals that need review
- 27 September 2026: A total review of fatalistic language: 153 phrases rewritten, the survival guard now says what a median is, and the red-flag card leads with calling
- 27 September 2026: A cancer with no NHS pathway page now says so in development as it does in production
- 27 September 2026: A word that is the source's is shown as the source's
- 27 September 2026: The half a keyword search cannot find: order, framing and the numbers printed as verdicts
- 27 September 2026: Say what the cancer does, not how to feel about it: fatalistic language out of OnCo's own voice, every quotation left exactly as its author wrote it
- 27 September 2026: Three dated fields the corpus lacked: accelerated approvals with their confirmations, a sourced first-description year on targets, and a trial start date
- 27 September 2026: Adenoid cystic carcinoma described without the word relentless
- 25 September 2026: Three dates the timeline was missing: every accelerated approval and what became of it, when each target was first described, and when each trial opened
- 25 September 2026: Measure what a reader downloads, not what the tests can render
- 25 September 2026: A record for every year and one timeline over all of them, with ten questions asked of the corpus and two it cannot answer
- 25 September 2026: Oncolytic virotherapy in full: four approved replicating viruses and not one randomised survival benefit, and the 2024 self-experiment read from its case report
- 25 September 2026: A record for every year in oncology, one timeline over all of them, and what the shape of the dates shows
- 25 September 2026: The for-me budget measures its own tiles, not the chrome every page carries
- 25 September 2026: Oncolytic virotherapy as a subject, not scattered records: the interferon defect, the approvals and what they really showed, and the virologist who treated herself
- 25 September 2026: Clicking a value in a table now filters by it: thirteen cells across eight tables, a year facet on trials, and a guard that a filter link can never come back empty
- 25 September 2026: Click the year to filter the table: thirteen cells across eight tables become filters
- 25 September 2026: Three owner asks on the roadmap: cells as filters, a record per year, and oncolytic virotherapy
- 25 September 2026: Six countries in depth, each read from its own registry and regulator: the United States, Germany, Japan, the United Kingdom, Israel and Russia
- 25 September 2026: Wave one of the country deep dives is done: six countries
- 25 September 2026: Four country pages said the figure excluded non-melanoma skin cancer; it never did
- 25 September 2026: The benchmarking partnership is hosted by Cancer Research UK, not founded by it
- 25 September 2026: Israel: a committee decides in public, once a year, inside a fixed sum, which cancer drugs the state will pay for
- 25 September 2026: One label over four health services: the United Kingdom deep dive, and the cost-per-QALY threshold the corpus had wrong
- 25 September 2026: Japan reads tenth in our own count and fifth in the world, so the Japan page is written from Japanese sources
- 25 September 2026: Russia read from Russian sources: the Herzen register and what it does not count, who pays, and the Eurasian approvals route
- 25 September 2026: Two country deep dives: the United States, where the question is who pays, and Germany, where a drug is paid for on the day it is approved and assessed afterwards
- 25 September 2026: The first two country deep dives: the United States and Germany
- 25 September 2026: In America the pill has a ceiling and the drip does not, and 239 accelerated approvals show what happens when nobody checks
- 25 September 2026: A red-card pattern can no longer match inside an unrelated word
- 25 September 2026: Compugen, which found PVRIG by predicting it, and the paper that first measured what a liposome does in a patient
- 25 September 2026: Germany pays for a new cancer drug on the day it goes on sale and asks what it is worth afterwards
- 25 September 2026: A blood-clot warning for a myeloma drug was reaching every fluoropyrimidine page, because the pattern matched inside the word pyrimidine
- 25 September 2026: Remove the scratch script used to survey what the corpus held for Israel
- 25 September 2026: Israel: the people and papers behind the country page, and the term for what a founder variant is
- 25 September 2026: The skin review: a page about a cream warned a reader about a blood clot, and an appraisal that refused a drug was recorded as one that funds it
- 25 September 2026: A second front page at /v2 for review, and table filters that find what you asked for: family cancers, phases in time order, search ranked by what you typed
- 25 September 2026: Country deep dives on the roadmap, ranked by what the corpus holds and by what that ranking gets wrong
- 25 September 2026: Filtering a table by a cancer family finds its subtypes, the phase filter runs in time order, and the facet search ranks what you typed
- 25 September 2026: The front page opens on the list again; the graph is one click away
- 25 September 2026: Four page-render tests were measuring how busy the machine is, not the code
- 25 September 2026: Four launch-list items were already done: tick them so nobody does them twice
- 25 September 2026: The answer to which page is mine now sits on the page a reader lands on, not the last tab
- 25 September 2026: Skin cancer on the NHS: nearly a third of England's urgent cancer referrals are for skin, and the commonest skin cancer is excluded from the standard that measures them
- 25 September 2026: Two layers of the skin round wrote the same trial: the ratchet caught it and the merge tool fixed it
- 25 September 2026: Record which of the skin layer's sources a program cannot open, checked one URL at a time
- 25 September 2026: The skin cancer NHS pathway, and the two exclusions that mean the published figures are not what they look like
- 25 September 2026: A reader on a breast subtype page now gets the cord compression card, and never two sepsis cards
- 25 September 2026: Skin cancer: what a person with a basal cell or squamous cell cancer faces, the family tree given its reason, and the counting rule that hides the commonest cancer there is
- 25 September 2026: The breast family review: the family page duplicates nothing, but the two receptor pages it routes to said everything twice
- 25 September 2026: What a person with a basal cell or squamous cell skin cancer actually faces, and a rule that lets a row cite the leaflet that carries its sentence
- 25 September 2026: The treatment of the keratinocyte cancers: the margin, Mohs surgery, the creams and the light, radiotherapy, the hedgehog pathway and the transplant recipient
- 25 September 2026: Three review lessons from the skin layer: a citation that does not contain the claim passes every gate
- 25 September 2026: The rows about living with a skin cancer now cite the leaflet that actually contains the sentence, and the photodynamic therapy figures move to the cream the trials used
- 25 September 2026: The skin family given its routing, the keratinocyte cancers given their subtypes and staging, and the counting rule that governs every figure on them
- 25 September 2026: A patient leaflet may be the source for a row about living with a disease, if the row names who wrote it
- 25 September 2026: What a person with a basal cell or squamous cell skin cancer actually faces: the choice between surgery and its alternatives with the trial figures, the operation on the face, Mohs as a day, and the ones that are not cured
- 25 September 2026: The family roll-up does not assume who is reading, and stops printing the cancer's name twice in one sentence
- 25 September 2026: Family cancer pages now reach what their subtypes hold: 3,683 trials, 1,079 medicines and 3,534 centres that no family page could reach before
- 25 September 2026: A family page now shows the trials, medicines and centres its subtypes hold, grouped by the subtype each came from
- 25 September 2026: The breast family page given its surgery, its NHS pathway and its shared decisions, and 83 duplicate records retired onto the ones that carry the reading
- 25 September 2026: The prostate review found an appraisal that refused a drug recorded as merely restricting it, and the breast family page given the routing a reader needs
- 25 September 2026: Breast cancer in the NHS: the screening programme the site never had, the family history service, both referral routes, and four wrong or stale funding claims corrected
- 25 September 2026: One thing, one id: 83 duplicate records merged, with the rule, the helper and the ratchet the three reviews asked for
- 25 September 2026: Breast cancer, the shared treatment spine: 22 trials on the operation, the axilla, radiotherapy and reconstruction, read at twenty and twenty-five years
- 25 September 2026: Breast cancer, living with it: the surgery choice with the twenty-year figures, the axilla and lymphoedema, fertility, sensation, hair, and four red cards
- 25 September 2026: The breast family page: the routing a reader needs in one click, the shared story of grade, stage and the receptor tests, and the classification edition nobody had noticed changed
- 25 September 2026: Prostate review: the appraisal that refused abiraterone was recorded as one that restricted it, eleven papers written twice, and the screening trials the whole section rests on
- 25 September 2026: The lung review: 33 lines the layers had written twice folded away, four contradictory figures resolved against their sources, and two duplicate-key bugs the lung data exposed
- 25 September 2026: The lung review: a placeholder idea rewritten from the UK page's own gaps, 33 duplicated base lines folded, three papers that existed twice merged, and two duplicate-key bugs the lung data exposed
- 25 September 2026: Prostate cancer in depth: 57 trials from their publications, the receptor landscape from eighteen deposits, the March 2026 screening recommendation, and four wrong NHS funding rows corrected
- 25 September 2026: Wire the two prostate pathology terms into the papers that found them
- 25 September 2026: Prostate molecular: the androgen receptor's five escape routes, the repair genes the four PARP labels disagree about, and what a PSMA PET cannot tell you
- 25 September 2026: The explained page budget measures its furniture, not how much the corpus knows
- 25 September 2026: Prostate glossary: fifteen new terms, with the screening figures, the two endpoint definitions and PI-RADS against the NICE Likert scale
- 25 September 2026: Prostate cancer on the NHS: the screening committee's March 2026 recommendation from its own coversheet, the risk in Black men with its cohorts, and the 62-day standard prostate fails worst
- 25 September 2026: Prostate treatment from its trials: 57 randomised comparisons, what each option costs a man, and the four NICE refusals
- 25 September 2026: Prostate cancer: five orthogonal classifications settled, the Cambridge Prognostic Groups added, and the decisions written with the trial figures rather than the word side effects
- 25 September 2026: Register the twelve prostate glossary drafts and link them from the decisions that use them
- 25 September 2026: Prostate cancer evidence: the 44 papers that made the field, a roadmap in twelve eras, seven ideas and nine open problems
- 25 September 2026: Prostate cancer, living with it: the ProtecT trade-off in numbers, hormone therapy for the long run, and cord compression named as the emergency
- 25 September 2026: An agent that has only the origin can now find the corpus: MCP and llms descriptors under .well-known, licence and provenance on every API response
- 25 September 2026: Prostate cancer has five classifications at once, and only one of them makes pages
- 25 September 2026: How to read the UK bodies that answer a script with a wall
- 25 September 2026: Lung cancer on the NHS: the screening programme from its own protocol, 34 centres, 21 appraisals and 8 refusals, the deprivation gradient from four national sources
- 25 September 2026: The UK lung pathway hangs off the family, not one branch of it
- 25 September 2026: Lung cancer gets its UK and NHS layer: the screening programme with its risk thresholds, the deprivation gradient in four nations, 108 funding decisions and the reflex testing clock
- 25 September 2026: Lung cancer given its trials, its molecular landscape and its evidence: 36 trials written from source, three landscapes, 44 papers, a roadmap of eleven eras
- 25 September 2026: A standard-of-care row for the antibody-drug conjugates and bispecifics entering lung cancer
- 25 September 2026: Lung molecular layer: adenocarcinoma, squamous and small-cell landscapes read separately, PD-L1 by assay, why tumour mutational burden failed, and resistance mechanism by mechanism
- 25 September 2026: Approval dates cut back to what the FDA notification page shows
- 25 September 2026: Lung cancer evidence: 44 landmark papers from Doll and Hill to tarlatamab, a roadmap in eleven eras with a 2032 registry watch, and seven open questions
- 25 September 2026: Registry routing reads the title and conditions, not the eligibility text
- 25 September 2026: Roadmap page quoted the old review gauge label
- 25 September 2026: Write down the three gauges no script can move, and what the owner holds
- 25 September 2026: Lung registry snapshot gets a breadth rule, later lines get their trials, and Ask keeps its floor
- 25 September 2026: Lung cancer given a family and a patient side: five tiers under lung-cancer, ten decision rows, 86 appointment questions, six red-card sets
- 25 September 2026: Europe PMC snapshots for 1,545 records, 42 logos, and a collection that had borrowed a charity's mark
- 25 September 2026: Take the backlink fill back out: it costs 0.002 of Ask recall, and the floor does not move
- 25 September 2026: Lung cancer: the patient side, written so a person who smoked and a person who never smoked are both addressed
- 25 September 2026: Read the three new lung pages in the dev server and drop one redundant alias
- 25 September 2026: Three more lung glossary terms the other layers will need, and an outlook paragraph on the family page
- 25 September 2026: Glossary terms: four Wikipedia links found, 58 absences recorded as checked
- 25 September 2026: Lung taxonomy settled and the core layer written: the family now hangs together, and lung cancer is described from its sources
- 25 September 2026: Lung cancer treatment layer: 884 registry trials, 31 landmark trials and the England access rows
- 25 September 2026: A test that fails when a gauge's denominator moves and its label does not
- 25 September 2026: Backlink fill for 1,002 weak records: two acronym collisions fixed first
- 25 September 2026: Provenance was blind to the generated files: 1,486 records get their commit line back
- 25 September 2026: Three gauges were measuring the wrong population; fix the questions, not the targets
- 25 September 2026: Colorectal reviewed against its sources: duplicate treatment rows folded, eleven NICE errors corrected, RAS wild-type recorded as a biomarker, 1,406 links checked
- 25 September 2026: Review the colorectal deep spike: fold the duplicated rows, settle the contradictory figures, fix eleven NICE errors and add the RAS wild-type readout
- 25 September 2026: Colorectal cancer deep spike complete (core, 710 trials, molecular landscape, evidence and roadmap); red cards re-sourced against the live toolkit; pages no longer grow with what is known about a reference; weekly jobs merge only when the gates pass
- 25 September 2026: Roadmaps and dossiers made robust to corpus growth: a reference costs the same whatever is known about it, the dossier export is a file, and no bot merges a tree the tests have not seen
- 25 September 2026: Check every cited URL and fix the one that was dead
- 25 September 2026: Register the colorectal treatment spike, its helper files and the sponsor supplement with the audit
- 25 September 2026: De-duplicate the NICE NG151 link across the three colorectal patches, and the CMS paper on its own term
- 25 September 2026: Thirteen glossary terms the evidence, living-with and molecular layers asked for, and the eight living-with drafts registered
- 25 September 2026: Colorectal: the historical trials the evidence and molecular layers cite, and targets for ten pipeline drugs
- 25 September 2026: Colorectal cancer deep spike, round one: the UK and NHS pathway across four nations with the national audit indicators, decisions, first 60 days, red cards and the adjuvant chemotherapy aid
- 25 September 2026: Red flags re-sourced: the UKONS triage tool found at its new URL, nine thresholds quote-checked against it, six redirects fixed, soft 404s caught by the weekly link check
- 25 September 2026: Colorectal: company links for the trials the registry names, and the sponsor backfill that keeps the rankings honest
- 25 September 2026: Colorectal molecular layer: 38-row genomic landscape from eight cBioPortal cohorts, sidedness as biology, the adenoma and serrated routes, CMS, immunity and ctDNA, with 47 paper records
- 25 September 2026: Colorectal cancer, the UK and NHS layer: the screening programme and its four-nation differences, the faecal immunochemical test that now governs referral, the National Bowel Cancer Audit, 13 NICE appraisals with the 2026 bevacizumab reversal, and the UK trial legacy
- 25 September 2026: Colorectal cancer deep spike: the evidence, the roadmap and the ideas
- 25 September 2026: Colorectal core, second pass: sidedness and consensus molecular subtype supplements, the screening standards source, and three claims tightened against their sources
- 25 September 2026: Colorectal: anti-EGFR rechallenge and the microsatellite-stable immunotherapy attempt
- 25 September 2026: Colorectal trials: cross-links into the records already in the corpus, and two corrections
- 25 September 2026: Colorectal cancer, living with it, care and decisions: ten decision rows, 74 appointment questions, a 19-item first 60 days checklist, six red-card sets and a NICE NG151 adjuvant decision aid
- 25 September 2026: Fold the duplicates the base colorectal record and spike carried: five history entries, seven biomarker lines, three state-of-the-art points and three open problems written twice
- 25 September 2026: Colorectal treatment layer: 38 hand-written trials from MOSAIC to ALTAIR, 661 registry trials, verified NICE and FDA approval rows, palliation
- 25 September 2026: Colorectal core layer: sourced epidemiology, the early-onset rise, risk, referral, screening, staging, pathology and prevention on the colorectal record; four subtype pages and eleven glossary terms
- 24 September 2026: LAUNCH: pancreatic spike and the cooperative-group home ticked
- 24 September 2026: Pancreatic reviewed against its sources: duplicates folded, figures settled, 1,006 links checked, mobile overflow fixed
- 24 September 2026: Pancreatic deep spike review: duplicates merged across seven files, daraxonrasib approval and NICE terminations settled, 13 paper duplicates supplemented, 47 redirected URLs rewritten, seven glossary terms and two journals, UK and tool pages lay out at 390 px; docs/PANCREATIC-QA.md
- 24 September 2026: Pancreatic cancer deep spike, round four: the molecular landscape with allele-level KRAS shares, subtype classes, precursor sequence and 82 papers
- 24 September 2026: Pancreatic molecular layer: the genomic landscape, subtypes, precursors, stroma and monitoring markers with their cohorts
- 24 September 2026: Pancreatic cancer deep spike, round three: 30 trials with outcomes, 284 registry trials, verified NICE and label rows, fifteen standard-of-care rows; Ask ranking weights curated records
- 24 September 2026: Ask concept index: inverse document frequency over curated records only; extractive recall 0.408 to 0.427, floor raised to 0.42
- 24 September 2026: Pancreatic treatment layer gates: cooperative groups under companies, pancrelipase flagged supportive, deep-dive tag described, stroma-enzyme schematic rule
- 24 September 2026: Pancreatic cancer deep spike, round two: the record extended with sourced epidemiology, risk, diagnosis and surveillance, six subtypes, 22 terms, 34 papers and a twelve-era roadmap
- 24 September 2026: Pancreatic core: classical versus basal-like (GATA6) and clinical benefit response terms for the evidence layer, high-risk individual folded into familial pancreatic cancer, disease-free survival note on the EFS term; the other requested ids resolve to existing records
- 24 September 2026: Pancreatic treatment layer: ESPAC-1 record, shorter TL;DRs, duplicate label links removed, explained-page budget note
- 24 September 2026: Pancreatic evidence: UNICANCER is a cooperative-group company, listed under companies
- 24 September 2026: Pancreatic treatment layer: 32 hand-written trials, 284 registry trials, drug approvals by regulator, standard-of-care export
- 24 September 2026: Pancreatic core: register the seven living-with glossary drafts (enzyme draft folded into pancreatic-enzyme-replacement, new-onset diabetes alias repointed), drop URLs the UK and living patches already link, subtype rows cite the neoadjuvant term rather than PRODIGE 24 so /explained/ stays under budget, audit list and stale zh summary updated
- 24 September 2026: Pancreatic cancer evidence: 34 Europe PMC paper records, a roadmap from Whipple 1935 to the 2031 registry watch, nine ideas
- 24 September 2026: Pancreatic cancer deep spike, round one: the UK and NHS pathway with the national audit findings, decisions, first 60 days, red cards and the first-treatment aid
- 24 September 2026: Pancreatic core layer: sourced epidemiology, risk factors, presentation and emergency share, diagnosis, resectability and TNM 8, pathology and precursors, surveillance programmes and outlook on the pancreatic record; six WHO subtype pages; thirteen glossary terms; five supplements
- 24 September 2026: Pancreatic cancer living with it, care and decisions: ten decision rows, 90 hand-written questions, first 60 days checklist, six red-card sets with the 111 and 999 wording, first-treatment decision aid from NICE NG85, sourced living-with notes on 26 side-effect and procedure records
- 24 September 2026: Pancreatic cancer UK and NHS page: NG12 diabetes rule, 28/31/62-day standards, NPaCA 2026 findings, 23 HPB hubs, NICE TA476/TA440/TA750/TA1052 and SMC decisions verified, PERT audit gap, EUROPAC and Precision-Panc legacy, four-nation registry figures
- 24 September 2026: Cooperative groups have one home: 35 trial groups move from institutions to cooperative-group companies with redirects
- 24 September 2026: One home for cooperative groups: 35 consortium institutions become cooperative-group companies (row 251)
- 24 September 2026: TNBC reviewed against its sources: figures reconciled, duplicates folded, 822 links checked
- 24 September 2026: Roadmap watch row: text column shrinks and wraps on phones
- 24 September 2026: TNBC QA: de-duplicate the six patches, correct KEYNOTE-522, BRCA share, NG101 1.3.6, TA992 and TROPION-Breast05, fix four dead links, roadmap and UK page fit 390 px; docs/TNBC-QA.md
- 24 September 2026: Wave 4: 99 cancer entity pages under the taxonomy rule; roadmaps page their eras; subtype pages rank below their parents in Ask
- 24 September 2026: Ask OnCo retrieval: subtype capped below its parent, provenance weight shared by both stages; extractive recall 0.403 to 0.411, floor held at 0.41
- 24 September 2026: LAUNCH: decisions and shipping of 25 Sept 2026
- 24 September 2026: Section planner test allows eight paged sections for NSCLC after the lung histologies; wave 4 pages weigh 0.7 in the Ask index
- 24 September 2026: Wave 4 cancer pages, family 7: sixteen pituitary, thymoma, salivary, cervical, vulvar and vaginal entities; roadmap Progress row
- 24 September 2026: Cancer hubs with section sub-pages, TNBC deep spike complete (core, treatments and 235 trials, molecular landscape), Ask recall repaired, route progress bar and edge caching, Methods and models glossary with 129 terms
- 24 September 2026: Roadmap pages: eras collapse behind Show era pills fed by /api/v1/roadmaps/<id>.json; watch table paged past 20; 300 KB markup budget
- 24 September 2026: Ask OnCo retrieval: drop function words and rank by kind and name in the word search; extractive recall 0.329 to 0.416, floor 0.41 with a ratchet
- 24 September 2026: Wave 4 cancer pages, family 6: fourteen rare tumour entities; cancer map SVG budget 320 KB
- 24 September 2026: TNBC treatment: reword a code comment to the page name
- 24 September 2026: TNBC treatment: LOTUS, PAKT, SCAN-B and ZEST detail, registry trials linked to subtype pages, test fixtures for the new rows
- 24 September 2026: Wave 4 cancer pages, family 5: sixteen lymphoma and leukaemia entities from WHO-HAEM5
- 24 September 2026: EntityDetail: remove the conflict markers committed with the architecture merge, drop the unused Tip import
- 24 September 2026: TNBC molecular layer: sourced genomic landscape, Lehmann and Burstein subtypes, ancestry and founder mutations, ctDNA studies, assay-specific PD-L1 and HER2-low thresholds, 55 landscape papers
- 24 September 2026: Wave 4 cancer pages, family 4: twenty colon, kidney and testicular entities; sibling linker so no new page arrives orphaned
- 24 September 2026: TNBC core: register the eight living-with glossary terms drafted by the living file, drop the brand-name aliases that hijacked Ask, trim two TL;DRs and a jargon phrase
- 24 September 2026: TNBC treatment deep dive: trial and drug records, approvals by regulator with NICE appraisal numbers, 229 registry trials, standard-of-care rows
- 24 September 2026: record-fold test: TNBC ceiling follows the new layers until the hub architecture lands, then drops to 300 KB
- 24 September 2026: CanSim terms, methods group: 58 "Methods and models" glossary terms with one-line definitions and why they appear in cancer papers; gap document gets a Done column
- 24 September 2026: CanSim terms, oncology group: 70 sourced glossary terms and the cancer-ai-vocabulary hub, 11 HGNC-sourced gene targets, TCGA cohort codes as cancer aliases, 12 data-source rows, Methods and models category
- 24 September 2026: Loading experience: navigation progress bar, route skeletons, intent prefetch on dense lists, pages hot at the edge, above-the-fold checks
- 24 September 2026: Decisions page holds 390 px: referenced-record and guideline pills truncate with tooltips, grid children may shrink
- 24 September 2026: TNBC core layer: sourced epidemiology, risk, presentation, diagnosis, pathology, staging, screening and outlook on the tnbc record; twelve subtype pages; nineteen glossary terms
- 24 September 2026: Modality hubs for twelve formats, TNBC deep spike round one (UK and NHS pathway, evidence and roadmap, decisions, first 60 days, red cards, after-chemotherapy aid), supportive care flag on 55 drugs, 22 cooperative-group records
- 24 September 2026: Geography section fits 390 px: grid items may shrink and source labels wrap
- 24 September 2026: Wave 4 cancer pages, family 3: fourteen breast histologies under breast-cancer from the WHO 2019 breast classification
- 24 September 2026: TNBC living with it, care and decisions: eleven decision rows, 77 hand-written questions, first 60 days checklist, three red-card sets with the 111 and 999 wording, after-chemotherapy decision aid, sourced living-with notes on 20 side-effect and procedure records
- 24 September 2026: TNBC UK and NHS layer: pathway page for tnbc with the screening caveat, NG12 and NG101 steps, every NICE and SMC decision including the TA992 refusal against SMC2608, R208 and M234 tests, eight UK-open trials with sites, TNT, POSH/OlympiA and PARTNER legacy, registry figures read from PHS, WCISU and NICR downloads, Breast Cancer Now and three researcher records, named gaps
- 24 September 2026: WIP: tnbc-core spike draft before merging main
- 24 September 2026: Cooperative groups as company records:
cooperative-groupcompany type with browser facet, glyph pill and tooltip; 22 group records (GORTEC, German CLL Study Group, French Sarcoma Group, AGO, AIO, MRC CTU, HORG, DPCG, DBCG, DAHANCA, GERCOR, ISG, SSG, EMN, IFM, ALFA, AMC, OCOG, KGOG, SARC, FIL, FILO) linked to 41 corpus trials as sponsor; sponsor aliases carry their ids and the IFM and KGOG mis-resolutions are fixed; the trials fetchers link and never give products to them - 24 September 2026: Supportive care medicines:
supportivedrug flag on 55 records, "Supportive care" pill with glyph and tooltip, Purpose facet on /drugs/, excluded from the home treatments count, the product rankings and the treatment references on standard-of-care rows; EMA and FDA fetchers flag candidates by a stated indication rule - 24 September 2026: Cancer records as a hub with ten sections: registry, section pages, shared strip, sections.json, budgets and deep-link tests
- 24 September 2026: Wave 4 cancer pages, family 2: ten lung histologies under nsclc from the WHO 2021 thoracic classification
- 24 September 2026: Front navigation: the kinds drawn as a linked graph, the body map as the entry point on phones; ship chain builds on Vercel only
- 24 September 2026: TNBC evidence: 45 papers verbatim from Europe PMC (guidelines, receptor and basal-like discovery, BRCA1 founder mutations, disparities, subtypes, pCR and RCB, platinum, CREATE-X, OlympiA updates, PD-L1 assays, TILs, TROPION-Breast02, CAPItello-290, HER2-low, ctDNA), tnbc-roadmap with 14 eras and a registry watch list to 2033, nine ideas
- 24 September 2026: Modality lens: /modalities/ and twelve format hubs assembling what the corpus records per shape of medicine
- 24 September 2026: Home page: the counts grid becomes a living graph of the kinds, with the body map as the entry point on phones
- 24 September 2026: Wave 4 cancer pages, family 1: entity pages under the seven parents without subtype records, taxonomy rule in docs/CANCER-PAGES.md
- 24 September 2026: LAUNCH: the ship chain no longer builds locally; Vercel builds and the chain verifies the alias
- 24 September 2026: LAUNCH: issue and PR sweep of 24 Sept, checkpoints, target statuses, ivermectin
- 24 September 2026: Ivermectin: the trial evidence so far, with the label toxicity table and the papers under expressions of concern stated
- 24 September 2026: Ivermectin evidence page: drug record with label toxicity table, four registry trials, 22 papers with expressions of concern and retraction stated, compact fenbendazole and mebendazole records, per-file citation test
- 24 September 2026: Checkpoint families mapped with immune and cell-cycle hubs, 26 new targets; 31 reader proposals applied as 23 trial records and 27 papers; Cancersim terms gap filed
- 24 September 2026: Cancersim terms gap: 378 of 504 terms not yet in OnCo, listed by bucket with the decision the methods terms need; IMPROVEMENTS row 250
- 24 September 2026: Target specificity and distribution on 904 targets with where each is found, gallbladder decision aids and comparison, world map of gallbladder cancer rates, six EU register rows decided by hand, PALD1 rewritten
- 24 September 2026: Issue 98: LITESPARK-011 (NCT04586231) readout written onto the record: Lancet 2026 dual primary progression-free and overall survival rows and toxicity as stated in the abstract, ASCO GU 2026 response, duration and treatment-related toxicity rows marked as conference data, Motzer 2026 paper record linked, plain-English summary, simple sentence and Chinese TL;DR
- 24 September 2026: Issue 97: INSITE (NCT03686215) trial record for pegulicianine with the NEJM Evidence 2023 coprimary endpoints and the existing Smith paper linked, pegulicianine.trials wired; status mixed because the sensitivity threshold was not met
- 24 September 2026: Issue 96: HBI0101 / NXC-201 multiple myeloma phase 1 (NCT04720313) trial record with the Haematologica 2023 response, survival and cytokine release endpoints, Asherie 2023 paper record, nxc-201-car-t wired to the trial and to multiple myeloma
- 24 September 2026: Issue 95: ScreenTrustCAD (NCT04778670) trial record for Lunit INSIGHT MMG with the Lancet Digital Health 2023 paired-reader detection endpoints, Dembrower 2023 paper record, lunit-insight-mmg.trials wired
- 24 September 2026: Issue 94: PSMA-PreRP (NCT03368547) trial record for Illuccix and 68Ga-PSMA-11 with the JAMA Oncology 2021 nodal accuracy endpoints, Hope 2021 paper record, illuccix.trials and ga68-psma-11.trials wired
- 24 September 2026: Issue 80: Vistogard Studies 1 and 2 (NCT01432301) trial record and Cancer 2017 paper; uridine-triacetate.trials wired with label link
- 24 September 2026: Issue 79: Study 0201 (NCT00003991) trial record and Blood 2006 paper; histamine-dihydrochloride.trials wired
- 24 September 2026: Issue 78: Study 201 (NCT00168064) trial record and JAMA Dermatology 2013 paper; mechlorethamine wired to the trial and to cutaneous-t-cell-lymphoma
- 24 September 2026: Issue 77: Study 2005-01 (NCT00358501) trial record and Blood 2016 paper; defibrotide.trials wired with label link
- 24 September 2026: Issue 76: CT041-ST-01 (NCT04581473) enriched in place with Lancet 2025 outcome and paper; satricabtagene-autoleucel.trials wired, false rivoceranib link and stale skip dropped
- 24 September 2026: Issue 75: MSB-GVHD001 (NCT02336230) trial record and BBMT 2020 paper; remestemcel-l.trials wired
- 24 September 2026: Issue 93: ROMAN (NCT03689712) trial record for avasopasem manganese with the eClinicalMedicine 2025 severe oral mucositis endpoints, Anderson 2025 paper record, avasopasem-manganese.trials wired; status mixed because the paper records the FDA complete response
- 24 September 2026: Issue 72: FOCUS (NCT02678572) enriched in place with Ann Surg Oncol 2024 outcomes; hepzato.trials wired with paper and label links
- 24 September 2026: Issue 71: eXalt3 (NCT02767804) enriched in place with JAMA Oncology 2021 outcomes; ensartinib cites the paper and label; stale zh TL;DR dropped
- 24 September 2026: Issue 70: Act.In.Sarc (NCT02379845) trial record and Lancet Oncology 2019 paper; nbtxr3.trials wired
- 24 September 2026: Issue 69: ROCKstar (NCT03640481) trial record and Blood 2021 paper; belumosudil.trials wired
- 24 September 2026: Issue 92: VISION (NCT02864992) enriched in place for tepotinib with the Paik NEJM 2020 response, duration and toxicity outcomes and the existing paper linked; capmatinib-tepotinib.trials wired to GEOMETRY mono-1 and VISION; geometry-mono-1 leads capmatinib.trials; simple sentence and Chinese TL;DR follow the record
- 24 September 2026: Issue 68: ARCHER 1050 (NCT01774721) enriched in place with separate Wu 2017 and Mok 2018 rows and papers; dacomitinib cites both
- 24 September 2026: Issue 67: ASCEND-4 (NCT01828099) enriched in place with Lancet 2017 outcomes and paper; ceritinib cites the paper
- 24 September 2026: Issue 66: CK-301-101 (NCT03212404) trial record and JITC 2023 paper; cosibelimab.trials wired, label and paper links replace the generic FDA listing
- 24 September 2026: Issue 65: ALTA (NCT02094573) trial record and JCO 2017 paper; brigatinib.trials wired to ALTA and ALTA-1L
- 24 September 2026: Glossary and record pages: checkpoint disambiguation term owns the bare word, Checkpoint families pills on target, term, pathway, technology and mechanics stage pages
- 24 September 2026: Checkpoint hubs: /checkpoints/ with a pill switch, /checkpoints/immune/ with the interactive synapse, /checkpoints/cell-cycle/ with the cell-cycle ring, class tables, JSON companions, nav entry in nine languages
- 24 September 2026: Checkpoint map: typed taxonomy of immune and cell-intrinsic checkpoints, 26 new targets from HGNC and UniProt, derived rows and tests
- 24 September 2026: Issue 91: Alliance A071401 (NCT02523014) trial record for GSK2256098 with the JCO 2023 six-month progression-free survival endpoints, Brastianos 2023 paper record, gsk2256098.trials wired
- 24 September 2026: Issue 90: PREEMPT CRC (NCT04369053) trial record for SimpleScreen CRC with the JAMA 2025 accuracy endpoints, Shaukat 2025 paper record, simplescreen-crc.trials wired
- 24 September 2026: Issue 89: TRANSCEND (NCT05774756) trial record for setmelanotide with the NEJM 2026 body-mass index and hunger endpoints, Miller 2026 paper record, setmelanotide refreshed with the 19 March 2026 US approval for acquired hypothalamic obesity and a CORRECTIONS row
- 24 September 2026: Issue 88: UX023T-CL201 (NCT02304367) trial record for burosumab with the JBMR 2021 serum phosphorus and fracture-healing endpoints, Jan de Beur 2021 paper record, burosumab.trials wired
- 24 September 2026: Issue 87: PATRICIA (NCT00122681, HPV-008) trial record for the bivalent HPV vaccine with the Lancet 2009 vaccine-efficacy endpoints, Paavonen 2009 paper record, hpv-bivalent-vaccine.trials wired
- 24 September 2026: Issue 85: XM01-22 (ISRCTN08063129) trial record for epoetin theta with the Archives of Drug Information 2011 haemoglobin response and transfusion endpoints, Tjulandin 2011 paper record, epoetin-theta.trials wired
- 24 September 2026: Issue 84: rolapitant Study 3 (NCT01500226, TS-P04834) trial record with the Lancet Oncology 2015 delayed-phase complete response endpoint, Schwartzberg 2015 paper record, rolapitant.trials wired and label links made explicit
- 24 September 2026: Issue 64: PALD1 (paladin) rewritten from the primary papers instead of the proposed GeneCards text; hand-written target records from reader proposals live in src/data/targets-reader-edits.ts and replace the generated gene record of the same id
- 24 September 2026: PR 74 residue decided by hand: six EU rows from the EMA register pages (olaratumab revoked 2019, pixantrone expired 2024, alitretinoin withdrawn 2021, cediranib application withdrawn 2016, ensartinib and senaparib positive CHMP opinions as under review); pixantrone status corrected to withdrawn, IMP4927 identified as senaparib (Sepalna) with PARP target and aliases, cediranib aliases; 15 rows closed as non-cancer medicines or pending
- 24 September 2026: Issue 83: XM22-03 (EudraCT 2009-015999-10) trial record for lipegfilgrastim with the BMC Cancer 2013 cycle 1 neutropenia endpoint, Bondarenko 2013 paper record, lipegfilgrastim.trials wired, id allowlisted as a phase 3 without an NCT
- 24 September 2026: Issue 82: MNTX 302 (NCT00402038) trial record for methylnaltrexone with the NEJM 2008 coprimary laxation endpoints, Thomas 2008 paper record, methylnaltrexone.trials wired and label links made explicit
- 24 September 2026: Gallbladder cancer geography: GLOBOCAN 2022 rates by country and sex for 185 countries, a reusable CancerGeography choropleth with incidence, mortality and sex pills, the high-burden regions with their papers, Chile's GES prophylactic cholecystectomy programme, India's NCRP registry rates and Japan's registry and guideline practice, prevention evidence, India and Chile spotlights, a geography.json companion and a gallbladder section on /countries/in/
- 24 September 2026: Target specificity explainer links the Human Protein Atlas collection record, whose licence now reads CC BY-SA 3.0
- 24 September 2026: Target specificity tests: enums cover every populated value, every row has a note and an https source, the graph carries the fields, HER2 reads tumour-associated and many types with a tumour-agnostic mark, BCR::ABL1 tumour-specific and one type, CD19 lineage antigen, PD-1 immune; browser facet counts match the data; the explainer and the pills render
- 24 September 2026: Target specificity in the pages: pills with glyphs and tooltips on target pages, a "Where it is found" section from the Human Protein Atlas rows, specificity and cancer-type facets on the target browser and the gene hub, and the explainer at /targets/specificity/
- 24 September 2026: Target specificity: blood-cancer family regex no longer swallows "(all types)" names, family names for the merged blood families, own-record sources for targets the atlases do not cover
- 24 September 2026: IMPROVEMENTS: rows 150 to 249, the 100 upgrade ideas of 24 September 2026
- 24 September 2026: Target specificity and distribution: schema, fetcher and data for 904 targets with an approved or clinical-stage drug
- 24 September 2026: Record pages stay inside a phone screen at 390 px; 130 more trials carry posted registry results
- 24 September 2026: Gallbladder decision aids and comparison: polyp aid on the 2022 European guideline, incidental cancer aid on AHPBA, Søreide, Ethun and CAPBIL, gallbladder compared with cholangiocarcinoma and ampullary cancer
- 24 September 2026: Record pages fit a 390 px phone and lose the Tabs key warning: grid children shrink (min-w-0 on Neighbours and What changed cards, *:min-w-0 on EntityDetail grids), GuidelineChip and DrugChip wrappers cap at max-w-full, tables in EntityDetail, InvestorPanels, StartupPanels, BiomarkerDetail, PrevalenceTable, ToxicityTable, AccessTable and ResearchOutput scroll inside ScrollRow with the year bars; each tab's content is a fragment keyed on the tab id so Flight no longer hands Tabs a keyless array; one record of every kind is a width-only check in scripts/mobile-audit.ts
- 24 September 2026: Registry passes over the gallbladder spike: outcomes for every NCT trial without its own, status re-read for all 4,102 NCT trials, key papers for 10 gallbladder trials
- 24 September 2026: LAUNCH: gallbladder deep spike of 24 Sept 2026
- 24 September 2026: Gallbladder cancer deep spike, final round: review reconciled the six facets to their sources, Wales and Northern Ireland figures, Cancer Drugs Fund status, prescription and benefit rules, lighter cancer pages
- 24 September 2026: Gallbladder deep spike review: duplicate terms, trials and history entries become supplements, HER2 and NICE figures reconciled, dead and redirected links fixed, backlinks for the ctDNA roadmap and the chemo-immunotherapy pairing, long relation lists capped with deep links so the cancer page drops from 997 KB to 652 KB, QA checklist in docs/GALLBLADDER-QA.md
- 24 September 2026: Gallbladder UK layer, second pass: Wales and Northern Ireland registry figures with stage, Scotland checked and found not to publish C23, CDF list v1.365 status on every biliary drug, four-nation prescription and special-rules benefit pages, GLH turnaround statements, CAPBIL tied to BILCAP, Hassan Malik record
- 24 September 2026: Gallbladder cancer deep spike, round three: treatments and trials, 131 registry trials, approval rows with NICE numbers, standard-of-care rows
- 24 September 2026: Gallbladder evidence: ARTEMIDE-Biliary01 points at its existing registry record instead of a second trial record
- 24 September 2026: Gallbladder cancer deep spike: the record rewritten with UK and world figures, eight subtypes, molecular landscape, UK and NHS pathway page, 40 papers, roadmap and ideas, decisions, first 60 days and red cards; weekly bot refreshes merged
- 24 September 2026: Gallbladder cancer treatments and trials: surgery, adjuvant, systemic, HER2 and palliation records with 131 registry trials
- 24 September 2026: Gallbladder cancer deep spike, first round: the record rewritten with UK and world figures, eight subtypes, molecular landscape, decisions, first 60 days and red cards
- 24 September 2026: Citation counts for the gallbladder evidence papers
- 24 September 2026: Gallbladder cancer roadmap, ideas, guideline and trial papers, terms and history
- 24 September 2026: Gallbladder cancer evidence: surgical, staging, UK, polyp, prevention, HER2 and ctDNA papers from Europe PMC
- 24 September 2026: UK and NHS page per cancer: /cancers/<id>/uk/, cancer-page pill, sitemap and JSON companion
- 24 September 2026: Gallbladder cancer: UK and NHS layer data, HPB centres, AMMF and UK trialists
- 24 September 2026: Gallbladder cancer record rebuilt with sourced UK, world and US figures, TNM 8th edition in plain words, risk factors with evidence, screening rules and patient FAQ; eight subtype pages and ten glossary terms
- 24 September 2026: Spike patches reach every cancer record wherever it lives, and fail loudly when the cancer id is missing; gallbladder landscape guard test
- 24 September 2026: Spike patches also merge into NCI coverage cancer records
- 24 September 2026: Gallbladder cancer molecular layer: sourced genomic landscape, regional cohorts, premalignant sequence, immune findings, HER2 testing, 30 landscape papers; spike supplements onto records other files own
- 24 September 2026: Gallbladder cancer: cancer-scoped red cards, dated first-60-days checklist, incidental-cancer journey
- 24 September 2026: Pipeline engine: a biparatopic antibody with one declared target resolves both arms at high confidence; zovodotin is a named auristatin payload
- 24 September 2026: Gallbladder cancer living-with spike: decision rows, question set and glossary records
- 24 September 2026: chore: weekly roadmap registry check (public/roadmap-watch.json)
- 24 September 2026: chore: refresh pulse, abstract and citation snapshots (#86)
- 24 September 2026: chore: refresh institution research output from OpenAlex (#81)
- 24 September 2026: chore: EU regional rows read from the EMA register pages (#73)
- 23 September 2026: Top bar fits at 1280 px with a classic scrollbar
- 23 September 2026: LAUNCH: owner asks of 23 Sept 2026
- 23 September 2026: Drugs browser fits its card with capped cells and clearer approval years; NHS-Galleri performance paper, trial outcomes and Galleri test page
- 23 September 2026: Header fits a 1280 px window with a classic scrollbar: star count folds into its icon, tighter nav gaps and 13 px labels between xl and 2xl
- 23 September 2026: NHS-Galleri test-performance paper (Nature Medicine, 22 Sept 2026) as a paper record, trial rebuilt on the registry and the abstract, result on Galleri, MCED and the ctDNA roadmap
- 23 September 2026: Drugs browser fits at 1280 and 1440: capped list cells with a "+N more" pill, Approved as first year plus muted latest with region flags, results tables scroll inside their card only when measured too wide
- 23 September 2026: Biomarker readouts under their parent genes at /biomarkers/, genome hub pages its genes
- 23 September 2026: Gene hub pages its role sections: first 30 genes per role in the HTML, the rest from one tables file, role and evidence deep links over the full set
- 23 September 2026: Proposals bot merges register-verified rows itself, mechanics of cancer rebuilt with 56 stage pages, mobile patterns for views where a control drives a visual
- 23 September 2026: Regenerate target cross-references for the seven new parent targets (HGNC and ChEMBL, 23 Sept 2026)
- 23 September 2026: Dependency map gets a touch path, and wide matrices scroll inside their own box
- 23 September 2026: Biomarker pages: /biomarkers/ browser with gene, measurement, cancer and approval facets; readout pages with a Part of strip; target, drug, term and tumour-test pages link their readouts
- 23 September 2026: Biomarker readouts: 80 records under 40 parent genes, thresholds quoted from FDA labels and the companion diagnostic list
- 23 September 2026: Add the biomarker kind: schema, KIND_META, glyph, colours, nav and kind labels in nine languages
- 23 September 2026: Mechanics atlas: a page per stage and a light journey hub
- 23 September 2026: Cancer gene layer of 1,447 genes, open-source oncology map, evidence-backed combination proposals on the engine, daily spotlight, iodine target correction
- 23 September 2026: LAUNCH: proposals bot, what merges itself and what waits
- 23 September 2026: Nightly proposals: auto branch squash-merged after the gates, review PR labelled needs-review with a reason on every EMA row
- 23 September 2026: Proposals bot decides EU rows from the EMA medicine pages: page status, exact attribution, biosimilar rule, drift check, apply script
- 23 September 2026: Regional approvals io helper: parse and write the hand-written file with a round-trip test, and R() takes a source
- 23 September 2026: Two-column tools get a phone layout: sticky preview, Choose and View pills, inline results
- 23 September 2026: Cancer genes, tier 4: 389 genes associated with cancer without a proven role
- 23 September 2026: Cancer genes, tier 3: 332 drivers called by cohort mutation analysis
- 23 September 2026: Cancer genes, tier 2: 507 genes with clinical evidence on their variants
- 23 September 2026: Cancer genes, tier 1: 219 genes with an approved or late-stage drug recorded against them
- 23 September 2026: Cancer gene layer: target roles, evidence tiers and sources, fetch-cancer-genes script, genome hub and browser facets
- 23 September 2026: Home spotlight rotates by kind each day: one hero record per kind (most connected), build day's set in the HTML, reader's day swapped in from /api/v1/spotlight.json without layout shift
- 23 September 2026: ADC payload fields and setidegrasib note: record only what the records say
- 23 September 2026: Open pipeline engine, tag power search pages and full-width tabs, Edge type and For you filters, API licence wording, For me browser-only notice
- 23 September 2026: Open-source catalogue tests: unique ids, https URLs, SPDX or placeholder licences with notes, every corpus id exists, 200 sources on the generation date, curated entries generated or explained
- 23 September 2026: Open source in oncology page: paged browser with category, licence, language, openness and activity facets, intro on how oncology is done in the open, and cross-links from technology, collection, organisation and data-source pages
- 23 September 2026: Open-source oncology catalogue: schema, curated list of 379 projects and the fetcher that reads licence, stars and dates from the GitHub API
- 23 September 2026: Radioactive iodine no longer linked to SSTR2: I-131 enters thyroid cells through the sodium-iodide symporter, which has no target page yet
- 23 September 2026: Document the open pipeline: how proposals are scored, searched and contributed
- 23 September 2026: Sixty combination proposals, each searched against trials, papers and patents
- 23 September 2026: Schema for combination proposals: a scored, evidence-backed cell of the modular-drug grid
- 23 September 2026: api layout: drop the entries duplicated by the engine merge
- 23 September 2026: Record pages: full-width tab strip above both columns; tag chips open /tagged/ power-search pages
- 23 September 2026: API page licence wording matches the footer and about page; For me says it is browser-only with a signed-in version coming
- 23 September 2026: Open drug engine: every medicine taken apart into its modules, and the permutation grid per format with each cell classified from records
- 23 September 2026: Edge: filter by type or For you, with URL state, per-cancer deep links and per-type feeds
- 23 September 2026: Search ranks cancers and treatments first and groups results by kind
- 23 September 2026: Search ranks cancers and treatments above journals and papers, with kind-grouped dropdowns
- 23 September 2026: Top bar without the tagline, with the weekly bot refreshes merged
- 23 September 2026: Top bar without the tagline
- 23 September 2026: Top bar: drop the tagline beside the wordmark; it took space the navigation needs
- 23 September 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE) (#61)
- 23 September 2026: chore: check regional approvals against the EMA register (#60)
- 23 September 2026: chore: refresh preprint tracker from Europe PMC (#59)
- 23 September 2026: chore: refresh FDA approvals feed (OCE notifications, openFDA drugsfda) (#58)
- 23 September 2026: chore: weekly citation link check (#57)
- 22 September 2026: Health gauges explain people without papers by role and exempt the closed section list
- 22 September 2026: Kind-size gauge holds open kinds only: the 19 treatment fronts are a closed OnCo taxonomy and are named in the note
- 22 September 2026: People-papers gauge counts roles that produce no papers as explained: 1,528 of 1,547 with a note on who is still without
- 22 September 2026: LAUNCH: chains 101 to 104 ticked
- 22 September 2026: Kind browser pages ship 60 rows and load the rest on demand, 402 registry trials for drugs and technologies, glossary terms without a Wikipedia article say so
- 22 September 2026: Kind browsers page their rows: first 60 in the HTML, the rest from /api/v1/tables/kind-<route>.json
- 22 September 2026: Content roadmap: wave 5 trial run recorded, headline numbers refreshed from content:gaps
- 22 September 2026: Wave 5 technologies: 32 technologies without a trial gain 65 registry trials and 7 corpus links from ClinicalTrials.gov
- 22 September 2026: fetch-entity-trials: hold technologies whose aliases name something else, stop words for ex vivo, Catalyst, STRIDE and hormone names
- 22 September 2026: Wave 5 drugs: 142 drugs without a trial gain 337 registry trials and 19 corpus links from ClinicalTrials.gov
- 22 September 2026: 75 glossary terms marked wikipediaChecked 2026-09-22; NO_ARTICLE comment lists retired
- 22 September 2026: fetch-entity-trials: ClinicalTrials.gov trials for drugs and technologies without one (wave 5, second half)
- 22 September 2026: Terms record a checked-and-absent Wikipedia state: wikipediaChecked field, gauge counts it as explained, page says so
- 22 September 2026: fetch-term-wikipedia: Wikipedia links for glossary terms, exact title or redirect match with a sense check
- 22 September 2026: Paper pages for 736 cited DOIs, 1,381 bare references now link to them
- 22 September 2026: Wave 7 batch 4: the last 155 paper pages for cited DOIs, 736 in all, 1,161 citing records linked; Progress row
- 22 September 2026: fetch-cited-papers: a preprint is "posted on bioRxiv", not "published in bioRxiv (preprint)"
- 22 September 2026: Trial statuses follow the registry with dated notes, iobenguane records merged
- 22 September 2026: Wave 7 batch 3: 194 more paper pages for cited DOIs, 581 in all, 1,042 citing records linked; intismeran autogene gains its aliases
- 22 September 2026: Wave 7 batch 2: 192 more paper pages for cited DOIs, 387 in all, 905 citing records linked
- 22 September 2026: Wave 7 batch 1: 195 paper pages for the most-cited DOIs without one, 785 citing records linked
- 22 September 2026: fetch-cited-papers: name citing pages by kind and count only, no year in TL;DR or id
- 22 September 2026: Registry status data: 13 trial status changes from 3,542 ClinicalTrials.gov records (active -> completed 5, active -> recruiting 3, recruiting -> active 2, completed -> withdrawn 2, active -> withdrawn 1) with dated notes and why-stopped text; iobenguane-i-131 (Azedra) merged into i131-mibg with its approval, brand, aliases, links and a redirect stub
- 22 September 2026: Registry status pass: scripts/fetch-registry-status.ts reads overallStatus, whyStopped and the registry dates for every trial with an NCT id and writes src/data/trial-registry-status.ts, applied in src/data/index.ts through applyRegistryStatus with a dated note; result statuses kept, hand-written statuses newer than the registry never downgraded; iobenguane-i-131 listed as a duplicate of i131-mibg in dedupe MERGES
- 22 September 2026: Wave 7 fetcher for cited DOIs: scripts/fetch-cited-papers.ts writes a paper page per DOI a record cites without one
- 22 September 2026: Explained page pages its sections, four duplicate companies and one duplicate drug merged with redirects
- 22 September 2026: Page /explained/ sections at 10 rows: 1,135 KB to 561 KB of markup, budget lowered to 600 KB
- 22 September 2026: LAUNCH: content waves through chain 100
- 22 September 2026: Merge five duplicate records: Orca Biosystems into orca-bio, InxMed (Shanghai) into inxmed, Cellectis S.A. into cellectis, the second Valius Sciences into valius, and the gap-fill nogapendekin alfa inbakicept into nogapendekin-alfa; trials, cancers, drugs, investors, aliases, links and a logo move to the kept records, 30 references repointed, sponsor aliases updated, stale simple text and translations dropped, redirects and static stubs added; biocon/biocon-biologics, jw-pharmaceutical/jw-therapeutics, astrazeneca/fusion-pharma and gtx/oncternal-therapeutics reviewed and kept apart
- 22 September 2026: Duplicate-record finder and merger for companies: scripts/dedupe-companies.ts flags pairs by normalised name (legal suffixes, descriptors and city words stripped), shared website domain, or shared Wikidata or Wikipedia identifier, prints hand-reviewed MERGE and SKIP verdicts, and with --apply moves the loser's fields onto the winner, removes the loser literal, rewrites every reference across src/data (dropping duplicates inside id arrays, renaming or dropping keyed simple, translation and wikidata entries), moves or deletes the logo and registers the redirect build-redirect-stubs.ts expects; institutions and drugs are report-only unless listed as obviously identical; the source-editing helpers in scripts/orphan-links.ts are exported for reuse
- 22 September 2026: Papers for people and ideas, trials for ideas and drugs for companies from wave 6
- 22 September 2026: Content roadmap: wave 6 progress row (people without a paper 318 to 300, ideas without a key paper 1,104 to 1,026, ideas without a trial 1,047 to 1,044, companies without a drug 720 to 718) with what was held back and why
- 22 September 2026: Wave 6 company drugs: 2 companies gain a drug through the ClinicalTrials.gov lead-sponsor field (Impact Therapeutics IMP4927, R-Pharm RPH-051), each verified on the registry record; 75 other sponsors held back because their corpus trials name only comparators with a maker on record
- 22 September 2026: Registry results for 144 trials, 24 more standard-of-care trials with outcomes, papers and standard-of-care rows linked
- 22 September 2026: Wave 6 idea evidence: 78 ideas gain key papers (124 new Europe PMC records, 98 existing reused) and 3 gain trials (4 ClinicalTrials.gov phase 2 or 3 records written, 4 corpus trials linked), matched on the drug or target the idea's text names plus its cancer
- 22 September 2026: heavy-pages test: explained budget follows the corpus after the trial waves, with the paging rule for the next rise
- 22 September 2026: Content gaps: the trial-acronym measure treats the programme stem before a hyphen as a known trial name; roadmap notes the 33 remaining tokens are all in the wave SKIP list
- 22 September 2026: Content wave 3, rare cancers: FIRSTMAPPP, InPACT, GETUG 13, ADIUVO, ADIUVO-2, TROPHIMMUN and BALLAD, 4 with structured outcomes, 4 primary papers, 13 standard-of-care rows linked
- 22 September 2026: Content wave 3, myeloma: DRAMMATIC (SWOG S1803, MRD-guided maintenance after transplant) recorded from the registry and linked from the myeloma maintenance row; NCI sponsor-of-record institution links removed across the wave
- 22 September 2026: Content wave 3, endometrial: RAINBO programme (four molecular-class trials including POLEmut-BLUE de-escalation) recorded from the registry; POLE-ultramutated standard-of-care row linked
- 22 September 2026: Roadmap Progress: wave 7 registry outcomes row (144 of 2,845 ingested trials gain 272 outcome rows from 153 records with posted results; 114 requests)
- 22 September 2026: Wave 7 data: registry outcomes for the first 2845 registry-ingested trials by family burden (144 trials with 272 outcome rows from 153 records with posted results)
- 22 September 2026: Content wave 3, ovarian: AURELIA (bevacizumab with single-agent chemotherapy in platinum-resistant ovarian cancer) with structured outcomes and its JCO 2014 paper; two standard-of-care rows linked
- 22 September 2026: Wave 7 data: registry outcomes for the first 2500 registry-ingested trials by family burden (144 trials with 272 outcome rows from 153 records with posted results)
- 22 September 2026: Content wave 3, head and neck: CONTINUUM (sintilimab added to induction-concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma) with structured outcomes and its Lancet 2024 paper; standard-of-care row linked
- 22 September 2026: Wave 7 data: registry outcomes for the first 2000 registry-ingested trials by family burden (111 trials with 209 outcome rows from 117 records with posted results)
- 22 September 2026: Wave 6 people papers: 18 people gain up to three most cited papers each from Europe PMC by author and affiliation (46 new paper records, 6 existing reused), administrators filtered by role before searching, 2 ambiguous names skipped with reasons
- 22 September 2026: Content wave 3, colorectal: CAPP2 (aspirin in Lynch syndrome, 10-year follow-up) with structured outcomes and its Lancet 2020 paper; Lynch syndrome standard-of-care row linked
- 22 September 2026: Wave 7 data: registry outcomes for the first 1500 registry-ingested trials by family burden (85 trials with 171 outcome rows from 91 records with posted results)
- 22 September 2026: Wave 7 data: registry outcomes for the first 1000 registry-ingested trials by family burden (61 trials with 126 outcome rows from 65 records with posted results)
- 22 September 2026: Content wave 3, lung: IMpower010 is the existing registry record nct02486718, which gains the IMpower010 alias, its positive status and disease-free survival outcomes from the registry results section and the Lancet 2021 report; JCOG0802 skipped (UMIN only)
- 22 September 2026: Content wave 3, anal family: ANCHOR, POD1UM-303/InterAACT-2, InterAACT and NCI9673 with structured outcomes, 5 primary papers, 6 standard-of-care rows linked
- 22 September 2026: Explained page: the Open explanation pill carries only its label; glyph and Close state move to CSS; row classes and cross-reference titles shortened
- 22 September 2026: Content wave 3, sarcoma family: ACTG A5263/AMC 066 (paclitaxel against etoposide or bleomycin-vincristine with antiretroviral therapy for AIDS-associated Kaposi sarcoma) with structured outcomes and its Lancet 2020 paper; Progress table rows for gastric, pancreatic and sarcoma
- 22 September 2026: Content wave 3, pancreatic family: 7 standard-of-care trials (ESPAC-3, ESPAC-4, CONKO-001, NORPACT-1, LAP07, ESPAC-5, PRECEDE), 6 with structured outcomes, 6 primary papers, 7 standard-of-care rows linked
- 22 September 2026: LAUNCH: chains 97 and 98 ticked
- 22 September 2026: Wave 7 data: registry outcomes for the first 500 registry-ingested trials by family burden (39 trials with 78 outcome rows from 40 records with posted results)
- 22 September 2026: Wave 7 script: fetch-registry-outcomes.ts copies structured outcomes from the ClinicalTrials.gov results section into a side file merged by index.ts
- 22 September 2026: Content wave 3, gastric family: CLASSIC (adjuvant CAPOX after D2 gastrectomy) with structured outcomes and two primary papers; SKIP list extended for UMIN- and ISRCTN-only trials
- 22 September 2026: Wave 1 trial papers from Europe PMC, wave 3 standard-of-care trials, wave 5 targets and EMA products and sponsors, seven heavy table pages and idea rankings load rows on demand
- 22 September 2026: Paged tables: the heavy StaticTable pages carry 30 rows and fetch the rest from /api/v1/tables/
- 22 September 2026: Content wave 3: structured outcomes for 8 hand-written trials from the ClinicalTrials.gov results section (ARANOTE, CheckMate 915, PACIFIC-2, INTELLANCE-1, ATEMPT, ASPEN, DESTINY-Gastric02, AREN0532); roadmap Progress notes the families not reached
- 22 September 2026: Content wave 3, lymphoma family: 7 standard-of-care trials (FoRT, GALLIUM, RELEVANCE, TRIANGLE, SYMPATICO, BMT CTN 0803, PTLD-1), all with structured outcomes, 7 primary papers, 9 standard-of-care rows linked
- 22 September 2026: Content roadmap: wave 5 progress row (targets 30 to 0, EMA products 12 to 0, sponsor companies 21 to 15) with what was not written and why
- 22 September 2026: Wave 5 sponsor companies: 6 trial sponsors and 2 EMA authorisation holders from Wikidata and the ClinicalTrials.gov sponsor field (Criterium, Artios Pharma, Ambrx, Nerviano Medical Sciences, Qurient, Immunovaccine, Grünenthal, 4SC); drugs and companies waves registered
- 22 September 2026: Wave 5 EMA products: 7 register products written from their EPAR pages (crisantaspase, burosumab, epoetin theta, human normal immunoglobulin, fentanyl, resminostat, Tacquell), 3 matching faults fixed with aliases, vedolizumab excluded
- 22 September 2026: Wave 5 targets: 26 pages for the symbols two or more drug records name without a target page (NRAS, CD28, HLA-A, MPL, SHP2, STAT5, IKZF1, JAK1, CD80, ABL1, FAK, IKZF3, PTCH1, CD137, HIF-1α, IDO1, BRD4, IRF4, B7-H4, TET2, NF1, ACVR1, HOXA9, MEIS1, BIM, BAX)
- 22 September 2026: Content wave 3, childhood family: 9 standard-of-care trials (ANBL1221, ANBL0531, ANBL17P1, AEWS0031, SIOPEL-3, SIOPEL-4, AGCT1531, AHOD1331, EuroNet-PHL-C2), 7 with structured outcomes, 6 primary papers, 11 standard-of-care rows linked
- 22 September 2026: Content wave 3, brain and CNS family: 10 standard-of-care trials (ACNS1123, ACNS0122, ACNS0333, ACNS0121, NOA-08, SJMB12, ACNS1422, IELSG32, MATRix/IELSG43, INTUITT-NF2), 8 with structured outcomes, 8 primary papers, 12 standard-of-care rows linked
- 22 September 2026: Content wave 3, leukaemia family: 18 standard-of-care trials with registry records and structured outcomes, 12 primary papers, standard-of-care rows linked
- 22 September 2026: Fetched paper records link only their trial and journal; wave 1 progress row; citation counts for the new papers
- 22 September 2026: Idea rankings page carries the first 30 rows of each view and fetches the rest per view from /api/v1/ideas/rankings/<view>.json
- 22 September 2026: Prostate trials: key papers from Europe PMC for the prostate family
- 22 September 2026: Skin trials: key papers from Europe PMC for the skin family
- 22 September 2026: Colorectal trials: key papers from Europe PMC for the colorectal family
- 22 September 2026: Breast trials: key papers from Europe PMC for 77 trials, 85 new paper records, 22 long-term follow-ups
- 22 September 2026: Lung trials: key papers from Europe PMC for 125 trials, 134 new paper records, 25 long-term follow-ups
- 22 September 2026: Cancer map DAG, every hand-written table on the shared header filter, explained page loads explainer bodies on demand, 3,056 corpus-only cross-links
- 22 September 2026: GuidelineConcordance keeps the guideline body's website link: a small external-link glyph beside each stance chip in the row's cell (sibling anchor, Tab-reachable, tooltip "Open the body's website"), with the test asserting one per body cell and no nested anchors
- 22 September 2026: Wave 2 corpus-only joins applied: 3,056 links from fields the records already carry, links still to make down from 12,295 to 10,335 Trial to technology 2,743 links on 1,739 trials (modality technologies of the studied agents); technology to trial 211 links, 26 technologies gaining their first trial; idea to trial 133 links on 30 ideas and idea to key paper 46 links on 32 ideas, only where the idea's text names the drug or target in the idea's cancers; drug to key paper 34 links on 25 drugs; drug to trial 35 links where the title names the drug; target drugs arrays 47 links on 21 targets; company to drug 6 links on 5 companies. No EU approval rows written: 59 of the 60 snapshot candidates already had rows and the last is a withdrawn application with no date. No target-to-drug mechanism links: both measured hits were substrings.
- 22 September 2026: Corpus-only joins script: scripts/link-joins.ts plans and applies wave 2 links from fields the records already carry, with every rule stated; content-gaps measures corrected Ten rules, dry run by default and --apply to write through the editor in scripts/orphan-links.ts (append only, never removes a link, sorted and de-duplicated): trial to technology through the studied agents' modality technologies; idea to trial and idea to key paper only where the idea's own text names the drug or target, in the idea's cancers, for actors that trials test, capped at five and three; company to drug through sponsored trials where the drug has no maker; drug to key paper and drug to trial through titles that name the drug; technology to trial; target drugs arrays mirroring drug.targets; target to drug by whole-word mechanism mention; EU approval rows from the EMA register snapshot with the file's A, C, V and W helpers, product name and snapshot date checked.
- 22 September 2026: Header filters for the toolbar facets that had no column: CountryRanking gains a Region column, ScorecardTable Type and Country columns (chips that select the value) and a Regions header filter, PipelineFunnel filters the crowding table by approved product and population completeness, ResearchRanking by parent university and five-year coverage; docs/TABLES.md carries every table's state
- 22 September 2026: Header filters on the client tables that keep their own controls: TrialFinder, TrialFinderGeo, AssistanceBrowser, GuidelineConcordance, ManufacturingMap, InteractionChecker, AutoPulse, SurvivorshipPlan, MarketEstimator, TumorBoard, Navigator and PlanRankings filter from their column headers through useHeaderFilters and FilterHead, sharing state with the existing facet controls where one exists; CaregiverPanel skipped (eight rows, no categorical column)
- 22 September 2026: Trial key papers fetcher: Europe PMC by registry id, one primary and one follow-up per trial, links merged from trial-key-papers-wave1.ts
- 22 September 2026: Header filters on every server-rendered table: StaticTable draws plain rows from the page (links, chips, bars, avatars as small objects) so deals, evidence, funding, universities, payloads, costs, status, freshness, eval questions, survival, cited papers, papers pulse, startup investors, audit, review, China trials and deals, India sites, pathway matrix and dossier trials all filter from their column headers with a N of M count and a Clear pill; docs/TABLES.md records every table's state and the skips under ten rows
- 22 September 2026: Trials in plain words keeps every trial's heading, status, summary and page link in the HTML and fetches the explanation on demand: one file per cancer section, prefetched as the section scrolls near and opened with an Open explanation pill
- 22 September 2026: LAUNCH: owner asks of 22 Sept 2026 and what shipped in chain 96
- 22 September 2026: Column headers filter every browser table, tumour testing redesign with laboratory logos, Edge feed, idea and corpus rankings, explore pagination, content roadmap, PR 54 and 55 rows, signed-in bridge
- 22 September 2026: Cancer map: a layered DAG of every cancer type at /cancers/map/, with organ systems, histology groupings, cancers and subtypes, badges switchable between trials, products, approvals and ideas, an accessible outline, graph.json for agents, and links from the cancer browser and every family strip
- 22 September 2026: Rankings hub: fourteen league tables computed from corpus counts and dates, one page each with basis, coverage and a JSON companion
- 22 September 2026: Content roadmap: pages still to write and cross-connections still to make, measured by scripts/content-gaps.ts; waves 143 to 149 on the roadmap
- 22 September 2026: Edge: one feed of the freshest signals in cancer, new papers, trial results, approvals, withdrawals, law, bot proposals and weekly issues, ranked by recency with a modest importance weight, with Atom and JSON feeds at /edge/feed.xml and /edge/feed.json
- 22 September 2026: Tumour testing: By scope and By sample become card grids with company logos, and the table filters by sample, scope, laboratory and status from the URL query
- 22 September 2026: Idea rankings: six views of the same ideas at /ideas/rankings/, every score from existing fields with its formula shown
- 22 September 2026: Explore, For me and the navigator page their sections: the first 30 rows of each kind ship in the HTML and the rest load per section from static JSON as the reader scrolls or presses Show 30 more; For me and the navigator fetch one file per cancer instead of carrying all 328
- 22 September 2026: Filter from the column header: every filterable column in the results tables is a button with a funnel glyph that opens a popover of value pills (counts, search past eight, Clear, Close; bottom sheet on phones), wired to the same setter and URL as the toolbar facets; sortable headers keep sort on the label and put the filter on a sibling glyph
- 22 September 2026: Four EMA application withdrawals recorded as withdrawn rows, melflufen US withdrawal row restored, FDA Tazverik communication dated 11 May 2026
- 22 September 2026: Bridge to the signed-in site: header greets a signed-in reader, Watch keeps pages on the account with a sign-up offer, a star on every list row, For me can be saved to the account; consent copy
- 22 September 2026: chore: weekly roadmap registry check (public/roadmap-watch.json)
- 22 September 2026: Upkeep runs on its own: weekly logos, structures, trial links and acronyms, monthly identifiers, and the bots' refreshes now deploy without a manual ship
- 22 September 2026: Weekly maintenance and monthly identifier workflows; bot pushes now deploy through the Vercel ignore test
- 22 September 2026: chore: refresh literature snapshot from Europe PMC (#56)
- 22 September 2026: Add FDA safety communication link and SPM rate to epithelioid sarcoma record
- 21 September 2026: Trial phases read as plain labels everywhere: Platform trial and Observational study instead of Phase platform, with old filter links still working
- 21 September 2026: Phase facet test asserts the string key and the shared normaliser
- 21 September 2026: Facet normaliser is a string key resolved in the client, not a function crossing the server boundary
- 21 September 2026: Trial phases read "Observational study" and "Platform trial" instead of "Phase observational", from one phaseLabel helper
- 21 September 2026: A JAMA Oncology 2026 comparison of tissue-free and tumour-informed residual-disease blood tests joins the ctDNA roadmap's sources
- 21 September 2026: c-TRAK TN tissue-free residual-disease assay paper added and linked from the tumour-informed assay term
- 21 September 2026: Trial pages say what their enrolment number counts, randomised, analysed or enrolled, with the registry figure explained on hover
- 21 September 2026: Four new publications found by the registry check are in, including the eight-year ADAURA survival update with its figures, and the check no longer flags screening studies
- 21 September 2026: Registry check: a non-drug interventional study matches the corpus's observational phase, clearing the PATHFINDER 2 flag
- 21 September 2026: Four publications flagged by the roadmap registry check recorded as key papers: the ADAURA eight-year overall survival update (J Thorac Oncol 2026) linked from the trial and the EGFR-mutant and resectable NSCLC pages with its stage II-IIIA and IB-IIIA survival figures added to the trial's outcomes, and the FLAURA2 long-term safety analysis (Lung Cancer 2026), the KRYSTAL-12 plain language summary (Future Oncol 2026) and the TROPION-Breast01 China cohort (ESMO Open 2026) linked from their trials only; citation counts fetched from Europe PMC
- 21 September 2026: Trial enrolment figures now say what they count: 25 landmark trials explain why their randomised or analysed numbers differ from the registry, and five stale figures are corrected from their sources
- 21 September 2026: Enrolment gaps on 30 roadmap trials reviewed one by one against ClinicalTrials.gov and the primary papers: 25 keep the paper's randomised, analysed, treated or registered count and now say so in a new enrolledBasis and enrolledNote, 5 stale or unsourced figures corrected from the registry or the paper; the roadmap watch reports explained gaps separately and its offline mode re-compares against the committed registry records
- 21 September 2026: MIMic-01 trial status corrected to active against ClinicalTrials.gov, the first fix from the new roadmap registry check
- 21 September 2026: Every roadmap now carries a registry check: a weekly script compares each referenced trial with ClinicalTrials.gov and Europe PMC, flags contradictions and overdue readouts, and shows the check date under What to watch
- 21 September 2026: MIMic-01 status and PATHFINDER 2 design corrected against ClinicalTrials.gov, as flagged by the roadmap watch
- 21 September 2026: Roadmap watch for every roadmap: scripts/roadmap-watch.ts compares each roadmap's referenced trials with ClinicalTrials.gov (status, phase, enrolment within 5 percent, moved completion dates), lists Europe PMC papers since asOf, flags watch items past their expected date, writes public/roadmap-watch.json for a weekly Thursday workflow and a "Registry check" line on roadmap pages
- 21 September 2026: A roadmap and timeline for circulating tumour DNA tests, from the 1948 discovery of cell-free DNA to the residual-disease and multi-cancer detection trials reading out next, with a watch list and a script that checks it against the registries
- 21 September 2026: PATHFINDER 2 status and ECLIPSE enrolment corrected against ClinicalTrials.gov, as flagged by the ctDNA watch script
- 21 September 2026: ctDNA tests roadmap: ten eras from the 1948 sighting of DNA in plasma to the 2029 randomised readouts, a "What to watch" list with registry and meeting dates, six trials the corpus lacked (TRACC, MERMAID-1 and -2, BESPOKE, CIRCULATE-US, NCI Vanguard), a tumour-informed versus tumour-naive term, and npm run ctdna:watch to keep it current
- 21 September 2026: Twenty-six landmark papers for the pancreatic cancer pages, from PRODIGE 24 and PREOPANC to the KRAS inhibitor cohorts and the IPMN guidelines, each checked against Europe PMC
- 21 September 2026: Every pancreatic subtype page now rests on two to four landmark papers: 26 new records (PRODIGE 24, ESPAC-4, PREOPANC, ESPAC5, Alliance A021501, LAP07, CodeBreaK 100 and KRYSTAL-1 pancreatic cohorts, POLO and its survival analysis, the BRCA/PALB2 platinum trial, KEYNOTE-158, the NRG1 fusion discovery and zenocutuzumab papers, Fukuoka, Kyoto and European cyst guidelines, and the acinar cell carcinoma and pancreatoblastoma reference series), each DOI checked on Europe PMC and doi.org, with Le 2017 reused for the MSI-high page and citation counts fetched
- 21 September 2026: Seventy-four registry trials linked to the newest pancreatic and nasopharyngeal cancer pages, with a guard that keeps neuroendocrine trials off the pancreatic adenocarcinoma pages
- 21 September 2026: Registry trials now reach the 50 subtype pages added this week: 74 trials linked to the pancreatic disease-state and driver pages and to recurrent or metastatic nasopharyngeal carcinoma, with a neuroendocrine guard so GEP-NET trials stay off the ductal adenocarcinoma pages
- 21 September 2026: Pages load about three times less script: the header no longer drags in the molecule viewer, every language dictionary and the search engine, so slow connections reach a working page far sooner
- 21 September 2026: Bundle split follow-ups: stars JSON out of the guarded data folder, layout test reads dictionaries from the full set, row 140 done
- 21 September 2026: Seven European approvals corrected to withdrawn against the EMA register, the PARTIQoL proton trial gains its reported result, and the KEYNOTE-A18 papers are split into their two Lancet reports
- 21 September 2026: Client JavaScript on every page cut from 3.0 MB to 1.0 MB: the layout no longer pulls the animated schematics, the structure index, all eight chrome dictionaries, zod or MiniSearch
- 21 September 2026: Paganetti 2014 RBE reference points at the real paper (Physics in Medicine and Biology)
- 21 September 2026: Visit counting now asks first: Google Analytics loads only after you allow it, the browser's privacy signal is honoured, and the choice can be changed in the footer
- 21 September 2026: Data follow-ups: seven withdrawn EU authorisations, PARTIQoL readout, KEYNOTE-A18 split into its two Lancet papers
- 21 September 2026: Roadmap row 141 marked done for onco.cc
- 21 September 2026: Google Analytics now loads only after the visitor presses Allow: a consent bar at the foot of the viewport, the choice kept in the browser, Global Privacy Control read as No thanks, an Analytics choice control in the footer and on /privacy/, strings in nine languages
- 21 September 2026: GitHub star count is baked in at build time, so the top-bar badge is full from the first paint and never flickers
- 21 September 2026: Launch doc: two dated account notes marked as removed
- 21 September 2026: Launch doc: old account instructions cut to one-line history notes pointing at me.onco.cc
- 21 September 2026: Sign in/up opens in the same tab: links to me.onco.cc are treated as part of the site rather than external
- 21 September 2026: Sign in/up in the top bar now opens the WorkOS sign-in directly, with no stop on a landing page
- 21 September 2026: Sign in/up on onco.cc now hands you to me.onco.cc, the signed-in side; onco.cc itself keeps no account data, in the browser or the cloud
- 21 September 2026: Sign in/up now links to me.onco.cc; onco.cc holds no account data
- 21 September 2026: Sign in/up now goes straight to the WorkOS sign-in page instead of stopping at the newsletter page
- 21 September 2026: Greptile review config encoding the corpus rules for community pull requests
- 21 September 2026: Your role, cancer choice and preferences now save to your OnCo account so they follow you across devices, and the outlook block is held back pending a wording review
- 21 September 2026: Merge cloud profile sync; outlook block held pending wording review
- 21 September 2026: Community fixes: alphagenome model corrected, epithelioid sarcoma record completed with verified facts, RMC-9805 pancreatic pairing and ubamatamab mechanism corrected, plain-English outlook for ten cancers behind the survival disclosure, and 15 hidden FDA events restored
- 21 September 2026: Cloud profiles stage one: Supabase tables under the WorkOS token, sync, delete, privacy text
- 21 September 2026: PR round 2: alphagenome weights gated, FDA regulatory events surfaced, epithelioid sarcoma withdrawal history
- 21 September 2026: Issues 43, 45, 46, 47: prognosis outlook on ten cancer pages, ubamatamab as MUC16xCD3 bispecific with corrected citation, g12d-plus-pan-ras phase and links from the registry and company release
- 21 September 2026: Roadmap rows 141 and 142: GDPR compliance for accounts and HIPAA readiness
- 21 September 2026: chore: render this week's issue to public/newsletter/ (#52)
- 21 September 2026: chore: refresh public/votes.json from Discussions reactions (#51)
- 21 September 2026: chore: weekly fact check, audit, and provenance refresh (#50)
- 21 September 2026: chore: refresh trial counts from ClinicalTrials.gov (#49)
- 20 September 2026: Fix duplicate entry for 'alphagenome' in model registry
- 18 September 2026: Health data compliance analysis: HIPAA does not apply today, GDPR and state health-data laws do; stay browser-only and prepare encrypted sync
- 18 September 2026: Top bar sign-in works even before the page script loads: it is now a link that upgrades to the direct WorkOS start
- 18 September 2026: Top bar button shortened to Sign in/up in every language, and cached pages refreshed so everyone sees the new header
- 18 September 2026: After sign-in a welcome page asks who you are and which cancer, the top bar shows you are signed in, four community pull requests and four issue fixes land, and secret scanning guards every commit
- 18 September 2026: Fix issues 42, 39, 37, 36: chip ellipsis and titles, daraxonrasib approval, clickable tooltips, urothelial basics
- 18 September 2026: Welcome step as its own page: sign-in leaves /signup/ for /welcome/ or the return path, signed-in header pill, preferences kept with the account profile
- 18 September 2026: Secret scanning: gitleaks on every push and pull request, a local pre-commit hook, and an allowlist for public ids and data prose
- 18 September 2026: Sign up or log in button in the top bar, a medical disclaimer in the footer, and new Terms of Use and Privacy Policy pages
- 18 September 2026: Trastuzumab carries the June 2026 FDA approval of palbociclib with trastuzumab as HER2-positive maintenance, the one bot proposal from PR 35 not already in the corpus
- 18 September 2026: Pages are far lighter: the shared header, footer and cancer list are no longer copied into every page's data, and the sign-in id ships with the code
- 18 September 2026: Terms of use and privacy policy pages, medical disclaimer in the footer, copyright to OnCo
- 18 September 2026: Header: a Sign up or log in pill when signed out; region, language and search controls sit on the centre line
- 18 September 2026: Stop serialising the cancer list and the shared chrome into every page's payload
- 18 September 2026: Sign-in is live: first-time visitors choose whether they are a patient, caregiver, researcher or clinician and can set a cancer, kept only in their browser
- 18 September 2026: Each ship now builds once: Git-triggered Vercel builds are skipped and only the verified deploy runs
- 18 September 2026: First sign-in welcome step: who you are, optional cancer, browser-only profile per WorkOS user
- 18 September 2026: Vercel: skip Git-triggered builds so each ship builds once, from the verified CLI deploy
- 18 September 2026: add: Strand AI (W26) to the YC oncology list
- 18 September 2026: Owner list: proposal for six technology sections to lift the section kind past the size gauge
- 18 September 2026: Every reference DOI on the site checked against Europe PMC: four wrong links corrected, and a checker script added for future waves
- 18 September 2026: DOI checker for citation links: four wrong DOIs corrected and two rare-cancer key papers added
- 18 September 2026: Sixty-six landmark and classification papers for the rare-cancer pages, each checked against Europe PMC, plus two corrected reference links
- 18 September 2026: Two rare-cancer reference links corrected to the verified POD1UM-303 Lancet 2025 and MEK inhibition Nature 2019 papers
- 18 September 2026: Key papers for the 39 rare-cancer subtype pages: 66 verified landmark trials, classifications and guidelines from ANCHOR and ACT II to FIRM-ACT, PATHFINDER, HD21 and FIRSTMAPPP, linked through keyPapers
- 18 September 2026: Fifth Chinese quality pass over the new rare and pancreatic cancer pages: 14 corrections
- 18 September 2026: Four pancreatic Chinese TL;DR fixes synced from the wave export into the dictionary
- 18 September 2026: Chinese TL;DR pass 5: fix 14 rare and pancreatic subtype entries
- 18 September 2026: Eleven pancreatic cancer pages by stage and driver, from resectable and borderline disease to KRAS G12C, BRCA-mutant and MSI-high tumours, each linked from its trials and drugs
- 18 September 2026: Add 11 pancreatic cancer subtype pages: stage, driver and histology
- 18 September 2026: Thirty-nine subtype pages for rarer cancers, from anal and vulvar cancer by HPV status to Hodgkin lymphoma by stage and mastocytosis, plus an IndexNow script for changed pages
- 18 September 2026: Add 39 subtype pages for the rare cancer families that had none: anal, penile, vulvar, vaginal, thymic epithelial, adrenocortical, appendiceal, small bowel, cancer of unknown primary, histiocytoses, Langerhans cell histiocytosis, systemic mastocytosis, Hodgkin lymphoma, gestational trophoblastic neoplasia, pheochromocytoma and paraganglioma, nasopharyngeal and sinonasal cancers, with organ-drawing mappings, reverse links from 76 existing trial and drug records, Chinese TL;DRs registered for fold-zh and parent phrases for the cancer-families test
- 18 September 2026: IndexNow script: submit record pages changed since a date, batched, with a dry run
- 18 September 2026: Target pages with a mutation hotspot map no longer throw a hydration error: chart tooltips are written as single strings, and the page test now checks markup structure
- 18 September 2026: Fix hydration error 418 on target pages: multi-child SVG titles rendered empty by the server
- 18 September 2026: Fourth Chinese quality pass: 22 corrections across researcher, institute, trial and company summaries, including arsenic trioxide and enzalutamide names
- 18 September 2026: Chinese quality pass 4 over 243 folded TL;DRs
- 18 September 2026: Thirty-five key papers gain their DOI and PubMed ids, so every key paper but one now shows its citation count
- 18 September 2026: Add DOIs and PMIDs to 35 key papers that had neither
- 18 September 2026: Drug cards no longer nest a link inside a link, and a permanent test renders every page to forbid nested anchors site-wide
- 18 September 2026: Gene targets carry HGNC, Ensembl, UniProt and NCBI Gene identifiers, and key papers show how often they have been cited
- 18 September 2026: Guard every page against nested anchors; unnest the product card
- 18 September 2026: Roadmap rows 22 and 97 marked done
- 18 September 2026: TRACERx 2023 paper DOI corrected (ends -5, verified at doi.org)
- 18 September 2026: Fill HGNC, Ensembl, UniProt and NCBI Gene ids on single-gene targets
- 18 September 2026: Citation counts for key papers from Europe PMC (improvement 97)
- 18 September 2026: Dependency map hydration error fixed: vendor tiles no longer nest a link inside a link, with a test that forbids nested anchors
- 18 September 2026: Fix React 418 on the dependency map: no anchor inside an anchor
- 18 September 2026: Health pass: 369 paper links for 270 researchers, PubChem structures for 43 drugs, six glossary Wikipedia links, refreshed literature snapshots for all 2,093 tracked records, provenance for every record, and 28 logos
- 18 September 2026: Six more glossary terms gain Wikipedia links; 74 recorded as having no article
- 18 September 2026: Molecules for 43 more small-molecule and peptide drugs via PubChem name lookup
- 18 September 2026: Link 369 key papers to 270 people from existing corpus links, people-papers gauge 73.8% to 79.4%
- 18 September 2026: Trial acronym aliases completed for every registry trial that has one (115 more), so searches by study name find them all
- 18 September 2026: Add 115 registry trial acronyms from the CT.gov acronym field
- 18 September 2026: Eighty more drug companies gain Wikipedia and Wikidata links
- 18 September 2026: Add Wikidata ids and Wikipedia links for 80 more companies
- 18 September 2026: Sixty-three more institutes and 48 drug companies gain Wikipedia and Wikidata links for readers and machines alike
- 18 September 2026: Add Wikidata ids and Wikipedia links for 48 companies
- 18 September 2026: Add Wikipedia links and Wikidata ids for 67 more institutions from the Wikidata API
- 18 September 2026: Sixty-six hospitals and institutes gain Wikipedia and Wikidata links, which also feed the machine-readable sameAs data for agents
- 18 September 2026: Add Wikipedia links and Wikidata ids for 66 institutions from the Wikidata API
- 18 September 2026: Final researcher identifiers pass: 64 ORCID ids and 60 Wikipedia links, taking 373 people to ORCID and 181 to Wikipedia, plus STRASS trial results
- 18 September 2026: Sixty-four more researchers carry ORCID ids and 60 gain Wikipedia links in the fourth identifier pass
- 18 September 2026: Seventy-seven landmark trials now show their results as structured outcomes transcribed from the published abstracts, and 146 more researchers carry ORCID ids
- 18 September 2026: Add structured outcomes to STRASS from its Lancet Oncology 2020 abstract
- 18 September 2026: Add identifiers pass three: 146 ORCIDs and 7 Wikipedia links for people
- 18 September 2026: Add structured outcomes to 77 subtype-wave landmark trials from Europe PMC abstracts
- 18 September 2026: A further 121 researchers carry ORCID ids and 18 gain Wikipedia links, each checked against their ORCID employment record
- 18 September 2026: Add 121 ORCIDs and 18 Wikipedia links in a second identifier pass
- 18 September 2026: Subtype cancer pages now link their sibling subtypes (667 links) and 188 researchers carry ORCID ids with 22 Wikipedia links
- 18 September 2026: Add 188 ORCIDs and 22 Wikipedia links to people records
- 18 September 2026: Forty-one hospitals and institutes added and 78 researchers linked to where they work
- 18 September 2026: Link cancer subtypes to their siblings and name parents in tldrs
- 18 September 2026: Fill institutions for 78 trial investigators and add 41 institution records
- 18 September 2026: Five duplicate person pages merged into one each with redirects, and a duplicate finder for people added
- 18 September 2026: Merge five duplicate person records and add a duplicate-person finder
- 18 September 2026: Update weights and URLs for alphagenome model
- 18 September 2026: A hundred and eleven trial leads and first authors get person pages, linked from the landmark trials and key papers they led, plus 160 more trial acronyms
- 18 September 2026: A further 160 trial acronyms added as aliases to registry trial records
- 18 September 2026: Add 111 trial investigators and lead authors named by the subtype trials and key papers
- 18 September 2026: Trial acronyms (MARIPOSA-2, SPARTAN, CheckMate 9DX and 700 more) added as aliases to registry trial records so searches by the name patients hear find them
- 18 September 2026: Trial acronyms for registry records: scripts/trial-acronyms.ts adds 711 aka aliases
- 18 September 2026: Seventeen more landmark trials named on subtype pages (ATTRACTION-2, MAIA, RESONATE-2, NeoSphere and others) recorded with confirmed registry ids, and acronyms added to three registry records
- 18 September 2026: Third Chinese quality pass: 19 corrections to new drug, company and trial summaries, including wrong drug names and Korean text left in Chinese sentences
- 18 September 2026: Confirm registry ids for 24 subtype-page trials: 17 new records, 3 acronyms on registry records, 4 links filled
- 18 September 2026: Third Chinese quality pass: 19 of 236 TL;DRs from the biomarker, drug, maker and trial waves corrected, and the 73 trial TL;DRs folded into zh.ts
- 18 September 2026: Seventy-three trials named on subtype pages now have their own records with confirmed registry ids, plus logos for the new drug makers
- 18 September 2026: Add 73 trials named by the cancer subtype pages (trials-subtypes-wave)
- 17 September 2026: Seventy-four drug makers added and 210 drug-to-company links filled, so pipeline drugs now show who is developing them
- 17 September 2026: Link 193 company-less drugs to their makers and add 74 maker records
- 17 September 2026: Key papers for 147 subtype pages: 364 pivotal trial, classification and guideline papers, each checked against Europe PMC
- 17 September 2026: Add key papers to 147 cancer subtype pages
- 17 September 2026: Thirty-nine drugs named by the new subtype pages now have their own records, from hormone therapies for pituitary tumours to antibody-drug conjugates in trials
- 17 September 2026: Add drugs named by the cancer subtype pages (drugs-subtypes-wave)
- 17 September 2026: Fifty biomarker glossary terms named by the new subtype pages (molecular groups, risk scores, resistance mutations), each linked from the pages that use it
- 17 September 2026: Add 50 biomarker terms named by the cancer subtype pages
- 17 September 2026: Registry trials linked to 109 subtype pages by driver and stage (1,018 links), with a re-runnable matcher script
- 17 September 2026: Link 1,018 registry trials to cancer subtype pages by driver and disease-state tokens
- 17 September 2026: Plain-English sentences for the 170 new subtype pages and trials, so every record carries one again
- 17 September 2026: Add simple sentences for the subtype-wave cancer pages and trials (part-s)
- 17 September 2026: Seven duplicate trial records folded into their named trials with redirects; second Chinese quality pass corrects 64 TL;DRs from tonight's new pages, including one inverted meaning, and adopts NMPA drug names
- 17 September 2026: Review Chinese TL;DRs of the subtype waves: standard drug names, terms and alignment with the English
- 17 September 2026: Merge duplicate trial records onto their named keepers
- 17 September 2026: Head and neck cancers by HPV status and site: HPV-positive and HPV-negative disease, recurrent or metastatic squamous cell carcinoma, hypopharyngeal cancer, three salivary gland histologies and three oral cavity subsites, tied to KEYNOTE-048, RTOG 1016, De-ESCALaTE, ECOG 3311, PATHOS and NIVOPOSTOP
- 17 September 2026: Head and neck cancers by HPV status and site: HPV-positive oropharyngeal, HPV-negative squamous, recurrent or metastatic state page, hypopharyngeal, adenoid cystic, salivary duct, mucoepidermoid, oral tongue, gingivobuccal (India) and lip, with NIVOPOSTOP, ECOG-ACRIN E3311, PATHOS and CAPTAIN-1st
- 17 September 2026: Neuroendocrine neoplasms by site and grade: small intestinal, pancreatic and lung neuroendocrine tumours, grade 3 NET and extrapulmonary neuroendocrine carcinoma, tied to NETTER-1 and 2, CLARINET, PROMID, RADIANT and CABINET; NETTER-2 refiled under neuroendocrine cancer
- 17 September 2026: Add neuroendocrine subtypes by site and grade
- 17 September 2026: Childhood cancers by type and risk: acute lymphoblastic leukaemia by risk group, Philadelphia status, infancy and relapse, paediatric AML, neuroblastoma by risk group, medulloblastoma by molecular group, and a page for adolescents and young adults
- 17 September 2026: Add paediatric cancers by type and risk group
- 17 September 2026: Sarcomas and bone tumours by type: chondrosarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, alveolar soft part sarcoma, PEComa, epithelioid haemangioendothelioma, nerve sheath tumours, retroperitoneal and extremity soft tissue sarcoma, with STRASS, EORTC 62012, AMPECT and ANGIOTAX
- 17 September 2026: Add sarcoma and bone tumour subtype pages with landmark trials
- 17 September 2026: Cancer pages by state for the common cancers: gynaecological cancers by molecular class and stage, skin cancers by state, lung cancer by driver and stage, breast cancer by state, 44 pages tied to their landmark trials and drugs; the My cancer chip leaves the header until accounts are on
- 17 September 2026: Breast cancer by state: high-risk early and post-CDK4/6 HR-positive, HER2-low, early HER2-positive and HER2-positive brain metastases, early and metastatic triple-negative, inflammatory breast cancer, Paget disease of the nipple and phyllodes tumour, each linked from the trials and drugs that treat them
- 17 September 2026: Lung cancer by driver and stage: 14 subtype pages and 10 landmark trials
- 17 September 2026: Add skin cancers by state: melanoma by mutation, stage and site, advanced cSCC, advanced BCC, DFSP
- 17 September 2026: Gynaecological cancers by molecular class and stage: endometrial cancer by POLE, MMR, p53 and NSMP class, advanced or recurrent endometrial cancer, uterine carcinosarcoma, cervical cancer by stage (early and fertility-sparing, locally advanced, recurrent or metastatic) and ovarian cancer by platinum sensitivity, each tied to its landmark trials and drugs
- 17 September 2026: Blood cancers by state: acute myeloid leukaemia by driver and fitness, acute promyelocytic leukaemia, myeloma from smouldering to relapsed, MDS by risk, CLL by line and Richter transformation, CML by phase and primary myelofibrosis, nineteen pages tied to 111 drugs and trials
- 17 September 2026: Blood cancers by driver, state and phase: nineteen subtype pages
- 17 September 2026: Upper gastrointestinal and liver cancers by state: gastric cancer by HER2, CLDN18.2, PD-L1 and MSI status and early gastric cancer, hepatocellular carcinoma by BCLC stage, intrahepatic and extrahepatic cholangiocarcinoma, and GIST by mutation, each tied to its landmark trials and drugs
- 17 September 2026: Colorectal cancer by state: rectal, MSI-high, BRAF V600E, HER2-amplified, KRAS G12C and early-onset pages with OPRA, PROSPECT, BEACON and other landmark trials; primary mediastinal B-cell lymphoma
- 17 September 2026: Add upper GI and liver subtypes: gastric by biomarker, early gastric, HCC by BCLC stage, cholangiocarcinoma by site, GIST by mutation
- 17 September 2026: Brain tumour subtypes: IDH-mutant astrocytoma, oligodendroglioma, meningioma, brain metastases, paediatric high-grade glioma, spinal cord tumours, vestibular schwannoma and CNS germ cell tumours, each linked from the drugs and trials that treat them
- 17 September 2026: Add colorectal subtype pages and primary mediastinal B-cell lymphoma
- 17 September 2026: Add brain and spinal tumour subtype pages
- 17 September 2026: Plain-English sentences for every remaining record: 1,167 early-phase trials, 138 people, 65 companies, 8 institutions and 3 ideas, so all 11,306 records now carry one
- 17 September 2026: Simple layer: part-r, fourth and final wave to full coverage
- 17 September 2026: Websites for 15 organisations and nine more logos, with archived addresses replaced by live sites; roadmap row 139 records the open dependency map hydration mismatch
- 17 September 2026: Add official websites to 15 sponsor records and fetch nine logos
- 17 September 2026: Roadmap row 139: dependency map hydration mismatch
- 17 September 2026: 969 more plain-English sentences for early-phase trials, key papers and collections, taking the simple layer to 9,930 records; one non-cancer registry record removed
- 17 September 2026: Simple layer wave 3: part-q with 969 sentences (trials, papers, collections)
- 17 September 2026: Orphan trials given content: ten drug matches, 17 sponsor aliases, 36 sponsor companies and 130 trials tied to their makers, two non-cancer records removed; backlinks round: 303 weakly linked records gain true relations from their own text; orphans down to 214
- 17 September 2026: After the trial removals: no dangling references, floor re-run, sponsor wave three Chinese folded
- 17 September 2026: Backlink fill: text-supported relations for 303 weakly connected records
- 17 September 2026: 1,024 more plain-English sentences: 279 companies, 104 institutions and 640 phase 3 trials, taking the simple layer to 8,961 records
- 17 September 2026: Orphan trials: link sponsor-only trial records to drugs, companies, institutions and cancers; 36 new sponsor companies (wave 3); remove two myasthenia gravis records
- 17 September 2026: Papers for 36 more researchers matched by institution; trial snapshots refreshed for all 1,024 products with 136 registry changes detected; paper snapshots refreshed for all 1,924 records
- 17 September 2026: Add simple part-p: 1024 plain sentences for companies, institutions, the theories pathway and phase 3 trials
- 17 September 2026: One papers block per person after the two paper waves met
- 17 September 2026: People papers: 36 more research-trained people via OpenAlex and Europe PMC
- 17 September 2026: docs(corrections): name the reporting clinician on the two glioblastoma rows
- 17 September 2026: Company content and sources for 33 makers, 26 sponsor corrections and papers for twelve researchers; 7,065 reverse links take orphaned trials from 2,467 to 279; Wikipedia links for six terms; structured outcomes with sources for 26 trials; 153 new logos; the schematic gauge counts aliased drawings
- 17 September 2026: Add structured outcomes to 26 reported trials flagged by the trial-outcomes gauge
- 17 September 2026: Schematic gauge counts aliased drawings as specific
- 17 September 2026: Add Wikipedia links to six terms lacking one
- 17 September 2026: Fold a doubled relation line after the sponsor merge
- 17 September 2026: Reverse links for orphaned trials: their drugs, companies (or sponsor via alias), technologies and cancers now list them back; orphan floor 2572 to 384
- 17 September 2026: Link orphan sponsor companies, repoint AAA trials to Novartis, add Europe PMC papers to twelve people
- 17 September 2026: 661 plain-English sentences: every cancer, 201 drugs, 179 technologies, 120 terms, 50 phase 3 trials and 63 targets; 451 reverse links give 126 orphaned drugs and 105 companies their first inbound link, with three maker corrections
- 17 September 2026: Reverse links for orphaned drugs and companies: their companies, trials, cancers, technologies and institutions now list them back; orphan floor 2827 to 2572
- 17 September 2026: Simple layer: part-o with 661 sentences, layer test
- 17 September 2026: Machine translation pipeline for record summaries with hash-checked cache and a report link; 157 Chinese summaries live (every cancer page and nine glossary terms) and two Spanish; model review panel populated for twenty cancers by Fable, each verdict tied to the record's own sources
- 17 September 2026: Every record has its own RDF Turtle file at /api/v1/rdf/<id>.ttl, linked from the page head, the hidden machine links, JSON-LD, the OpenAPI document and llms.txt
- 17 September 2026: Machine-translated summaries: cached per record and language under public/i18n/summaries, shown only while the English hash matches, marked as machine translated with a report link and an English toggle; prioritised batch script with a fetch call to the Messages API and a validator for NCT ids, doses, gene symbols and leftover English; hand-written Spanish and Chinese examples for pCR; coverage script counts them
- 17 September 2026: Per-record RDF: one Turtle file per record at /api/v1/rdf/<id>.ttl, linked from every record page
- 17 September 2026: For me from a real situation: setting, biomarkers, treatments had, country and trial interest drive what is standard, what your biomarkers change, trials that fit, warnings and questions, all from record fields with sources; dependency map renders identically on server and client
- 17 September 2026: Theme stays light even when React recovers from a hydration mismatch; the counts grid fills its rows again with twenty kinds
- 17 September 2026: Fix hydration mismatch on the dependency map
- 17 September 2026: For me from a real situation (roadmap item 101): setting, biomarkers, treatments had, country and trials drive record-backed sections
- 17 September 2026: Machines of oncology, second wave: 23 more machine families from boron neutron capture and FLASH beams to hyperthermia, fluorescence surgery, positioning, gating and dosimetry, with 32 vendors; roadmap rows marked done for the day's work
- 17 September 2026: Decisions you may face: a page per cancer laying out each treatment setting's options, evidence and trade-offs; expert centres as a sortable table of what can be measured, with a near-you marker; your remembered cancer follows you through the header, home, hubs, trials and search; a what-changed page per cancer; red cards for warnings on cancer pages
- 17 September 2026: Machines wave 2: BNCT accelerators, FLASH, electron, hyperthermia, PDT lasers, LITT, focused ultrasound, ECT, HIPEC, endoscopy, skin and cervical imaging, RT guidance and QA, CSTDs
- 17 September 2026: Prostate cancer by state: eight subtype pages from low risk to neuroendocrine, linked from 45 trials and drugs; Tregzi added from the FDA notice and the remaining update bot proposals checked against the registry; Hansoh merged into one record with a redirect
- 17 September 2026: Patient roadmap 102, 104, 106: remembered cancer, per-cancer what changed, red cards
- 17 September 2026: Decision pages per cancer and outcome-based centre tables (roadmap items 107 and 108)
- 17 September 2026: Prostate risk-group and disease-state pages, update bot leftovers, Hansoh merge
- 17 September 2026: Chinese quality pass: 82 TL;DRs corrected (standard NMPA drug names, basket trial term, methotrexate spelling, idioms), account strings in the formal register
- 17 September 2026: Radiation wave 5: LET, RBE and when protons beat IMRT
- 17 September 2026: Chinese quality pass on today's TL;DRs and interface strings: 篮式试验 for basket trial, 甲氨蝶呤 typo, 磁共振直线加速器, established drug names in 61 templated trial lines, natural wording in 30 machine-flavoured sentences, 您 throughout the account strings
- 17 September 2026: First sixty days after diagnosis: a week-by-week guide for every cancer built from its records, and a printable appointment sheet per cancer with questions, words you may hear and treatments you may be offered
- 17 September 2026: Model review panel: schema, batch script and page for AI model commentary on records, with two example panels; diagnostics wave two: 24 tests from RAD51 foci and CTC counts to pharmacogenomics, cardiac markers and low-resource screening, with five companies; institution networks: Parker Institute members and leaders, CRUK, NCI, UNICANCER and DKTK links, and ten weakly linked centres strengthened
- 17 September 2026: Add the first 60 days guide and per-cancer appointment sheets
- 17 September 2026: Mine institution networks (rows 110, 111): PICI, CRUK, NCI, UNICANCER, DKTK members and leaders; strengthen weak institution pages
- 17 September 2026: Diagnostics wave 2: 24 tests around sequencing, 5 companies (roadmap row 119)
- 17 September 2026: Animations pause off screen, when the tab is hidden and on slow phones, with a shared budget of six spinning molecules or drawings at once; the record page sidebar stays inside its column and never reaches the footer
- 17 September 2026: Model panel: AI models comment on records beside the human review path
- 17 September 2026: Search results page as an index: kind chips, did-you-mean, pages strip, Ask OnCo card, related strip; 29 trial design terms and a design picker page; startup requests ranked by urgency and commerciality with every input cited; 51 law and regulation terms by jurisdiction with a law page; translation hygiene: language tags, no-translate on names and doses, a browser translation offer
- 17 September 2026: Animation budget for slower phones: one hook (use-animation-budget) pauses molecules, wireframe schematics, the docking scene, the garden sway, the body map, the resistance map and the steppers when off screen or the tab is hidden, draws a still frame under reduced motion, caps thumbnails at six spinning per kind, animates on tap on Save-Data or four-core devices, defers structure fetches until on screen, lazy-loads the gallery 3D viewer; record page sidebar confined to its grid column and not sticky when taller than the viewport; roadmap rows 127 and 138
- 17 September 2026: Add laws around oncology: 51 regulatory terms and /law/ page (roadmap 137)
- 17 September 2026: Manufacturing in oncology: seven supply chains, 18 technologies and 14 makers; theories of cancer: a hub map and sixteen theory records with status; platform trials at depth: 21 master protocol trials and a hub term; technology dependency map with 119 edges and a viewer; Chinese TL;DRs folded in for every new record
- 17 September 2026: Browser translation and language attributes (roadmap row 128, part three): summaries, field values, data tables, bullets and table bodies carry lang="en" while TL;DRs keep their own language; drug, gene, company, trial and person names, aka lines, NCT ids, gene symbols, database ids, molecule labels, formulas and doses carry translate="no" with the notranslate class; TranslateOffer shows one dismissible line at the top of the main column that switches to a carried language or explains the browser's translator in nine languages; wireframe canvas labels repeated as hidden real text; scripts/translation-coverage.ts measures the share of a page in the chosen language per kind
- 17 September 2026: Rank startup requests by urgency and commerciality (row 112)
- 17 September 2026: Trial designs at depth: 29 new terms, 40 enriched, design picker page (row 136)
- 17 September 2026: Search results page as a proper index (roadmap row 123)
- 17 September 2026: Manufacturing wave: remove the Hitachi remnant
- 17 September 2026: Platform and adaptive trials at depth (roadmap row 124): master-protocol hub term, 21 platform, basket and umbrella trials, STAMPEDE enriched
- 17 September 2026: Theories of cancer: hub map and sixteen theory records in the mechanics section
- 17 September 2026: One Hitachi record (machines wave)
- 17 September 2026: Machines of oncology: 21 machine technologies, 17 vendors and 66 centres with their proton, carbon, MR-linac, Gamma Knife and other rare machines, with a machines page; Free in oncology page with 62 services; tumour sequencing tests compared across 13 laboratories; useful 404 page with nearest matches; section tabs, aligned header icons and unsqueezed tables; machine-readable links, Wikidata sameAs and short titles for search engines and agents; footer credit; navigation starts at the top
- 17 September 2026: Technology dependency DAG viewer (roadmap 134)
- 17 September 2026: Manufacturing wave: seven supply chains, 18 technologies, 14 makers
- 17 September 2026: Merge fixes: single Strata Oncology record, Chinese dictionary without duplicate keys
- 17 September 2026: Machines wave: imaging, radiotherapy, particle, ablation, surgical and laboratory hardware with vendors and centres
- 17 September 2026: Free in oncology and tumour sequencing test pages (roadmap 117, 118)
- 17 September 2026: SEO and agent surface on record pages: titles within 60 chars, Wikidata sameAs, hidden machine-readable landmark
- 17 September 2026: Compact section tabs, table column widths and header icon alignment
- 17 September 2026: Make the 404 page useful: nearest matches, ways in, local miss log
- 17 September 2026: Tables: one shared stand-in for rows with no picture, so no visual slot is ever an empty gap
- 17 September 2026: Header star count stays put on reload; counts grid fills its rows; region menu closes after the tap so it cannot fall through to the profile link; drawer close button without a border; pills never break inside a word; page titles capitalised; landing cards show a corner arrow; off-site links open in a new tab; intoDNA STRIDE and Strata Oncology with sequencing links for testing companies; roadmap rows 115 to 121
- 17 September 2026: Accounts through WorkOS: browser-only sign-in behind the same account functions, recorded in WorkOS, on when the client id is set; README retitled Total information dominance on cancer with an open-repository note and a screenshot gallery; site title to match; pivot modality headers use one classifier so every header links
- 17 September 2026: Search index is fresh on every visit (service worker network-first for the API, cache rule narrowed to snapshots and images); site pages ranked higher in search; models table shows each maker's logo or an initials tile; orphan detector script and ratchet test; hub page linked from digital twins
- 17 September 2026: Apply the update bot's proposals (PR 16): 55 EU approval rows from the EMA register and 28 FDA regulatory events; pancreatic cancer wave: four failed phase 3 programmes, nimotuzumab's NOTABLE approval, elraglusib, their sponsors and cross-links; PDAC and Cloudflare rows on the roadmap
- 17 September 2026: Merge PRs 25, 28 and 29 (CheckMate split, topic cards, WebMCP); mobile region menu stays on screen; one heading per cancer group; bevacizumab NICE note; glioblastoma MGMT and tovorafenib wording; mathematical models hub and site pages in search; long lists load in pages as you scroll
- 17 September 2026: Add progressive WebMCP tools for public oncology search and lookup
- 17 September 2026: fix: filter cancer topic cards by relevance
- 17 September 2026: fix(glioblastoma): split CheckMate 143/498/548, add extent of resection and CCTG CE.6
- 17 September 2026: Pivot headers all link to pages: modality, front, status and phase; new small molecule and cancer vaccine pages; day-long cache headers for snapshots; Cloudflare caching on the roadmap
- 17 September 2026: Changelog sync keeps the pending entry through the build
- 17 September 2026: Changelog kept current from the commit log; linked from the README
- 17 September 2026: Link 51 new technologies back from their drugs, targets and base drawings
- 17 September 2026: Point 27 trials, drugs, targets, pathways and terms at their 44 landmark papers
- 17 September 2026: Link 28 cancer subtype pages from the drugs and trials that treat them
- 17 September 2026: Refresh provenance for this week's records
- 17 September 2026: Cancer links for 20 unlinked trials; Chinese version complete for trials
- 17 September 2026: Watch button confirms each click
- 17 September 2026: Country pages: cancer site labels link to their OnCo pages in both tables
- 17 September 2026: Chinese TL;DRs for the last 87 curated trials and drugs
- 17 September 2026: Mathematical and biophysical models: 22 model technologies, a third type on the models page
- 17 September 2026: Types strip as pills, navigator visuals, account-style signup, linked grid headers
- 17 September 2026: chore: refresh pulse, abstract and citation snapshots (#20)
- 17 September 2026: chore: refresh institution research output from OpenAlex (#17)
- 17 September 2026: chore: draft change proposals from feed snapshots
- 16 September 2026: Add Anocca; biophysics sources as data-source candidates
- 16 September 2026: Prevalence rows for 20 more targets
- 16 September 2026: Prevalence rows for 36 targets
- 16 September 2026: Molecules for 26 more drugs and tracers
- 16 September 2026: Molecules for 29 more small-molecule drugs
- 16 September 2026: Pipelines and missing rows for 29 new cancer pages
- 16 September 2026: Keep the corpus out of the tool pages' JavaScript
- 16 September 2026: Keep the corpus out of the guideline pages' JavaScript
- 16 September 2026: Load translation tables on demand; Chinese TL;DRs for 2,678 registry records
- 16 September 2026: Chinese TL;DRs for the remaining 131 people
- 16 September 2026: Subtype pages: leiomyosarcoma, liposarcoma, synovial sarcoma, marginal zone lymphoma, cutaneous T-cell lymphoma
- 16 September 2026: Subtype pages: kidney, testicular, oesophageal, bladder
- 16 September 2026: Fix accessibility regressions in shared UI components
- 16 September 2026: Subtype pages: thyroid, head and neck, ovarian
- 16 September 2026: Chinese TL;DRs for every company, institution, term and idea
- 16 September 2026: Radiation wave 4 (21 landmark trials) and Chinese TL;DRs for every cancer, target, technology and curated drug
- 16 September 2026: Parent pages for breast, lung, leukaemia and biliary cancer; radiation drugs; audit link report; Chinese TL;DRs
- 16 September 2026: check-links: separate blocked from broken in the report (#15)
- 16 September 2026: Cancer subtype pages (pleural and peritoneal mesothelioma), radiation wave 2, roadmap 112
- 16 September 2026: Mobile search opens into the box; radiation wave 1
- 16 September 2026: Add SciRouter, a prevention-first longevity start-up
- 16 September 2026: Molecules for 31 small-molecule drugs; gumarontinib folded into glumetinib
- 16 September 2026: Essential thrombocythaemia page, aspirin record, vorolanib
- 16 September 2026: Polycythaemia vera: dedicated page, seven pivotal trials, eight terms, two ideas
- 16 September 2026: China deep dive: fifteen trial sponsors as company records
- 16 September 2026: Offline page only on real failures, China wave 1, favicon set
- 16 September 2026: Registry trials wave 6 and products wave 7
- 16 September 2026: Clickable breadcrumbs, pipeline products wave 6, checklist additions
- 16 September 2026: Header signup, trial wave 5 and Ask weighting
- 16 September 2026: trials: wave 4 from ClinicalTrials.gov, 309 recruiting or active industry phase 3 oncology trials each linked to a recorded drug and cancer (295 to their sponsor); wave 3 trials gain sponsor links; search lifts the kind named at the start of a question so a 'drug for' query ranks drugs above trials and people
- 16 September 2026: data: pipeline wave 2 from ClinicalTrials.gov, curated: 27 products missing from the corpus (ten China-approved kinase and checkpoint drugs, Japan's amrubicin and pirarubicin, tabelecleucel, HER2 and GDF-15 antibodies, PSMA and CAIX PET tracers, CD45 radioimmunotherapy and others) with 32 phase 3 trial records and China regional rows; launch checklist gains the agentic and AI accessibility to-do
- 16 September 2026: cancers: the four thin pages filled from sources (epithelioid sarcoma, extragonadal germ cell tumour, metastatic cancer, NUT carcinoma) with state of the art, history and development pipelines; six trials (TIGER, SABR-COMET, the tazemetostat run-in, three NUT carcinoma trials) and the BET inhibitor ZEN-3694; gaps page counts only developers as missing products
- 16 September 2026: site: Google Analytics tag with an honest disclosure on the about page; refresh workflows merge their own pull requests once validate and tests pass (the proposals workflow stays a human gate); deploys the FCCT directory and the nine merged weekly snapshots
- 16 September 2026: chore: draft change proposals from feed snapshots (#1)
- 16 September 2026: chore: refresh pulse, abstract and citation snapshots (#2)
- 16 September 2026: chore: refresh trial counts from ClinicalTrials.gov (#3)
- 16 September 2026: chore: refresh public/votes.json from Discussions reactions (#5)
- 16 September 2026: chore: weekly citation link check (#7)
- 16 September 2026: chore: refresh FDA approvals feed (OCE notifications, openFDA drugsfda) (#8)
- 16 September 2026: chore: refresh preprint tracker from Europe PMC (#9)
- 16 September 2026: chore: check regional approvals against the EMA register (#10)
- 16 September 2026: chore: refresh universe lists (NCI drugs and types, NCI centres, OECI, NHS alliances, NLM journals, OpenAlex, KEGG, ChEMBL, ClinicalTrials.gov, FDA OCE) (#11)
- 16 September 2026: data: the Sijbrandij Foundation and Future of Cancer Care Today as entities with their leads, Sid Sijbrandij linked, and the FCCT directory brought in: 39 suppliers, tools and services and 10 clinics and centres for tissue preservation, tumour profiling, functional drug testing, liquid biopsy, theranostics, vaccines, cell therapy, trial finding and navigation
- 16 September 2026: owner requests: aldoxorubicin and Gemini Therapeutics; anetumab ravtansine, its two mesothelioma trials, the UCL proton therapy trial and an idea on why ADCs have failed in mesothelioma; cancer pages replace the curated Pipeline list with an In development tab built from the whole corpus; Even One Ventures and fourteen portfolio companies with a weekly-refreshed universe list
- 16 September 2026: data: forty-six approved cancer drugs missing from the corpus, curated from every ChEMBL molecule with an oncology indication (historic hormonal and cytotoxic agents, photodynamic and diagnostic agents, growth factors, antiemetics, drugs approved in Japan, China, India or Australia); approval pill no longer wraps
- 16 September 2026: header: profile icon on every page opens an email capture dialog (magic-link sign-in when accounts are on, list endpoint otherwise); weekly-issue signup boxes removed from footer and newsletter page; strings in nine languages
Regulatory events, past 7 days
Dated filings, approvals, letters and label changes recorded on product pages.
Corrections, past 7 days
Confirmed factual corrections to the corpus, with the fixing commit.
- 2026-11-03 · Trastuzumab deruxtecan in HER2-low breast cancer, England: Eleven sentences across the triple-negative and breast UK pages, the coverage table and the guideline map said NICE does not recommend trastuzumab deruxtecan for HER2-low disease (TA992, 2024) and that a rapid review had no date. NICE replaced TA992 with TA1197 on 7 October 2026, which recommends it within the marketing authorisation; the four-nation table still said patients in England, Wales and Northern Ireland could not have it (Accuracy round 2 full sweep found it on the triple-negative page and widened to every mention of TA992; the TA992 page ("This guidance has been updated and replaced by NICE technology appraisal guidance 1197") and TA1197 recommendation 1.1 read in raw text) · England, Wales and Northern Ireland rows, the access row, approval notes, the guideline map stance and the coverage note now give TA1197 as the current decision and TA992 as the 2024 refusal it replaced
- 2026-11-03 · MARIPOSA and its plain-language lines: Said amivantamab with lazertinib gave "a survival benefit exceeding a year" and "more than a year of life"; the median was not reached with the combination, so no such difference has been measured (Accuracy round 2 found it on the lung cancer page and widened to every copy; NEJM 2025 abstract (doi 10.1056/NEJMoa2503001, PubMed 40923797) read through Europe PMC) · Now gives hazard ratio 0.75 and three-year survival 60 against 51 percent, and the trial links the 2025 paper
- 2026-11-03 · Lung cancer screening text in six places: NELSON's "overall referral rate for suspicious nodules was 2.1%" was written as "2.1 percent of participants referred", and once as "a tenth of the American false-positive burden", a comparison of two different measures no source makes (Accuracy round 2; NELSON abstract (doi 10.1056/NEJMoa1911793) read in raw text) · Each now uses the abstract's own measure; the unsourced comparison removed
- 2026-11-03 · HR-positive breast cancer subtype list, ESR1 term and TAILORx text: The same unsourced shares the sweep corrected on the page itself remained in three other places: ESR1 mutations in "30-40%", HER2-low as "~60% of HR+", and TAILORx sparing "roughly seventy percent" (69 percent was the midrange-score share) (Widened from the accuracy round 2 sweep; Brett 2021 (doi 10.1186/s13058-021-01462-3) and the TAILORx paper read in raw text) · ESR1 now about 20-40 percent in metastatic disease after an aromatase inhibitor, with Brett 2021 linked; the HER2-low share removed; TAILORx gives the authors' "up to 85 percent" and the 69 percent midrange share
- 2026-11-03 · Familial pancreatic cancer glossary note and CA 19-9 note: Klein 2004 was read as "9.0 times, rising to 6.4 times with two" relatives; CA 19-9's medians across studies were called pooled estimates (Widened from the accuracy round 2 sweep; Klein 2004 and Goonetilleke 2007 abstracts) · Now 4.6, 6.4 and 32 times with one, two and three relatives; "median sensitivity 79% and specificity 82% across studies"
- 2026-11-03 · Nasopharyngeal, Kaposi sarcoma, laryngeal, hypopharyngeal, HPV-negative head and neck, anal and retinoblastoma burden lines: Worldwide counts "a year" with no year or source: hypopharynx's 84,000 is the 2020 estimate (2022: 86,257), head and neck's "close to 900,000" the 2018 one (2022: 947,211); anal cancer's 50,000 and retinoblastoma's 8,000 children had no source on the record, and GLOBOCAN 2022 gives no separate anal estimate (The sweep found undated GLOBOCAN counts on more than twenty of the 60 most-linked pages; widened to every cancer burden line with
src/data/burden-dated.test.ts, which now fails on any undated worldwide count) · Dated to GLOBOCAN 2022 from the repository's copy of the IARC data (public/globocan/countries.json) with the Cancer Today link added; the two unsourced counts removed - 2026-11-03 · Qin Shukui paper list: The ZGDH3 donafenib trial was listed with DOI 10.1200/JCO.20.02672, which is the ASCO guideline on systemic therapy for advanced liver cancer (Found on the China page by the accuracy round 2 sweep and widened to every copy; both DOIs resolved through Crossref) · Corrected to 10.1200/JCO.21.00163 (Qin et al., JCO 2021)
- 2026-11-03 · Hansoh Pharmaceutical and the aumolertinib EU approval row: Presented the EU authorisation of aumolertinib (Aumseqa, February 2026) as current, and called it the first China-originated lung cancer tablet authorised in Europe; the European Commission revoked it on 25 September 2026 because the application relied in part on another medicine's data still under regulatory data protection (Found on the China page by the accuracy round 2 sweep and widened to every copy; EMA EPAR page read in raw text) · Company text, plain-language line and the regional approvals row now give the authorisation and its revocation, with the EMA page linked; the eight machine translations that repeated the claim removed until retranslated
- 2026-11-03 · R. Angelo de Claro machine translations: Eight translations said he has directed the FDA Oncology Center of Excellence since March 2025; the FDA profile gives Deputy Center Director from March 2025, as the English record now does (Widened from the accuracy round 2 sweep; FDA profile page) · Translations removed until retranslated from the corrected English
- 2026-11-03 · CD7, isolated limb perfusion, sleep and circadian interventions and KEYNOTE-426: Four links pointed at DOIs that do not exist (a "NEJM 2022" CD7 CAR-T paper, an "Ann Surg 2006" perfusion paper, an "ASCO sleep guideline JCO 2024" and a KEYNOTE-426 overall-survival source); CD7's "90%+ complete remission" rested on the non-existent paper (Accuracy round 2 resolved all 7,062 DOIs in the corpus against Crossref and doi.org; replacements read through Europe PMC) · KEYNOTE-426 now cites the Nature Medicine 2025 five-year analysis, whose full text gives 47.2 against 40.8 months, HR 0.84; CD7 cites Pan, Blood 2025 (89% partial remission or better in 55 patients, median survival 8.5 months); the other two links removed, no source for their intended papers being found
- 2026-11-03 · starglo: Cited 10.1016/S0140-6736(24)02565-4, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1016/S0140-6736(24)01774-4 (Abramson et al., Lancet 2024, STARGLO)
- 2026-11-03 · acupuncture-aromatase-inhibitor-arthralgia: Cited 10.1001/jama.2018.11350, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1001/jama.2018.8907 (Hershman et al., JAMA 2018)
- 2026-11-03 · log-kill-hypothesis: Cited 10.1002/1097-0142(196409)18:9<1111::AID-CNCR2820180903>3.0.CO;2-Z, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites https://pubmed.ncbi.nlm.nih.gov/14117037/ (paper is in Cancer Chemotherapy Reports, which has no DOI) (Skipper, Schabel, Wilcox, Cancer Chemother Rep 1964)
- 2026-11-03 · [salivary gland subtype (unresectable row)](/): Cited 10.1016/j.annonc.2022.04.011, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1016/j.esmoop.2022.100602 (van Herpen et al., ESMO-EURACAN guideline, ESMO Open 2022)
- 2026-11-03 · [person (CheckMate 214 paper)](/): Cited 10.1016/j.esmoop.2020.001079, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1136/esmoopen-2020-001079 (Albiges et al., ESMO Open 2020)
- 2026-11-03 · keynote-671: Cited 10.1016/S0140-6736(23)02241-2, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1016/S0140-6736(24)01756-2 (Spicer et al., Lancet 2024)
- 2026-11-03 · [person (TRIANGLE paper)](/): Cited 10.1016/S0140-6736(24)00184-0, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1016/S0140-6736(24)00184-3 (Dreyling et al., Lancet 2024)
- 2026-11-03 · picai-prep: Cited 10.1016/S1470-2045, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1016/S1470-2045(24)00220-1 (Saha et al., PI-CAI, Lancet Oncol 2024)
- 2026-11-03 · [person (Malmo tomosynthesis paper)](/): Cited 10.1016/S1470-2045(18)30610-0, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1016/S1470-2045(18)30521-7 (title corrected to the paper's own) (Zackrisson et al., Lancet Oncol 2018)
- 2026-11-03 · propel: Cited 10.1016/S1470-2045(23)00382-9, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1016/S1470-2045(23)00382-0 (Saad et al., Lancet Oncol 2023)
- 2026-11-03 · craniopharyngioma: Cited 10.1016/S1470-2045(23)00492-9, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1056/NEJMoa2213329 (label and timeline year corrected to NEJM 2023) (Brastianos et al., NEJM 2023)
- 2026-11-03 · monarche: Cited 10.1016/S1470-2045(23)00525-2, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1200/JCO.23.01994 (Rastogi et al., JCO 2024 (5-year analysis; HR 0.680 IDFS, 7.6% absolute))
- 2026-11-03 · b-prevention-adoption: Cited 10.1016/S2214-109X(21)00347-3, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1016/j.ypmed.2020.106399 (journal corrected to Preventive Medicine) (Bruni et al., Prev Med 2021; abstract: global final-dose coverage 2019 estimated at 15%)
- 2026-11-03 · [pdgfrb (DFSP prevalence)](/): Cited 10.1038/ng0997-95, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1038/ng0197-95 (Simon et al., Nat Genet 1997)
- 2026-11-03 · [person (CLAM paper)](/): Cited 10.1038/s41551-020-00682-4, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1038/s41551-020-00682-w (Lu et al., Nat Biomed Eng 2021)
- 2026-11-03 · [egfr exon 20 hotspot](/): Cited 10.1038/s41571-018-0081-y, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1038/s41392-019-0038-9 (label corrected to Signal Transduct Target Ther 2019) (Vyse and Huang, STTT 2019)
- 2026-11-03 · [person (Rojas paper)](/): Cited 10.1038/s41586-023-06063-w, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1038/s41586-023-06063-y (Rojas et al., Nature 2023)
- 2026-11-03 · alphagenome: Cited 10.1038/s41586-025-09937-1, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1038/s41586-025-10014-0 (Avsec et al., Nature (issued 2026))
- 2026-11-03 · [person (iStopMM SMM paper)](/): Cited 10.1038/s41591-023-02195-w, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1038/s41591-022-02183-6 (Thorsteinsdottir et al., Nat Med 2023)
- 2026-11-03 · [person (Dutch TME paper)](/): Cited 10.1056/NEJM200108303450901, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1056/NEJMoa010580 (Kapiteijn et al., NEJM 2001)
- 2026-11-03 · [vital omega-3 outcome](/): Cited 10.1056/NEJMoa1809946, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1056/NEJMoa1811403 (Manson et al., NEJM 2019 (marine n-3 fatty acids))
- 2026-11-03 · [person (IASLC mesothelioma paper)](/): Cited 10.1097/JTO.0b013e3182641c0b, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1097/JTO.0b013e31826915f1 (Rusch et al., JTO 2012)
- 2026-11-03 · [person (Kinzler FAP paper)](/): Cited 10.1126/science.1651174, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1126/science.1651562 (Kinzler et al., Science 1991)
- 2026-11-03 · [empower-cscc-1](/): Cited 10.1136/jitc-2020-002757, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1136/jitc-2021-002757 (Rischin et al., JITC 2021; abstract ORR 46.1%)
- 2026-11-03 · pyradiomics: Cited 10.1158/0008-5472.CAN-17-0339_, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1158/0008-5472.CAN-17-0339 (van Griethuysen et al., Cancer Res 2017)
- 2026-11-03 · [person (vorasidenib phase 1)](/): Cited 10.1158/1078-0432.CCR-20-4164, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1158/1078-0432.CCR-21-0611 (Mellinghoff et al., CCR 2021)
- 2026-11-03 · [person (Sadelain CAR design)](/): Cited 10.1158/2159-8290.CD-13-0148, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1158/2159-8290.CD-12-0548 (Sadelain et al., Cancer Discov 2013)
- 2026-11-03 · [r-cvp](/): Cited 10.1182/blood-2004-06-2175, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1182/blood-2004-08-3175 (Marcus et al., Blood 2005)
- 2026-11-03 · [wilms-tumor (very low risk row)](/): Cited 10.1200/JCO.18.02102, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1097/SLA.0000000000001716 (label corrected to Annals of Surgery 2017) (Fernandez et al., Ann Surg 2017, AREN0532 very low risk, nephrectomy only)
- 2026-11-03 · [person (Weber PET paper)](/): Cited 10.1200/JCO.2003.06.120, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1200/JCO.2003.12.004 (Weber et al., JCO 2003)
- 2026-11-03 · cbt-fatigue-distress: Cited 10.1200/JCO.2005.04.8270, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1200/JCO.2006.06.8270 (Gielissen et al., JCO 2006)
- 2026-11-03 · [dfsp](/): Cited 10.1200/JCO.2009.25.9899, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1200/JCO.2009.25.7899 (Rutkowski et al., JCO 2010)
- 2026-11-03 · aphinity: Cited 10.1200/JCO.23.02231, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1200/JCO.23.02505 (Loibl et al., JCO 2024 (third interim OS, 8.4-year follow-up))
- 2026-11-03 · SIO_ASCO_FATIGUE (4 records): Cited 10.1200/JCO.24.00575, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1200/JCO.24.00541 (label corrected to the ASCO-SIO guideline update's title) (Bower et al., JCO 2024)
- 2026-11-03 · [ielsg37](/): Cited 10.1200/JCO.24.01373, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1200/JCO-24-01373 (Martelli et al., JCO 2024 (ASCO's hyphenated DOI form))
- 2026-11-03 · tropion-lung01: Cited 10.1200/JCO.24.01544, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1200/JCO-24-01544 (Ahn et al., JCO 2025 (ASCO's hyphenated DOI form))
- 2026-11-03 · panova-3: Cited 10.1200/JCO.25.00361, a DOI that does not exist (Crossref and doi.org both 404) (Accuracy round 2 full sweep; Crossref and Europe PMC record for the intended paper read in raw text) · Now cites 10.1200/JCO-25-00746 (Babiker et al., JCO 2025; abstract OS 16.2 v 14.2, HR 0.82 (0.68-0.99), P=.039)
- 2026-11-03 · Multiple myeloma: Summary and base burden said median survival in fit patients now exceeds ten years; no source on the record says this. Base burden also undated (~190,000 cases per year) (Accuracy round 2 full sweep; record links (PERSEUS, IMROZ, SEER) and GLOBOCAN 2022 read in raw text) · Removed the survival claim; base burden now "In 2022, GLOBOCAN estimated ~188,000 new cases worldwide; SEER estimates ~36,000 in the US in 2026"
- 2026-11-03 · Sarcomas: "More than 70 subtypes" in the summary and base burden, with no source (Accuracy round 2 full sweep; NCI PDQ adult soft tissue sarcoma read in raw text) · Now "dozens of subtypes", matching the burden line
- 2026-11-03 · DREAMM-8: Said the trial supported a 2025 US approval with pomalidomide; the FDA approved belantamab only with bortezomib-dexamethasone, on DREAMM-7 (Accuracy round 2 full sweep; FDA approval notice of 23 October 2025 read in raw text) · Corrected, with the FDA notice added to the trial's links
- 2026-11-03 · CARTITUDE-4: Overall survival HR 0.55 was attributed to the 2023 NEJM paper (which gave HR 0.78) and to "ASCO 2024" (Accuracy round 2 full sweep; Lancet Oncology 2026 updated analysis read on Europe PMC) · OS row now cites the Lancet Oncology 2026 paper (HR 0.55, 0.39 to 0.79, p 0.0009); paper also linked on cilta-cel and the CARTITUDE-4 key paper
- 2026-11-03 · ISG-STS 1001: Said "grade 3, deep tumours over five centimetres"; the trial took high-grade, deep tumours 5 cm or larger (Accuracy round 2 full sweep; Lancet Oncology 2017 abstract read on Europe PMC) · Now "high-grade, deep tumours five centimetres or larger"
- 2026-11-03 · Acute myeloid leukaemia: Base burden "~20,000 US cases per year; median age 68" was out of date (Accuracy round 2 full sweep; SEER Cancer Stat Facts read in raw text) · Now SEER's ~22,700 new US cases in 2026 and median age 70, with the SEER page linked
- 2026-11-03 · Japan: Said JCOG0403 "established" stereotactic radiotherapy for operable stage I lung cancer; the single-arm phase 2 called it standard only for inoperable patients and "promising" for operable ones (Accuracy round 2 full sweep; IJROBP 2015 abstract read on Europe PMC) · Rewritten to the paper's conclusion, with the paper linked on the card
- 2026-11-03 · EGFR-mutated non-small-cell lung cancer: Subtype shares (exon 19 about 45, L858R about 40, exon 20 about 10 percent) had no source (Accuracy round 2 full sweep; the record's linked papers read) · Percentages removed from the subtype list
- 2026-11-03 · Non-small-cell lung cancer: "About 1.8 million deaths a year" presented as current; it is the GLOBOCAN 2022 estimate (also on the lung cancer page) (Accuracy round 2 full sweep; GLOBOCAN 2022 data read) · Dated to 2022 in three places, GLOBOCAN 2022 linked
- 2026-11-03 · Breast cancer: B-32 survival figures (90.3 against 91.8 percent) were presented for all 5,611 women; they come from the 3,986 with clear sentinel nodes (Accuracy round 2 full sweep; Lancet Oncology 2010 abstract read on Europe PMC) · History note and "Doing less to the armpit" now say the figures are from the 3,986
- 2026-11-03 · Germany: Link to the Deutsches Kinderkrebsregister fails (expired certificate; plain address redirects to a poison centre) (Accuracy round 2 full sweep; Krebs in Deutschland 2025 chapter 4 read in raw text) · Broken link removed; corpus-gaps card now links the KID 2025 chapter on the registry
- 2026-11-03 · Pembrolizumab: US coverage: List price $11,115.20 (2024) cited to a page that no longer exists; drug page had $11,564 (2024) (Accuracy round 2 full sweep; Merck KEYTRUDA financial support page read in raw text) · Now $12,517.44 per 200 mg dose, current as of September 2026, with the live Merck page
- 2026-11-03 · R. Angelo de Claro: Called Director of the FDA Oncology Center of Excellence; the FDA says he has been Deputy Center Director since March 2025 (Accuracy round 2 full sweep; FDA profile read in raw text) · Role, summary, plain summary and the US regulator card corrected; FDA profile linked on the card
- 2026-11-03 · United States: Accelerated-approval counts were typed into the prose (dated 25 September) and could drift from the table beside them (Accuracy round 2 full sweep; src/data/accelerated-approvals.ts and the FDA tables) · Sentence now generated from the same data file as the table (read 17 September 2026)
- 2026-11-03 · Colorectal cancer: Two more copies of the ctDNA range (after chemotherapy "17 to 51", lead time "10 to 16 months"); Heald's TME said to cut local recurrence to "under 10 percent" or "from a quarter to almost none" (Accuracy round 2 full sweep; Henriksen 2022 and Heald 1982 abstracts read on Europe PMC) · ctDNA copies now match the corrected range (11 to 51; 9 to 10 months, up to 16.5); Heald lines now give the paper's own result (no pelvic recurrence in 50 curative operations at two years)
- 2026-11-03 · Zoldonrasib: Second-line response figures were attributed to all 60 patients; ctDNA clearance and "phase 3 planning" were not in the source (Accuracy round 2 full sweep; OncLive ESMO GI 2026 report read in raw text) · Now gives the second-line cohort of 30, the third-line cohort, first-line rates with their numbers, and the RASolute 305 and 309 trials
- 2026-11-03 · Neuroendocrine tumours: Said an FDA decision on 177Lu-edotreotide was due 28 August 2026; the FDA issued a complete response letter on 7 August on manufacturing grounds (Accuracy round 2 full sweep; ITM press release of 10 August 2026 read in raw text) · Updated in the cancer page, the drug, COMPETE, the technology, the regional-approvals row, the plain summary and the ITM company page
- 2026-11-03 · The margin in skin cancer surgery: A dermoscopy figure (16.8 per cent) and an incomplete-excision range (2.6 to 15 per cent) had no source (Accuracy round 2 full sweep; the four linked papers read) · Both figures removed
- 2026-11-03 · Ovarian, endometrial and cervical cancer: Base burdens gave GLOBOCAN 2022 figures as if current (Accuracy round 2 full sweep; GLOBOCAN 2022 data read) · Dated to 2022; ovarian 320,000 corrected to 325,000
- 2026-11-03 · 212Pb-DOTAMTATE (AlphaMedix): Response rate 54.3 percent and survival percentages were not in the cited Sanofi release, which gives no figures (Accuracy round 2 full sweep; Sanofi release of 8 October 2025 read in raw text) · Figures removed from the drug, ALPHAMEDIX-02, the technology page and the plain summaries; cohort sizes and the February 2024 Breakthrough date added
- 2026-11-03 · EPCORE DLBCL-1: Enrolment given as 552 (Accuracy round 2 full sweep; ClinicalTrials.gov NCT04628494 read) · Now 483 (actual)
- 2026-11-03 · CD79b: "More than 95 percent" of DLBCL said to express CD79b, cited to a signalling paper and to a DOI that is a blinatumomab trial (Accuracy round 2 full sweep; Crossref and Europe PMC records read) · Percentage removed in five places; wrong link replaced with the polatuzumab phase 1 paper
- 2026-11-03 · Follicular lymphoma: "About 85 percent" with a BCL2 translocation had no source (Accuracy round 2 full sweep; NCI PDQ (health professional) read in raw text) · Now "more than 90 percent" with a BCL2 rearrangement, NCI PDQ linked
- 2026-11-03 · JCOG9801: Called the only randomised trial ever run in adult T-cell leukaemia/lymphoma; a randomised phase 2 was published in 2015 (Accuracy round 2 full sweep; Ishida 2015 (British Journal of Haematology) read on Europe PMC) · Reworded in seven places; the 2015 trial is named and linked
- 2026-11-03 · Peripheral T-cell lymphoma: History said romidepsin was approved for PTCL in 2009; that approval was in 2011 (Accuracy round 2 full sweep; FDA accelerated-approval tables) · Corrected
- 2026-11-03 · Varnimcabtagene autoleucel (Qartemi): Approval in India dated 2024 with no source; AABB reported it as recent on 29 January 2025 (Accuracy round 2 full sweep; AABB news item read in raw text) · Year removed from the prose in six places; AABB linked
- 2026-11-03 · KEYNOTE-564: Overall survival p-value given as 0.002 and the 48-month survival figures labelled as 57-month follow-up, citing a news report (Accuracy round 2 full sweep; NEJM 2024 abstract (10.1056/NEJMoa2312695) read in raw text) · p corrected to 0.005, endpoint relabelled overall survival at 48 months (median follow-up 57.2 months), source changed to the NEJM paper
- 2026-11-03 · CheckMate 274: Overall survival figures (75 vs 50.1 months, HR 0.83) cited to the 2021 NEJM paper, which reports disease-free survival only (Accuracy round 2 full sweep; Europe PMC abstract of 10.1056/NEJMoa2034442 and Urology Times 5-year report read in raw text) · Source changed to the 5-year interim report and endpoint labelled as interim
- 2026-11-03 · ArteraAI Prostate: FDA de novo authorisation dated August 2025 (event 14 August 2025) (Accuracy round 2 full sweep; FDA De Novo database entry DEN240068 read in raw text) · Date corrected to 31 July 2025 in the summary, regulatory event, regional approval note and benchmark answer
- 2026-11-03 · Bladder cancer: Called the tenth most common cancer worldwide (GLOBOCAN 2022 has it ninth) and the most expensive per patient with no source (Accuracy round 2 full sweep; GLOBOCAN 2022 data and Botteman et al. 2003 abstract read in raw text) · Rank corrected and dated to GLOBOCAN 2022; cost claim scoped to the 2003 review of US costs and the review added as a link, also on the urine tumour DNA idea
- 2026-11-03 · Elevar Therapeutics: Third complete response letter for camrelizumab plus rivoceranib dated 23 July 2026 (the PDUFA date) (Accuracy round 2 full sweep; Targeted Oncology report of the 10 July 2026 Elevar release read in raw text) · Date corrected to 10 July 2026 in the company summary, the drug's regulatory event and the regional approval note
- 2026-11-03 · Gallbladder cancer: Zanidatamab eligibility given as HER2 IHC 3+ or amplified; the FDA, EU and NICE wording is IHC 3+ only (Accuracy round 2 full sweep; NICE TA1153, FDA label (openFDA) and EMA EPAR read in raw text) · Zanidatamab scoped to IHC 3+ on the gallbladder row and on the cholangiocarcinoma row
- 2026-11-03 · United States: cancer burden: "Mortality-to-incidence ratio of 0.22" was the ratio of age-standardised rates, unlabelled (the ratio of counts is 0.25); the gaps list said the percentage fall in the death rate since 1991 was only in the paper's tables (Accuracy round 2 full sweep; GLOBOCAN 2022 country data (public/globocan/countries.json) and Siegel et al, Cancer statistics 2026 full text (Europe PMC) read in raw text) · Relabelled as a ratio of age-standardised mortality to incidence; added the paper's own "34 per cent drop from 1991 through 2023" and removed the gap entry
- 2026-11-03 · United States: modifiable risk factors: The 2014 estimate (42.0 and 45.1 per cent) had no source on the card, and "the small fall is mostly smoking" was not supported (smoking's share of cases rose); "smoking ... and falling" had no source (Accuracy round 2 full sweep; Islami et al 2018 and 2024 abstracts (Europe PMC) and CDC FastStats read in raw text) · Added the Islami 2018 paper as a link; replaced the smoking claim with the stated difference in scope (26 cancer types and six infections against 30 and seven); removed "and falling"
- 2026-11-03 · United States: screening: Colorectal screening uptake given as 76.3 per cent against 41.5 per cent in 1999, and 78.1 against 33.0 per cent by insurance, figures in no cited source; plain summary said three of four screenings reach three quarters; cervical recommendation had no link (Accuracy round 2 full sweep; Sabatino et al, Use of cancer screening tests, United States, 2023 (Prev Chronic Dis 2025) and USPSTF pages read in raw text) · Colorectal uptake corrected to 67.4 per cent of adults 45 to 75 (73.4 at 50 to 75, 37.1 at 45 to 49); insurance split corrected to 64.7 per cent privately insured against 23.8 per cent uninsured, under 65; plain summary corrected; PCD paper and USPSTF cervical page added as links
- 2026-11-03 · United States: Medicare Part B and Part D: Pembrolizumab list price (11,115.20 dollars, 2024) cited to a Merck page that now returns Not Found; ASP plus 6 per cent had no source on the card (Accuracy round 2 full sweep; keytruda.com financial support page and CMS average sales price page read in raw text) · Price updated to Merck's current 12,517.44 dollars per three-weekly dose (read November 2026) with the live link; CMS ASP page added as a link
- 2026-11-03 · United States: insured but not able to afford it: "88 per cent of covered workers" face a deductible; KFF says 88 per cent of workers with single coverage (Accuracy round 2 full sweep; KFF 2025 Employer Health Benefits Survey read in raw text) · Corrected to workers with single coverage
- 2026-11-03 · United States: NCCN guidelines and evidence: Wagner et al's conclusion stated as fact ("NCCN was justifying"), where the paper says its findings "raise concern"; Kurzrock et al's aggregate conflict threshold is "more than" 50,000 dollars (Accuracy round 2 full sweep; Wagner et al (BMJ 2018) abstract and Kurzrock et al (Ann Oncol 2019) full text read in raw text) · Conclusion reworded to the paper's own hedge; "more than 50,000 dollars"
- 2026-11-03 · United States: prior authorisation and pathways: ClinicalPath 80 per cent and Evolent 50 per cent figures had no source on the card; "which absorbed New Century Health" unsourced (Accuracy round 2 full sweep; Elsevier ClinicalPath and Evolent oncology pages read in raw text) · Added both vendor pages as links; removed the unsourced aside
- 2026-11-03 · United States: drug prices: RAND said to leave rebates "substantial and undisclosed", when RAND estimates them (brand-name prices 308 per cent after adjustment); Enhancing Oncology Model said to have "a much smaller group of practices", not in the source (Accuracy round 2 full sweep; RAND RR-A788-3 report PDF and CMS OCM final evaluation report read in raw text) · Rebate clause replaced with the 308 per cent figure; EOM sentence now gives its start date (1 July 2023) and similar episode-based design, as the report says
- 2026-11-03 · United States: the FDA: Project Orbis partner list omitted Japan; "led the FDA's oncology review since 1999" for Richard Pazdur had no source (Accuracy round 2 full sweep; FDA Project Orbis page and 2024 OCE annual report read in raw text) · Japan added; Pazdur described as signing the report as the centre's director
- 2026-11-03 · United States: approval pathways: Breakthrough therapy and RTOR details had no source on the card; RTOR said not to change "the statutory clock", which the FDA page does not say (Accuracy round 2 full sweep; FDA breakthrough therapy and RTOR pages read in raw text) · Added both FDA pages as links; RTOR now "without changing the statutory and regulatory requirements for approval", as the FDA states
- 2026-11-03 · United States: trial enrolment: Unger et al's pathway shares of all patients (55.6, 21.5, 14.8 per cent) presented as conditional rates, and 77.1 per cent called a share "of non-enrolment" (Accuracy round 2 full sweep; Unger et al (JNCI 2019) abstract read in raw text) · Rewritten as shares of all patients; 77.1 per cent of patients, more than three in four
- 2026-11-03 · United States: oncology workforce: CDC death rate of 180 per 100,000 is for nonmetropolitan rural counties, not all nonmetropolitan counties; the 1.0 and 1.6 per cent annual falls are for 2006 to 2015 (Accuracy round 2 full sweep; Henley et al (MMWR 2017) read in raw text) · Labelled rural and dated the trend
- 2026-11-03 · United States: equal-access systems: Medicaid expansion literature (Lam et al, a cross-sectional difference-in-difference study) described as showing the result "prospectively" (Accuracy round 2 full sweep; Lam et al (JAMA Netw Open 2020) abstract read in raw text) · Changed to "points the same way"
- 2026-11-03 · United States: what could not be sourced: Said the 2025 OCE annual report PDF could not be read (it can); listed the Hispanic and Latino statistics as the 2021 report and the ACS series as three-yearly, when a 2026 Hispanic and Latino report exists (Accuracy round 2 full sweep; FDA 2025 OCE annual report PDF and Europe PMC record for Saka et al, Cancer statistics for Hispanic/Latino people, 2026 read in raw text) · OCE entry now says the 2025 report gives approvals by category rather than one HTML total; ACS entry says "every few years" and names the 2026 Hispanic and Latino report as not yet drawn on
- 2026-11-03 · United Kingdom: an ordinary rich country's cancer rate: Mortality-to-incidence ratios for Australia (0.19), Canada (0.26) and Sweden (0.28) did not match the GLOBOCAN 2022 rates the sentence says it uses; the plan quotation had dropped a dash (Accuracy round 2 full sweep; GLOBOCAN 2022 country rates and the National Cancer Plan read in raw text) · Ratios corrected to 0.18, 0.28 and 0.27; the plan's wording restored inside the quotation
- 2026-11-03 · United Kingdom: how the country counts cancer: The 1 October 2021 move of the registry from Public Health England to NHS Digital had no source on the card (Accuracy round 2 full sweep; NHS Digital NDRS page read in raw text (archived copy)) · Added the NHS Digital source
- 2026-11-03 · United Kingdom: what drives it: 37 percent of pancreatic cancers called preventable where Cancer Research UK says 31; the 169 percent skin cancer rise, the smoking and UV shares and the deprivation gradient had no source on the card (Accuracy round 2 full sweep; Cancer Research UK statistics pages read in raw text) · Pancreatic figure corrected to 31 percent; six Cancer Research UK pages added as sources
- 2026-11-03 · United Kingdom: four health services: The section 2(1) quotation put words inside the quotation marks that the statute does not use; "five" trusts omitted the sixth (ambulance) trust; devolution dates had no source (Accuracy round 2 full sweep; legislation.gov.uk and nidirect read in raw text) · Quotation closed where the statute's words end; trusts described as five area trusts and an ambulance trust; three commencement orders added as sources
- 2026-11-03 · United Kingdom: four waiting-time standards: England's 28-day standard was said to include consultant upgrades (it does not) and the 31-day standard was described as first treatment only; Northern Ireland's 31-day and breast figures had no source on the card (Accuracy round 2 full sweep; NHS England guidance and the Department of Health (NI) workbook read in raw text) · Standards restated as the guidance gives them; guidance and NI workbook added
- 2026-11-03 · United Kingdom: what each nation publishes: Said Northern Ireland publishes the 62-day standard without a tumour-site split; its quarterly workbooks carry 62-day waits by tumour site (Accuracy round 2 full sweep; Department of Health (NI) workbooks read in raw text) · Corrected, with the NI release and the registry's lung report (and its 2019 to 2023 cohort) added
- 2026-11-03 · United Kingdom: different screening ages: Northern Ireland was said to be still considering a lower bowel screening age when it has started extending to 50 by 2031; the 49 percent rise was attributed to the minister rather than Public Health Scotland; an unsourced Welsh cervical date; "March 2030" for lung screening where the plan says 2030; Scottish, Welsh and breast screening ages had no source on the card (Accuracy round 2 full sweep; nidirect, NHS inform, Public Health Wales, SPICe, GOV.UK and the National Cancer Plan read in raw text) · Updated Northern Ireland's plan, attributed the figure, removed the date, corrected the year, added eight sources
- 2026-11-03 · United Kingdom: free at the point of use: Tax credits were said to have ended on 23 June 2025 (NHSBSA: payments ended 5 April 2025); two later exemption dates and the parking dates had no source (Accuracy round 2 full sweep; NHSBSA, GOV.UK parking principles, NHS England's March 2021 letter and the Scottish Government's 2008 release read in raw text) · Tax credit date corrected, unsourced dates removed, parking dates restated with four sources
- 2026-11-03 · United Kingdom: prescription charges: The 2009 regulations' title and wording were misquoted; the 2024 charge date, the 2007/2010/2011 abolition dates and the Welsh form had no source (Accuracy round 2 full sweep; legislation.gov.uk, the NI Assembly record and the Welsh Government page read in raw text) · Title corrected, quotation marks removed, six sources added
- 2026-11-03 · United Kingdom: paying privately for a drug: Two quotations attributed to the 2008 Richards report do not appear in it; the day of publication is not in it either (Accuracy round 2 full sweep; the Richards report read in raw text) · Replaced with the report's own words; dated November 2008
- 2026-11-03 · United Kingdom: one licence, four decisions: The MHRA was called the sole UK regulator since 2021 (UK-wide only since 1 January 2025); regulation 7 was said to set a 30-day period it does not contain; Scottish Medicines Consortium counts and other figures had no source (Accuracy round 2 full sweep; MHRA, legislation.gov.uk, NICE, SMC and Northern Ireland Formulary pages read in raw text) · Corrected the regulator and funding-period statements, removed unsourced SMC counts, added five sources
- 2026-11-03 · United Kingdom: the three kinds of no: NICE's cancer appraisal counts quoted as 596 and 666 with 96 refusals; the page now says 600 and 672 and gives no refusal count (Accuracy round 2 full sweep; NICE cancer appraisal data page read in raw text) · Quotation and summary updated to the page's current figures
- 2026-11-03 · United Kingdom: the Cancer Drugs Fund: "14 cancer medicines" in managed access where NICE's page lists nine; an unsourced count of three Innovative Medicines Fund recommendations; a quotation that expanded "CDF" inside the quotation marks (Accuracy round 2 full sweep; NICE managed access page and spreadsheet and the NHS England 2016 document read in raw text) · Counts corrected to NICE's page; quotation restored; spreadsheet linked
- 2026-11-03 · United Kingdom: how often the nations disagree: Scotland's second-tier PACS dated February 2018 (the announcement is December 2016); an unsourced October 2018 ultra-orphan date and 2017 Welsh review (Accuracy round 2 full sweep; Scottish Government release, SMC and AWTTC pages read in raw text) · Dates corrected or removed
- 2026-11-03 · United Kingdom: trials that ask whether a treatment is worth having: STAMPEDE credited with "one million life years" and a 2023 end date that no source gives; an unsourced "100 trials, 80,000 people" for Cancer Research UK; unsourced "nine centres" for ProtecT (Accuracy round 2 full sweep; UCL trials unit, CRUK annual report, Europe PMC abstracts read in raw text) · Unsourced figures removed; ECMC and UCL sources added
- 2026-11-03 · United Kingdom: national cancer audits: Lung audit figures were England's but read as the audit's; an unchecked prostate audit claim (Accuracy round 2 full sweep; NLCA and NBOCA reports read in raw text) · Labelled "for England"; prostate clause removed
- 2026-11-03 · United Kingdom: genomics as a national service: "More than 85,000 participants" (Genomics England: around 85,000 patients); seven hubs, the 2012 announcement and both neuro-oncology studies had no source on the card (Accuracy round 2 full sweep; Genomics England, NHS England, GOV.UK and Europe PMC read in raw text) · Wording corrected; four sources added
- 2026-11-03 · United Kingdom: one screening committee: The prostate consultation was said to close on 24 February 2026 (deadline 20 to 23 February); NHS-Galleri start month and an ASCO claim had no source; modelling, TRANSFORM, 1996 and 2040 claims had no source on the card (Accuracy round 2 full sweep; UK NSC blog and coversheet, Prostate Cancer UK, Nature Medicine and the code of practice read in raw text) · Date softened to February 2026, unsourced Galleri details removed, six sources added
- 2026-11-03 · United Kingdom: last of seven comparable countries: The partnership was quoted "in its own words" with words its page does not use, and said to be hosted by Cancer Research UK; the SURVMARK-2 quotation had its dates restyled (Accuracy round 2 full sweep; Cancer Research UK ICBP page and the Lancet Oncology abstract read in raw text) · Reworded to the page's stated aim; quotation restored
- 2026-11-03 · United Kingdom: a waiting-time standard last met in December 2015: A count of 17,404 people waiting over 62 days had no source; the December 2015 figures were not in the linked time series (Accuracy round 2 full sweep; NHS England time series (2023 and 2026 editions) and the National Cancer Plan read in raw text) · Unsourced sentence removed; the older NHS England series added
- 2026-11-03 · United Kingdom: spending and equipment: CT scanners given as 9.9 per million (OECD now: 9.5 in 2024, fourth lowest of 33) and bed and spending ranks out of date; the King's Fund quotation was abbreviated inside the quotation marks; an unconfirmed charity-register removal date for the National Cancer Research Institute (Accuracy round 2 full sweep; OECD SDMX health data, the King's Fund report and the NCRI letter read in raw text) · Figures and ranks updated, quotation restored, unconfirmed date removed, NCRI letter linked
- 2026-11-03 · United Kingdom: slowest at getting a trial started: The O'Shaughnessy review dated February 2023 (published May 2023); 394 trials read as phase 3 when it is all commercial trials; "up to 121 million over three years" not in the source; the 250-to-150-day pledge credited to the plan (Accuracy round 2 full sweep; GOV.UK review pages and the Life Sciences Competitiveness Indicators data tables read in raw text) · Dates and attributions corrected; data tables and review page linked
- 2026-11-03 · United Kingdom: named gaps: Said the Northern Ireland Cancer Registry answers HTTP 403 to every request; it now opens (Accuracy round 2 full sweep; qub.ac.uk read in raw text) · Gap rewritten
- 2026-11-03 · Germany: cancer profile: Survival range said "95 percent or more" for melanoma and testicular cancer; the RKI report says around or above 95 percent (Accuracy round 2 full sweep; Krebs in Deutschland 2025, Krebs gesamt chapter, read in raw text) · Now "around 95 percent or more"
- 2026-11-03 · Germany: why the German and international numbers differ: Called the old European standard population "younger-weighted" than the World standard; it is the other way round, and the RKI methods chapter does not say either (Accuracy round 2 full sweep; Krebs in Deutschland 2025 methods chapter read in raw text) · Removed the comparison; it now says only that the RKI uses the old European standard, not the World standard
- 2026-11-03 · Germany: what is actually changing: Said the report calls the lung cancer divergence its "flagship trend" (it does not); credited the report with the colonoscopy explanation for falling bowel cancer, which is in the ZfKD fact sheet; the HPV "women up to about 35" figure came from that fact sheet too, and the card did not link it (Accuracy round 2 full sweep; KiD 2025 lung, colorectal and cervix chapters and the ZfKD Krebs gesamt fact sheet read in raw text) · Lung sentence now says the report describes rates moving in opposite directions; the colonoscopy sentence is credited to the fact sheet; fact sheet added as a link
- 2026-11-03 · Germany: registering a cancer is a legal duty: Said dentists must report and that the Länder pay the rest of registry costs; no linked source says either (Accuracy round 2 full sweep; section 65c SGB V, Plattform 65c and basisdatensatz.de read in raw text) · Now "every doctor"; removed "with the remainder falling to the Länder"
- 2026-11-03 · Germany: where the data goes: Said Hamburg's registry goes back to 1926, which none of the sources read states; the 1967 and 2009 dates had no source on the card (Accuracy round 2 full sweep; ZfKD completeness-estimation page read in raw text) · Removed the Hamburg clause; added the ZfKD page that gives 1967 (Saarland) and 2009
- 2026-11-03 · Germany: how complete is it: The 8 percent survival-registry criterion and the DCO survival bias were not stated in any source on the card (Accuracy round 2 full sweep; ZfKD survival-methods page read in raw text) · Added the ZfKD survival-methods page as a link
- 2026-11-03 · Germany: what the registry does not count: The skin-cancer method details and the childhood registry figures (95 percent complete since 1987, 80,000 cases, 2,350 a year) were correct but sourced only to the full report, which the card did not link; kinderkrebsregister.de cannot be read (expired certificate) (Accuracy round 2 full sweep; Krebs in Deutschland 2025 full report, chapters 2 and 4, read in raw text) · Added the full KiD 2025 report as a link
- 2026-11-03 · Germany: the fastest country in Europe for a new cancer medicine: Said Germany had all 56 oncology medicines in the EFPIA W.A.I.T. 2025 survey, the only country at 100 percent, ahead of Austria at 51 and Italy at 50. The report gives Germany 51 of 56 (91 percent), Italy 50 and Austria 48; the 100 percent is Germany's share of its 51 with full availability. The median ranking also skipped Serbia (235 days) (Accuracy round 2 full sweep; EFPIA Patients W.A.I.T. Indicator 2025 PDF read in raw text) · Corrected to 51 of 56, the most of any country, ahead of Italy at 50 and Austria at 48, all 51 fully available; Serbia added to the ranking; plain summary corrected to match
- 2026-11-03 · Germany: the price guardrails of 2022, and their repeal: The 2022 guardrails were described as applying to every drug with minor or unmeasurable benefit, but they applied only where the comparator was patent-protected; the 2026 rebate-contract classes were called three cancer classes when the law names two (PARP, PD-1/PD-L1); the Medizinforschungsgesetz figures had no link on the card (Accuracy round 2 full sweep; GKV-FinStG and GKV-BSaStabG texts (buzer) and BGBl. 2024 I Nr. 324 read in raw text) · Added the patent-protected condition in plain and detail; two cancer classes, with JAK inhibitors noted as including myelofibrosis drugs; Medizinforschungsgesetz link added
- 2026-11-03 · Germany: reimbursed on day one, judged afterwards, priced last: Said the seventh-month rule "used to be the thirteenth", which no cited source states; the 95 percent negotiated / 5 percent arbitrated figure had no link on the card (Accuracy round 2 full sweep; G-BA procedure page, GKV-FinStG text and Bundestag Drucksache 20/3448 read in raw text) · Removed the thirteenth-month claim and kept the verified dates; added the GKV-FinStG and vfa AMNOG in 10 Zahlen links
- 2026-11-03 · Germany: what happens when the answer is no added benefit: Opt-out count dated 13 August 2026 (twenty plus two mixed); the register now lists twenty-one opt-outs plus two mixed (Accuracy round 2 full sweep; GKV-Spitzenverband register queried by status) · Updated to twenty-one plus two, twenty-three in all, as read on 3 November 2026
- 2026-11-03 · Germany: six grades, and how often cancer drugs reach them: The falling 58 to 43 percent trend read as the oncology share; in the vfa report it is the share across all procedures (Accuracy round 2 full sweep; vfa AMNOG in 10 Zahlen 2026 read in raw text) · Said explicitly that the share across all medicines has been falling
- 2026-11-03 · Germany: the argument about the method: Plain summary said IQWiG only counts a quality-of-life difference that reaches 15 percent of the scale; the 15 percent applies to responder thresholds, and continuous data are also accepted through standardised mean differences (Accuracy round 2 full sweep; IQWiG Allgemeine Methoden 7.0 read in raw text) · Reworded to the responder-threshold rule
- 2026-11-03 · Germany: Europe now does part of the assessment: "Four joint assessments had been published by 1 September 2026" had no source on the card (Accuracy round 2 full sweep; IQWiG press release of 1 September 2026 read in raw text) · Added the IQWiG press release as a link; figure unchanged
- 2026-11-03 · Germany: who approves a cancer drug: The figure of about 1,350 BfArM staff had no source on the card; the linked tasks page does not state it (Accuracy round 2 full sweep; BfArM "About us" page read in raw text ("roughly 1,350 employees")) · Added the BfArM about page as a link; figure unchanged
- 2026-11-03 · Germany: how certification works: The link to the 2026 annual report of the certified Onkologische Zentren returned a 404 page (Accuracy round 2 full sweep; DKG Jahresbericht OZ 2026 (working file) read in raw text) · Link repaired; the 2003/2006/2008/2023 history it supports was confirmed
- 2026-11-03 · Germany: what the certification criteria demand: Presented the follow-up rule (below 60 percent, no recertification) as applying to every centre; the Erhebungsbogen sets it for bowel, pancreatic and prostate cancer, not breast (Accuracy round 2 full sweep; DKG Erhebungsbögen Brust (11 Dec 2025) and Darm (16 Dec 2025) read in raw text) · Plain summary now says "a bowel centre"; detail now opens "For bowel, pancreatic and prostate cancer"
- 2026-11-03 · Germany: WiZen: Said the registry analysis "showed no effect at all" for rectum, pancreas and ovary, when the hazard ratios were below 1 but not significant (0.978, 0.972, 0.964); a source label named Schoffer as first author of the pancreatic paper, whose first author is Roessler (Accuracy round 2 full sweep; WiZen Ergebnisbericht Tabelle 6 and Europe PMC record for 10.1186/s12885-022-09731-w read in raw text) · Now "showed no significant effect"; label now "Roessler 2022"
- 2026-11-03 · Germany: nNGM lung cancer network: Said the network has more than 500 network partners; no nNGM page states a partner count (29 centres is right) (Accuracy round 2 full sweep; nNGM home, centres, partners and cooperating-funds pages read in raw text) · Removed the 500 figure; kept 29 centres
- 2026-11-03 · Germany: MASTER: Plain summary said the genome was sequenced in all 1,310 patients; the paper says whole-genome or whole-exome plus RNA sequencing (Accuracy round 2 full sweep; Horak 2021 abstract (Europe PMC) read in raw text) · Now "the whole genome or exome and the RNA"
- 2026-11-03 · Germany: the 700 million euro model project: Said the contract deadline was pushed back three times; the GKV-Spitzenverband lists the original 1 January 2023 deadline and two postponements (1 January 2024, then 1 April 2024) (Accuracy round 2 full sweep; GKV-Spitzenverband section 64e page read in raw text) · Now "the deadline was pushed back twice"
- 2026-11-03 · Germany: off-label use: Said most of the 58 active Annex VI entries are oncology; about 25 of 58 are cancer indications (Accuracy round 2 full sweep; G-BA Annex VI in force 11 June 2026 read in raw text) · Now "many of them in oncology"; counts 42 and 16 confirmed
- 2026-11-03 · Germany: organised screening: Listed lung cancer among the programmes people are invited to by letter, and said the G-BA asked IQWiG to re-examine the colonoscopy age limit and frequency, which the cited decision does not say (IQWiG was asked to revise the invitation materials); lung screening was described in the future tense though it began in April 2026, with an unsourced claim that Germany was one of the first large European countries to fund it (Accuracy round 2 full sweep; G-BA Tragende Gründe of 16 January 2025 and Krebsinformationsdienst screening page read in raw text) · Lung screening stated separately (paid by the funds since April 2026, heavy smokers 50 to 75, yearly low-dose CT); IQWiG clause replaced by the decision's two-yearly stool test from 50; European comparison removed
- 2026-11-03 · Germany: academic trial groups: Said the German Hodgkin Study Group had randomised tens of thousands of patients since 1978; its site says over 15,000 patients and gives no founding year (Accuracy round 2 full sweep; GHSG "About the GHSG" page read in raw text) · Now "has enrolled more than 15,000 patients in its trials"
- 2026-11-03 · Israel: cancer profile, high incidence and low mortality: Arab men's later survival period was given as 2010-2016 (the registry says 2010-2015); GLOBOCAN ranks (40th, 110th) were undated (Accuracy round 2 full sweep; Israel National Cancer Registry 2021 update (Hebrew PDF) read in raw text) · Period corrected; ranks dated as Global Cancer Observatory 2022 estimates
- 2026-11-03 · Israel: one health system, four sets of numbers: 'Did not move at all' overstated a stable Arab breast-mortality trend; plain summary said Arab men smoke at 'nearly twice' the Jewish rate (report: 1.7 times) (Accuracy round 2 full sweep; registry breast report and Health Minister's smoking report 2025 read in raw text) · Now 'was stable' and '1.7 times'
- 2026-11-03 · Israel: cervical cancer and pre-cancer: HPV vaccination said to cover both sexes since September 2013 (it began for eighth-grade girls in 2013 and was later extended to boys); 2024 screening definition said to admit HPV and self-testing (not in the source); cervical rank undated; programme deck link dead (Accuracy round 2 full sweep; Chodick and Strassberg (J Clin Med 2026) full text, registry cervical report and NPQICH 2024 deck read in raw text) · Sentence corrected and source added; definition clause replaced; rank dated 2022; link repointed to the live deck
- 2026-11-03 · Israel: screening programmes: The 1990 campaign and 1995 national mammography start were not in any source the card cited (Accuracy round 2 full sweep; registry breast report read in raw text) · Breast registry report added as a source
- 2026-11-03 · Israel: the registry's own warning about its numbers: Stage-completeness and receptor-status figures came from reports not linked on the card; 'the 2020 report reflected only about 92 percent of expected cases' had no source (Accuracy round 2 full sweep; registry breast, colorectal, cervical and melanoma reports and Moore (IMAJ 2021) read in raw text) · Four registry reports added as sources; the 92 percent clause removed
- 2026-11-03 · Israel: how the health basket committee works: Claimed the 2010 procedure followed an Israel Medical Association High Court case; no source says so (Accuracy round 2 full sweep; State Comptroller May 2022 report and Knesset research paper read in raw text) · Clause removed
- 2026-11-03 · Israel: 650 million shekels against a basket of 75 billion: Called the Comptroller's 460 million against 500 million an unresolved discrepancy, though its own footnote says the table leaves out dental care; the 26 percent shortfall was attributed to the wrong calculation; 300 million and 550 million figures had no linked source (Accuracy round 2 full sweep; State Comptroller report, Taub Center paper, Adva Center paper and IMA position paper read in raw text) · Footnote explanation given; 26 percent correctly attributed (population and prices only); Adva and IMA added as sources
- 2026-11-03 · Israel: cancer's share of the basket: 'About half the 2019 budget went to cancer' had no source; 2025 described as the first time oncology was outbid (not stated); plain summary said an infant vaccine alone outbid cancer (it was infectious disease as a category) (Accuracy round 2 full sweep; ESMO Open 2022, IJTAHC 2023 and Calcalist 6 Feb 2025 read in raw text) · 2019 sentence removed; 'for the first time' removed; plain summary corrected
- 2026-11-03 · Israel: what happens to a drug that does not get in: Personal or pharmacy import attributed to the Comptroller's list of routes, which does not include it (Accuracy round 2 full sweep; State Comptroller report and National Health Insurance Law read in raw text) · Import removed; treatment abroad attributed to section 11 of the law
- 2026-11-03 · Israel: what the state auditor says is wrong with it: Said rejected applicants are never told why (the procedure requires the forum to notify them; the finding concerns the committee); implied the cancer registry cannot compel reporting; per-year 40 percent set beside a period total (Accuracy round 2 full sweep; State Comptroller May 2022 report read in raw text) · Wording corrected in detail and plain summary
- 2026-11-03 · Israel: the four health funds: Health-tax rates given as '2026' with a 123-shekel minimum not in the cited report (Accuracy round 2 full sweep; National Insurance Institute Annual Report 2024, chapter 4, read in raw text) · Now 3.235 and 5.165 percent since 2025; minimum removed
- 2026-11-03 · Israel: what a cancer patient pays: Maccabi figures (33, 257, 1,199 and 367 shekels) were superseded and not on the linked page (Accuracy round 2 full sweep; Maccabi tariff (October 2026) and Leumit schedule (July 2026) read in raw text) · Updated to 34, 266, 1,259 and 379; Maccabi tariff linked
- 2026-11-03 · Israel: supplementary insurance: Meuhedet premium figures had no source (Accuracy round 2 full sweep; Leumit rulebook July 2026 and Adva Center paper read in raw text) · Premium sentence removed; listed as a gap
- 2026-11-03 · Israel: a small health budget: OECD figures (7.089 percent of GDP, 39th of 50, financing 65.24/12.83/20.49) superseded by the current OECD release (Accuracy round 2 full sweep; OECD SHA SDMX data read in raw text) · Now 6.76 percent (flagged by OECD), Japan 10.4, financing 62.7/11.7/24.4; rank dropped; plain summary now 'about a quarter' paid directly
- 2026-11-03 · Israel: who licenses a cancer drug: Said oncology carried 'the highest risk' of label change (the paper says it was an independent predictor); 620-application figure from an unlinked paper (Accuracy round 2 full sweep; Hiayev (BMJ Open 2023) and Vishkautzan (BMJ Open 2026) read in raw text) · Wording corrected; Vishkautzan added
- 2026-11-03 · Israel: leaning on other regulators: The 70-day route was presented without its exclusion of biologics and blood products (Accuracy round 2 full sweep; Pharmacists Ordinance s.47A read in raw text) · Exclusion added to detail and plain summary
- 2026-11-03 · Israel: what a founder variant is: Ahmad 2023 cited under an invented title; Neuhausen 1996 cited without a link (Accuracy round 2 full sweep; Europe PMC records read) · Label corrected; Neuhausen added
- 2026-11-03 · Israel: the three Ashkenazi BRCA founder variants: Struewing 1995 and Oddoux 1996 figures cited without their papers (Accuracy round 2 full sweep; Europe PMC abstracts read) · Both papers added as sources
- 2026-11-03 · Israel: the national BRCA programme: Plain summary called it a 'three-variant test' (the circular says common mutations; Clalit tested 14) (Accuracy round 2 full sweep; MoH circular 3/2020 and Greenberg (GIMO 2023) read in raw text) · Now 'founder-variant test'
- 2026-11-03 · Israel: founder variants that get less attention: Four of six paper labels had invented titles; Ethiopian-descent date and numbers (1 Sept 2025, a million, 42,000-47,000) unsourced; a 68-family Arab panel finding unsourced; carrier clinics given as ten with a geographic gap (source: nine, no geography) (Accuracy round 2 full sweep; Europe PMC abstracts, ICA annual report 2025 and Michaelson-Cohen (2026) read in raw text) · Labels corrected; unsourced figures removed; clinics corrected to nine; ICA report and Michaelson-Cohen added
- 2026-11-03 · Israel: APC I1307K: Implied the Leshno cancer patients came from the healthy screening cohort; a 128/84 founder-panel finding had no source (Accuracy round 2 full sweep; Leshno (Int J Cancer 2016) and InSiGHT 2023 read in raw text) · Two groups named; panel clause removed
- 2026-11-03 · Israel: what knowing changes: POLO overall-survival paper credited to Golan (first author is Kindler); the Sheba breast-surveillance cohort was uncited (Accuracy round 2 full sweep; Europe PMC records read) · Label corrected; Bernstein-Molho (Breast 2020) added
- 2026-11-03 · Israel: why sponsors come: Clalit data span, KSM and Leumit figures had no source; Pfizer agreement called 'weekly' (Accuracy round 2 full sweep; archived Clalit page, Dagan (NEJM 2021) and Rosen (IJHPR 2021) read in raw text) · Unsourced figures removed; 'weekly' removed
- 2026-11-03 · Israel: two hospitals that make their own cell therapies: Sheba commercial-rescue claim and 'more than a decade before any regulator' unsourced (Accuracy round 2 full sweep; Itzhaki (JITC 2020) full text read) · Both removed
- 2026-11-03 · Israel: four things the world uses: Eshhar 1993, Gabizon 1994 and the Doxil approval month cited without sources; SEC settlement said to record a 60-million expense and cetuximab sales, which it does not (Accuracy round 2 full sweep; SEC exhibit 10.40, openFDA NDA 050718 and Europe PMC records read) · Sources added; settlement now described as two 60-million lump sums; sales figure removed
- 2026-11-03 · Israel: diagnostics and devices: Insightec's 'only oncology approval' overstated; going-concern, P-Cure indication, Gamida insolvency and Teva revenue had no source; Nucleix, P-Cure and motixafortide dates uncited (Accuracy round 2 full sweep; FDA PMA P110039, De Novo DEN220077 summary and openFDA records read) · Wording corrected; unsourced items removed; FDA records added
- 2026-11-03 · Israel: who organises it: Eilat January 2026 conference and ICA founding year 1952 unsourced; 1990/1995 screening dates uncited (Accuracy round 2 full sweep; IMA union page, ICA annual report 2025 and registry breast report read in raw text) · Two details removed; registry reports added
- 2026-11-03 · Israel: page sources: IJTAHC paper credited to 'Hanin' (authors Luxenburg et al.); ESMO Open paper credited to 'Shapira-Frommer' (authors Wolf et al.) (Accuracy round 2 full sweep; Europe PMC full-text records read) · Both labels corrected
- 2026-11-03 · India: a different shape of cancer: India's incidence of 98.5 per 100,000 was called "roughly a third" of the US rate; the US rate is 367, so it is about a quarter (Accuracy round 2 full sweep; GLOBOCAN 2022 (public/globocan/countries.json) read in raw text) · "roughly a quarter of the US rate of 367"
- 2026-11-03 · India: tobacco: State gutka bans were dated "from 2012", which the cited NTCP page does not say (Accuracy round 2 full sweep; ntcp.mohfw.gov.in read in raw text) · Year removed
- 2026-11-03 · India: public cancer centres: Cancer Institute (WIA) was said to treat "about 60% of its 100,000 annual patients" free or subsidised; its site says about 15,000 new patients a year and "a significant number" free or heavily subsidised. "Twenty AIIMS were operating by January 2023, each with oncology services" matched nothing on PMSSY, which lists 22 new AIIMS with 18 running hospital services. The Tata Memorial figure was marked uncheckable (Accuracy round 2 full sweep; cancerinstitutewia.in/history, pmssy.mohfw.gov.in and the Department of Atomic Energy 2023 overview read in raw text) · WIA and AIIMS sentences rewritten to the sources; Tata Memorial now "close to 125,000 new patients a year at its Mumbai hospitals, more than 60% almost free", with the DAE document linked
- 2026-11-03 · India: why cancer drugs cost less: Natco licence given as "March 2012" cutting the price "by about 97%", and biosimilar launch years (2007, 2014, 2016), none of which the cited sources state (Accuracy round 2 full sweep; Wikipedia Natco Pharma page read in raw text) · Rewritten to "In 2012 Natco obtained a compulsory licence to make a cheaper generic version of Bayer's sorafenib"; biosimilar years removed
- 2026-11-03 · India: CDSCO: Qartemi's approval dated 2024; the only report found (AABB, 29 January 2025) says CDSCO had "recently approved" it (Accuracy round 2 full sweep; AABB news item, ImmunoACT site and Vaccines 2026 (PMC12944895) read in raw text) · Qartemi year removed; CERVAVAC dated July 2022; ImmunoACT and Vaccines 2026 linked
- 2026-11-03 · India: prevent what can be prevented: Said single-dose HPV vaccination "halved the cost of vaccinating a girl worldwide" (not in the source); Kerala's one-third cut applies to users of tobacco or alcohol, not tobacco users; Mumbai 31% had no link (Accuracy round 2 full sweep; Lancet Oncol 2021, Lancet 2005 and JNCI 2014 abstracts read in raw text) · Cost clause removed; "users of tobacco or alcohol"; JNCI 2014 linked
- 2026-11-03 · India: low-dose and metronomic trials: METRO PLUS and gefitinib-plus-chemotherapy results had no source on the card (Accuracy round 2 full sweep; JCO Glob Oncol 2026 and JCO 2020 abstracts read in raw text) · Both papers linked; figures already right
- 2026-11-03 · India: make it here: ISB 2001 called "Indian-discovered" (the licensor is Glenmark's New York-based Ichnos Glenmark Innovation, and the $700 million upfront is subject to regulatory clearance); Qartemi dated 2024; Dr Reddy's EU rituximab and the AbbVie deal had no source (Accuracy round 2 full sweep; AbbVie press release of 10 July 2025, EMA Ituxredi EPAR and AABB read in raw text) · Plain text rewritten; Qartemi "approval reported in January 2025"; AbbVie, EMA and AABB linked
- 2026-11-03 · India: National Cancer Grid: Said the grid "launched" its EMR initiative in 2025; the 2025 paper describes one that began with a 2022 survey. "Twenty AIIMS by January 2023" and "AIIMS from one to twenty" unsupported (Accuracy round 2 full sweep; Bull WHO 2025 full text and pmssy.mohfw.gov.in read in raw text) · EMR sentence corrected; AIIMS now 18 of 22 new AIIMS with hospital services (nineteen with New Delhi); PMSSY linked
- 2026-11-03 · India: gallbladder trials: NEOGB (114) and RUGB (249) shown as patient numbers; both are planned enrolment, and the card had no registry link (Accuracy round 2 full sweep; ClinicalTrials.gov API for NCT06712420 and NCT06214572 read in raw text) · "patients planned"; both registry entries linked
- 2026-11-03 · Country ranking: incidence, mortality and population: 28 of 32 rows had a GLOBOCAN 2022 rate or a 2024 population that matched neither source, some far off (Saudi Arabia incidence 122 against 87, Korea 300 against 235, China mortality 129 against 96, Germany incidence 313 against 274, India population 1,440 against 1,451 million); Taiwan's rates had no source at all (Accuracy round 2 full sweep; public/globocan/countries.json (GLOBOCAN 2022 API, code 39) and World Bank SP.POP.TOTL 2024 read in raw text) · All rows reset to the two sources; Taiwan incidence and mortality removed
- 2026-11-03 · Country ranking: funder budgets: 12 of 17 budget lines were wrong, imprecise or out of date: DKFZ €400m (now €515m), INCa €100m+ for research (€80m in 2024), AECC €100m (€40m new grants in 2025), KWF €150m (€190m in 2025), Swiss Cancer Research CHF 30m (CHF 16m), AMED ¥140bn (¥124.5bn), NSFC ¥33bn (¥35bn), CIHR C$1.3bn (C$1.4bn spent), FAPESP R$1.9bn (R$1.8bn), CRUK "£400m+" (£399m in 2023/24); Korea's NRF figure cited another agency (Accuracy round 2 full sweep; each funder's annual report or government budget document read in raw text) · Each line corrected with its year and the document that states it; Korea's NRF figure removed
- 2026-11-03 · Japan: a different mix of cancers: Breast, lung, prostate and pancreas incidence, death and survival figures were correct but the card linked no page that states them (Accuracy round 2 full sweep; ganjoho.jp site statistics pages read in raw text) · Added the ganjoho breast, lung, prostate and pancreas statistics pages to the card's links
- 2026-11-03 · Japan: a screened population: Plain summary said nine in ten people with localised stomach cancer are alive at five years; the registry figure (94.0) is relative survival, not the share alive (Accuracy round 2 full sweep; national cancer registry survival xlsx (cancer_survivalNCR 2016-2018) read in raw text) · Now gives five-year survival of 94 percent measured against people of the same age without cancer
- 2026-11-03 · Japan: screening uptake: Plain summary said about half of adults aged 40 to 69 had each screen; the survey ranges from 36.5 to 53.7 percent and the cervical and two-year stomach figures use other age bands (Accuracy round 2 full sweep; MHLW 2022 Comprehensive Survey of Living Conditions, health chapter, read in raw text) · Now says between about a third and a half of each target age group, depending on the test and on sex
- 2026-11-03 · Japan: treating the cause: Title dated hepatitis action to "the 2000s", which no linked source states; hepatitis B and C positivity figures were given without saying they come from people tested in local-government screening (Accuracy round 2 full sweep; Fourth Basic Plan to Promote Cancer Control (MHLW PDF) read in raw text) · Title now "Helicobacter since 2013, and hepatitis B and C"; positivity now labelled as among people tested in local-government hepatitis screening
- 2026-11-03 · Japan: the high-cost medical expense ceiling: Plain summary said a middle-income household pays at most about 80,000 yen a month; the ceiling is 80,100 yen plus 1 percent of the bill above 267,000 yen. The ceilings table said the multiple-month reduction was not applicable to the residence-tax-exempt band; for people under 70 it is 24,600 yen (Accuracy round 2 full sweep; MHLW high-cost medical expense leaflet (August 2018) and December 2025 revision PDF read in raw text) · Plain summary gives the formula and the 87,430 yen worked example; table row now shows 24,600 yen
- 2026-11-03 · Japan: the 2026 ceiling reform: Plain summary opened with "after a public row in 2025", which the cited ministry document does not mention (Accuracy round 2 full sweep; MHLW revision of the high-cost medical expense benefit (December 2025) read in raw text) · Removed the unsourced clause
- 2026-11-03 · Japan: what insurance does not pay for: The advanced medical care list was given as 74 techniques in August 2026; the ministry page now lists 70 as of October 2026 (Accuracy round 2 full sweep; MHLW advanced medical care page read in raw text) · Updated to 70 techniques in October 2026
- 2026-11-03 · Japan: particle therapy: Plain summary said Japan treated the world's first carbon-ion patient in 1994, which no linked source says; the detail dated a centre's suspension to March 2026 with no source and gave the facility page's update month as September; it also listed skull base tumours as patient-paid, though Gunma's page says unresectable skull-base bone and soft tissue tumours are insured (Accuracy round 2 full sweep; ANTM facility page, ANTM patient register PDF and Gunma University indications page read in raw text) · Now "began treating patients with carbon ions at Chiba in 1994"; facility page update set to October 2026 and the suspension left undated; skull base tumours removed from the patient-paid list
- 2026-11-03 · Japan: endoscopic resection: Said the ministry guidance requires screening endoscopy to be double-read; the guidance only asks that endoscopy follow the JSGCS manual, and requires double reading for barium films (Accuracy round 2 full sweep; MHLW cancer screening guidance (revised 24 December 2025) read in raw text) · Sentence corrected to match the guidance
- 2026-11-03 · Japan: JCOG: Core funding grant given as 2023-J-03; JCOG's 2026 evaluation committee report shows 2026-J-03 (Accuracy round 2 full sweep; JCOG evaluation committee report 2026 PDF read in raw text) · Grant number updated to 2026-J-03
- 2026-11-03 · Japan: genomic medicine: 262 cooperating hospitals from 1 October 2026; the ministry page now lists 263 from 1 November 2026 (Accuracy round 2 full sweep; MHLW designated cancer hospitals page read in raw text) · Updated to 263 from 1 November 2026
- 2026-11-03 · Japan: medical oncologists: The president's address was paraphrased as naming three problems as "the society's three unsolved problems"; it lists them among many remaining problems (Accuracy round 2 full sweep; JSMO president's greeting read in raw text) · Now "among the problems the society still has to solve"
- 2026-11-03 · Japan: trials that changed Western practice: Called the prophylactic cranial irradiation trial a West Japan Oncology Group trial, which the cited paper does not say, and said the prior standard rested on a European meta-analysis; the paper says it rested on a previous phase 3 study without brain imaging before enrolment (Accuracy round 2 full sweep; Lancet Oncology 2017 abstract (Europe PMC, PMID 28343976) read in raw text) · Now "A Japanese multicentre trial … an earlier European phase 3 trial that did not require brain imaging before enrolment"
- 2026-11-03 · Russia: what the Russian cancer register is: A co-editor of the Herzen volumes was named Aida Shakhzadova; the volumes give А.О. Шахзадова, Anna Olegovna (Accuracy round 2 full sweep; Herzen institute 2025 and 2024 volumes read in raw text) · Corrected to Anna Shakhzadova, "among the co-editors"
- 2026-11-03 · Russia: how the reporting differs: The report's warning about failures in matching deaths and coding causes was attached to the non-cancer-death share as a whole; the report says only low values may point at such failures (Accuracy round 2 full sweep; Herzen institute 2025 volume read in raw text) · Warning now attaches to low values, as the report says
- 2026-11-03 · Russia: compulsory medical insurance: Article 80 of 323-FZ was said to require "inpatient" palliative care (it says palliative care in medical organisations) and the programme was said to be reissued yearly (the law sets a three-year term); the line that the federal cancer project "paid for much of the equipment renewal since 2019" was in no cited source (Accuracy round 2 full sweep; 323-FZ article 80 (consultant.ru) and Herzen 2025 volume read in raw text) · Wording aligned to article 80 parts 1 and 4; the unsourced 2019 equipment claim replaced with what the 2025 volume says
- 2026-11-03 · Russia: what comes out of the patient's pocket: 70.04 per cent was labelled "government and compulsory contributory schemes" but is the domestic general government share of health spending; and the unstaged share was said to run "from under 1 per cent", when the lowest region is 1.9 per cent (Accuracy round 2 full sweep; WHO GHED via World Bank API and Herzen 2025 volume table 27 read in raw text) · Relabelled 70.04 as domestic general government spending, including compulsory insurance funds; range now from 1.9 per cent in Saratov oblast and Chukotka
- 2026-11-03 · Russia: who approves a cancer drug: The four-working-day decision term was attributed to article 27 with no link to it (Accuracy round 2 full sweep; 61-FZ article 27 (consultant.ru) read in raw text) · Added a link to article 27; wording now "from receiving the expert commission's conclusions"
- 2026-11-03 · Russia: what changed after February 2022: The ranked list of the largest lead sponsors in 2018 to 2021 skipped the Rogachev centre (13), and the foreign sponsors from 2023 left out Ascentage Pharma (2) while reading as complete (Accuracy round 2 full sweep; ClinicalTrials.gov API v2 re-queried) · Rogachev centre (13) inserted in rank order; Ascentage Pharma (2) added and the one-each list marked as partial
- 2026-11-03 · Russia: Biocad: Prolgolimab's 2020 Russian approval for melanoma had no source on the card (Accuracy round 2 full sweep; FLAT paper (Front Oncol 2024, PMC11408354) read in raw text) · Added the FLAT paper as a link; figure unchanged
- 2026-11-03 · Russia: Petrov, Rogachev, Tomsk and the societies: The Petrov institute (1927) was called the oldest cancer institute in the country, which the same page contradicts (Herzen institute, 1898); the Tatarstan Cancer Centre's founding year 1946 had no source on the card and is absent from the centre's own history page (Accuracy round 2 full sweep; Petrov history page, nmicr.ru and oncort.ru read in raw text) · "Oldest" removed; "founded in 1946" removed
- 2026-11-03 · Healthy China 2030 (China country facts): The survival target was given as "15 percentage points"; the State Council outline says "提高15%" (raise by 15%) (Accuracy round 2 full sweep; gov.cn Healthy China 2030 outline read in raw text) · Now "raise the overall cancer five-year survival rate by 15% by 2030"
- 2026-11-03 · NRDL renewal study (China country facts): Said 68 of 104 anticancer drugs "went through renewal negotiations"; the paper says 68 were renewed (Accuracy round 2 full sweep; Guo et al., Expert Rev Pharmacoecon Outcomes Res 2026, abstract read in raw text) · Now "68 were renewed"
- 2026-11-03 · Sintilimab: First-line gastric cancer approval dated 2023; it was June 2022. NRDL "steep price cut" had no source. The FDA vote and complete response letter were cited to a meeting notice that reports neither (Accuracy round 2 full sweep; Innovent/Lilly releases (June 2022, November 2019), Lilly CRL release and FDA ODAC final minutes read in raw text) · Approval year 2023 changed to 2022; "since November 2019" without the price-cut claim; regulatory event now cites the ODAC minutes; four sources added
- 2026-11-03 · Sugemalimab: China approval dates and the "first in the EU" claim had no source on the record (Accuracy round 2 full sweep; Drugs first-approval paper, CStone releases and the EMA EPAR read in raw text) · Four sources added; text confirmed
- 2026-11-03 · Adebrelimab: March 2023 approval had no source (Accuracy round 2 full sweep; Hengrui exchange filing read in raw text) · Filing added as a link
- 2026-11-03 · Envafolimab: November 2021 approval, "first subcutaneous PD-L1" and "30-second injection" had no source (Accuracy round 2 full sweep; Simcere/3DMed/Alphamab releases read in raw text) · Two releases added as links
- 2026-11-03 · Relmacabtagene autoleucel: RELIANCE 75.9% was the best overall response, not the primary response rate (60.3% at three months); approval dates had no source (Accuracy round 2 full sweep; RELIANCE full text (Europe PMC), JW Therapeutics and Fosun Pharma releases read in raw text) · Now "best overall response rate of 75.9% ... (the primary endpoint, response at three months, was 60.3%)"; three sources added
- 2026-11-03 · Zevorcabtagene autoleucel: Said satricabtagene autoleucel was approved in 2025; it was approved in June 2026 (Accuracy round 2 full sweep; CARsgen approval release read in raw text) · Now "followed in June 2026"; release added
- 2026-11-03 · Inaticabtagene autoleucel: 2023 approval had no source (Accuracy round 2 full sweep; CASI Pharmaceuticals 6-K exhibit read in raw text) · Exhibit added as a link
- 2026-11-03 · Fulzerasib: Said it arrived "within weeks of garsorasib"; garsorasib was approved in November 2024, three months later. The claim that no Western KRAS G12C drug was approved in China first could not be confirmed (Accuracy round 2 full sweep; Drugs first-approval papers, Innovent release and Sino Biopharm 2024 results read in raw text) · Now "three months before garsorasib, China's second domestic KRAS G12C inhibitor"; unconfirmed clause removed; three sources added
- 2026-11-03 · Garsorasib: Approval dated August 2024; it was November 2024. "Second market with domestic KRAS G12C inhibitors" was unsourced (Accuracy round 2 full sweep; Sino Biopharm 2024 annual results (HKEX) read in raw text) · Now "November 2024" and "gave China two domestic KRAS G12C inhibitors"; source added
- 2026-11-03 · Furmonertinib: Approval dates and ArriVent rights had no source (Accuracy round 2 full sweep; Allist exchange filing and ArriVent 10-K read in raw text) · Two sources added
- 2026-11-03 · Aumolertinib: EU approval presented as current, and the summary said "under evaluation in Europe"; the European Commission revoked the authorisation on 25 September 2026. China approval dates had no source (Accuracy round 2 full sweep; EMA Aumseqa page, Hansoh release and 2021 results read in raw text) · EU row and summary now give the February 2026 authorisation and September 2026 revocation with the EMA's reason; three sources added
- 2026-11-03 · Icotinib: Called "the first cancer drug invented and developed in China" (Betta: first small-molecule targeted anticancer drug with Chinese IP) and "the first drug in the 2016 negotiation pilot" (Betta: first domestic innovative drug through it, 54% price cut); dates unsourced (Accuracy round 2 full sweep; Betta exchange filing and 2021 annual report, icotinib expert consensus and EVIDENCE paper read in raw text) · Both claims narrowed to what Betta states; four sources added
- 2026-11-03 · Savolitinib: Said SAFFRON was "continuing"; AstraZeneca filed in the US on SAFFRON in September 2026. Approval dates and the 2011 partnership had no source (Accuracy round 2 full sweep; AstraZeneca June 2021 release and Hutchmed 6-K exhibits read in raw text) · SAFFRON clause updated; three sources added
- 2026-11-03 · Anlotinib: Medullary thyroid cancer approval dated 2020; it was January 2021. Other approval dates and the 2018 NRDL entry had no source (Accuracy round 2 full sweep; NMPA approval summary (Cancer Commun 2019), Sino Biopharm 2019 and 2021 reports, J Glob Health 2022 read in raw text) · Summary and approval row changed to January 2021 / 2021; four sources added
- 2026-11-03 · Rivoceranib (apatinib): Said the FDA letters were over "trial conduct"; the FDA cited manufacturing and incomplete clinical-site inspections. Approval dates had no source (Accuracy round 2 full sweep; Hengrui exchange filing and OncLive report of the third CRL read in raw text) · Now "(the first in May 2024, the third in July 2026) over manufacturing inspections and incomplete clinical-site inspections"; two sources added
- 2026-11-03 · Donafenib: The ZGDH3 link pointed to an ASCO guideline (10.1200/JCO.20.02672), and "the first drug to beat sorafenib on survival" is not what the trial paper says (Accuracy round 2 full sweep; Crossref, Europe PMC abstract of 10.1200/JCO.21.00163 and Zelgen filing read in raw text) · DOI corrected to 10.1200/JCO.21.00163; claim now "a survival gain over sorafenib for a single targeted drug"; Zelgen filing added
- 2026-11-03 · Orelabrutinib: Called the marginal zone lymphoma approval "the first approval for any BTK inhibitor in that disease"; InnoCare says first in China (Accuracy round 2 full sweep; InnoCare April 2023 release and Drugs first-approval paper read in raw text) · Now "added in April 2023, the first BTK inhibitor approved for that disease in China"; two sources added
- 2026-11-03 · Dalpiciclib: Approval dates and NRDL reimbursement had no source (Accuracy round 2 full sweep; Hengrui exchange filings read in raw text) · Two filings added
- 2026-11-03 · Tucidinostat (chidamide): Approval dates in China and Japan had no source (Accuracy round 2 full sweep; Chipscreen 2021 annual report and filing read in raw text) · Two sources added
- 2026-11-03 · Innovent Biologics: "Now in six indications" was the 2022 count (eight on the NRDL by December 2025); "four biosimilars" included a trastuzumab biosimilar not found in Innovent's releases; "China's best-selling PD-1 antibody" had no source (Accuracy round 2 full sweep; Innovent HKEX announcements (Oct and Dec 2025, Feb, Mar, May, Jun 2026) and releases read in raw text) · Counts and biosimilar list corrected; ranking claim removed; four sources added
- 2026-11-03 · Shanghai Junshi Biosciences: Coherus licence terms, FDA approval and EU, UK and Australian approvals had no source (the Coherus link is a news index) (Accuracy round 2 full sweep; Coherus 8-K exhibits, Junshi releases and 2025 results read in raw text) · Six sources added
- 2026-11-03 · Hutchmed: "Three NMPA-approved originals" no longer true after fanregratinib (August 2026); founding year and Takeda upfront had no source (Accuracy round 2 full sweep; Hutchmed 20-F and 6-K exhibits on SEC EDGAR read in raw text) · Now "whose first three NMPA-approved originals were"; two sources added
- 2026-11-03 · CSPC Pharmaceutical Group: Founded given as 1997; CSPC's articles say incorporated 16 June 1992 (listed 1994). June 2025 AstraZeneca collaboration had no source (Accuracy round 2 full sweep; CSPC articles of association, corporate information page and HKEX announcements read in raw text) · founded changed to 1992; three sources added
- 2026-11-03 · Sino Biopharmaceutical (Chia Tai Tianqing): Said anlotinib was approved in 2018 "across lung cancer, sarcoma and thyroid cancer"; only the lung cancer approval came in 2018, and neither approval date had a source on the record (Accuracy round 2 full sweep; NMPA approval summary (Cancer Commun 2019) and Sino Biopharm HKEX announcement of May 2024 read in raw text) · Now says first approved in May 2018 for lung cancer and later for other cancers; both sources added
- 2026-11-03 · WuXi AppTec: Said the whole WuXi ATU arm "was sold in 2024 to 2025"; the December 2024 agreement covered only the US and UK operations (Accuracy round 2 full sweep; WuXi AppTec HKEX business update read in raw text) · Now says the US and UK operations were sold to Altaris under a December 2024 agreement; announcement linked
- 2026-11-03 · WuXi Biologics: Gave a founding year of 2010 that no source supported, and said the Irish vaccine plant "was sold" to Merck in 2025 when the January 2025 deal had only been agreed (Accuracy round 2 full sweep; WuXi Biologics history page and BioSpace report read in raw text) · Founding year removed; now says it agreed in January 2025 to sell the plant; BioSpace linked
- 2026-11-03 · JW Therapeutics: Out of date: listed mantle cell lymphoma as pipeline when relma-cel was approved for it in August 2024; the CN¥1.29 million price had no source (Accuracy round 2 full sweep; JW Therapeutics history page and Flcube read in raw text) · Added the 2024 mantle cell lymphoma approval; history page and price source linked
- 2026-11-03 · InventisBio: Said garsorasib was approved in August 2024; InventisBio says the NMPA approved it on 8 November 2024. Founding year and stock code had no source (Accuracy round 2 full sweep; InventisBio approval release and exchange profile data read in raw text) · Changed to November 2024; approval release, exchange profile and Betta milestones linked
- 2026-11-03 · Suzhou Zelgen Biopharmaceuticals: Said the 2022 thyroid cancer approval rested on ZGDH3 against sorafenib; it rested on the placebo-controlled ZGDD3 trial (ZGDH3 was the liver cancer trial) (Accuracy round 2 full sweep; Zelgen 2024 annual report and announcement 2022-065 read in raw text) · Rewritten: June 2021 for liver cancer on ZGDH3, August 2022 for radioactive iodine-refractory thyroid cancer on ZGDD3; both linked
- 2026-11-03 · Betta Pharmaceuticals: Called icotinib "the first cancer drug invented in China"; Betta itself calls it China's first small-molecule targeted cancer drug. The December 2024 FDA date had no source (Accuracy round 2 full sweep; Betta company profile and FDA approval notice read in raw text) · Wording corrected in the summary and the one-line summary; FDA notice and Betta pages linked
- 2026-11-03 · National Cancer Center of China: Founding year 2011 had no source; said "more than 700" registries where the report says 700; said mortality has been falling 1.3% a year "since 2000" where the report measures 2000 to 2018 (Accuracy round 2 full sweep; Han et al., J Natl Cancer Cent 2024 read in raw text) · Founding year removed; changed to 700 registries and age-standardised mortality from 2000 to 2018
- 2026-11-03 · National Healthcare Security Administration: Called the 2017 figure an "average 48.9% cut" when it is the fall against the expected trend; the 2018 founding, the 1.3 billion insured, "more than half" discounts and the 2021 dual-channel policy had no source (Accuracy round 2 full sweep; BMJ Glob Health 2021, gov.cn (June 2018), the NHSA 2025 bulletin and Lancet Reg Health West Pac 2026 read in raw text) · 48.9% relabelled; four sources added
- 2026-11-03 · China Anti-Cancer Association: "More than a hundred professional committees" and guidelines "released annually since 2022" had no source (Accuracy round 2 full sweep; CACA's own About page read in raw text (it confirms 1984 and Tianjin)) · Both unsupported figures removed
- 2026-11-03 · Peking University People's Hospital: "More than a thousand transplants a year" had no source (Accuracy round 2 full sweep; Huang et al., Bone Marrow Transplant 2006 read in raw text) · Clause removed
- 2026-11-03 · Chongqing University Cancer Hospital: "More than a thousand beds" had no source (Accuracy round 2 full sweep; hospital site gave no readable content) · Bed count removed
- 2026-11-03 · ORIENT-11: Paraphrased the FDA advisory committee's 14 to 1 vote as a finding about the comparator; the vote was on whether more trials showing the results applied to US patients were needed. The approval and refusal dates had no source (Accuracy round 2 full sweep; FDA ODAC final minutes (10 February 2022), Lilly's March 2022 release and Innovent's February 2021 release read in raw text) · Vote reworded to match the minutes; three sources added
- 2026-11-03 · ORIENT-16: Said the NMPA approved it in 2023; it was approved in June 2022 (Accuracy round 2 full sweep; Pharmafile report of 27 June 2022 read in raw text) · Changed to June 2022; source linked
- 2026-11-03 · JUPITER-06: Put both analyses at "the interim analysis" when the progression-free survival result was the final analysis; listed KEYNOTE-590 as a Chinese trial; gave China "about half the world's cases" with no source (Accuracy round 2 full sweep; Cancer Cell 2022 abstract, ClinicalTrials.gov results and Junshi's May 2022 release read in raw text) · Timing of each analysis corrected; KEYNOTE-590 labelled global; unsourced share removed; approval source added
- 2026-11-03 · ALTER 0303: Placebo arm given as 145 patients; it was 143 (Accuracy round 2 full sweep; JAMA Oncol 2018 full text read in raw text) · Changed to 143; NMPA approval summary added for the May 2018 approval
- 2026-11-03 · LEGEND-2: Said "a further 17 patients" were treated at three other sites; the paper gives four sites but no figure of 17. The ASCO 2017 presentation, the $350 million deal and the FDA and NMPA approvals had no source (Accuracy round 2 full sweep; J Hematol Oncol 2018 full text, the ASCO 2017 abstract, Janssen's December 2017 release, ASCO Post and Pharma Focus Asia read in raw text) · Figure 17 removed; four sources added
- 2026-11-03 · FUMANBA-1: Gave the 96% response rate as a share of "infused patients"; it is 96.0% of 101 patients evaluable for efficacy (103 were infused) (Accuracy round 2 full sweep; JAMA Oncol 2024 abstract read in raw text) · Summary and result corrected; source added for the June 2023 approval
- 2026-11-03 · RELIANCE: Gave 75.9% as the response rate for 59 patients; it is the best overall response among 58 evaluable patients (the primary 3-month response was 60.3%), and severe neurotoxicity was 5.1%, not about 3% (Accuracy round 2 full sweep; Cancer Med 2021 full text read in raw text) · Summary, result and outcome corrected; source added for the September 2021 approval
- 2026-11-03 · ZGDH3 (donafenib vs sorafenib): The cited DOI 10.1200/JCO.20.02672 is the ASCO liver cancer guideline, not the ZGDH3 paper (Accuracy round 2 full sweep; Crossref and Europe PMC records for 10.1200/JCO.21.00163 read in raw text) · DOI corrected in the links and the outcome source; Zelgen annual report added for the June 2021 approval
- 2026-11-03 · Other China trial and company cards: Approval dates and deal facts were correct but had no source on the record: CStone and GEMSTONE-302 (EU July 2024, China December 2021), ORIENT-32, RATIONALE-302, CameL, HARMONi-A, CAPSTONE-1, FURLONG, AENEAS, LUMMICAR STUDY 1, DAWNA-1, Alphamab, CAMS haematology institute (Accuracy round 2 full sweep; EMA EPARs, company filings and releases, and approval reviews read in raw text) · Primary or company sources added to each record; text unchanged
- 2026-11-03 · Non-small-cell lung cancer: Summary said screening "cuts mortality by 20-24%": the trials measured lung cancer mortality, and NELSON's 24% is the male primary analysis; a smoking-initiation risk figure from a cohort of women was stated for everyone (Accuracy round 2 full sweep; NLST and NELSON abstracts (Europe PMC) and the Cancer Research UK lung cancer risk factors page read in raw text) · Now "cuts lung cancer mortality by 20-24% (20% in NLST; 24% in men in NELSON)", and "in a cohort study of women, lung cancer death risk was 37 percent higher per five years younger at starting"
- 2026-11-03 · Non-small-cell lung cancer: The NELSON screening summary said "2.1 percent of participants" were referred for a suspicious nodule; the trial abstract gives an overall referral rate of 2.1% without saying the denominator is participants (Accuracy round 2 full sweep; de Koning, N Engl J Med 2020 (NELSON) abstract read in raw text via Europe PMC) · Reworded to the abstract's own terms: "an overall referral rate for suspicious nodules of 2.1 percent"
- 2026-11-03 · Non-small-cell lung cancer: The histology split (45.6% adenocarcinoma in men, and so on) was given in the present tense with no year, though it is an estimate built on GLOBOCAN 2022 (Accuracy round 2 full sweep; Lancet Respiratory Medicine 2025 abstract (Europe PMC) read in raw text) · Dated to 2022 and labelled as estimates from GLOBOCAN 2022
- 2026-11-03 · Non-small-cell lung cancer: MARIPOSA was said to give "median OS more than 12 months longer", but the median was not reached with amivantamab-lazertinib, so that gap is a projection (Accuracy round 2 full sweep; MARIPOSA final OS, NEJM 2025 (doi 10.1056/nejmoa2503001) read in raw text) · Now gives what was measured: HR 0.75, 3-year survival 60% vs 51%, median not reached vs 36.7 months
- 2026-11-03 · Non-small-cell lung cancer: Open problems: the US screening uptake figure had no source; the ADC sentence said no ADC had beaten platinum chemotherapy on survival after TKI failure, which OptiTROP-Lung04 (NEJM 2026, OS HR 0.60) now contradicts, and it described TROPION-Lung01 as a comparison with platinum when it was against docetaxel; "brain metastases occur in 30-50% of driver-positive patients" had no source, and the published 30-50% is for NSCLC as a whole (Accuracy round 2 full sweep; American Lung Association State of Lung Cancer, OptiTROP-Lung04 abstract, CNS Oncol 2024 abstract read in raw text) · Uptake now 18.2% (2022), with the ALA linked; ADC sentence rewritten with OptiTROP-Lung04, which is now linked; brain-metastasis figure removed
- 2026-11-03 · Non-small-cell lung cancer: Open problem on fusion testing put fusions plus MET exon 14 skipping at "about 8 to 10%" of adenocarcinoma, below what the page's own cBioPortal rows add up to (9.8 to 11.3%) (Accuracy round 2 full sweep; cBioPortal counts re-run through the public API) · Now "about 10 to 11% of lung adenocarcinoma in the large panel cohorts"
- 2026-11-03 · EGFR-mutated non-small-cell lung cancer: Said three Boston groups found EGFR mutations in 2004; the third paper (Pao) came from New York. Put ADAURA's stage IB to IIIA five-year survival (78 to 88 percent) on the stage II to IIIA group. Gave about 15 percent EGFR prevalence for North America, where the source says 22 percent. Gave an 85 percent share for exon 19 plus L858R that no primary source read supports. IPASS had no source on the record; The 2004 timeline entry placed all three discovery groups in Boston; Pao's group was at Memorial Sloan-Kettering in New York (Accuracy round 2 full sweep; Lynch NEJM 2004, Paez Science 2004, Pao PNAS 2004, ADAURA NEJM 2020 and 2023, mutMapII (Am J Cancer Res 2015), Arcila Mol Cancer Ther 2013, Riess JTO 2018 and IPASS NEJM 2009 read in raw text via Europe PMC and PMC; Europe PMC records for PMIDs 15118073, 15118125, 15329413) · Now "two Boston groups"; ADAURA survival figure labelled "across stage IB to IIIA"; prevalence now 15 percent Europe, 22 percent North America, 47 percent Asia-Pacific; exon 20 insertions now "9 to 12 percent in two large series" with the 85 percent removed; IPASS, ADAURA OS, mutMapII, Arcila and Riess links added; Timeline title now reads "in Boston and New York (Lynch, Paez, Pao)"
- 2026-11-03 · Resectable stage I to III non-small-cell lung cancer: Gave ADAURA's stage II to IIIA recurrence cut (83 percent, HR 0.17) as the stage IB to IIIA result (80 percent, HR 0.20), and left the stage II to IIIA label off the ADAURA and ALINA hazard ratios in the state of the art. Gave LACE's all-stage 5.4 percent benefit as the stage II and III figure. Said perioperative immunotherapy runs a year after surgery, but KEYNOTE-671 gives about nine months. Burden figures (a quarter to a third resectable, over 80 percent and about 40 percent five-year survival) and the Graham 1933 and 1995 Lung Cancer Study Group history had no source on the record; The stage IB to IIIA treatment row gave adjuvant pembrolizumab as limited to PD-L1-positive disease and credited it to IMpower010, which tested atezolizumab (Accuracy round 2 full sweep; ADAURA NEJM 2020 and 2023, ALINA NEJM 2024, LACE JCO 2008, KEYNOTE-671, AEGEAN and CheckMate 77T NEJM, I-ELCAP NEJM 2006, LCSG Ann Thorac Surg 1995 and Graham JAMA 1933 (Crossref) read in raw text; PEARLS/KEYNOTE-091 abstract (Lancet Oncology 2022, doi 10.1016/s1470-2045(22)00518-6) read in raw text through Europe PMC) · ADAURA now "80 percent (83 percent in stage II to IIIA)"; hazard ratios labelled "recurrence or death in stage II to IIIA"; LACE now "about 5 percent overall, with the benefit seen in stage II and III"; adjuvant phase now "about nine months to a year"; burden rewritten to I-ELCAP's 85 percent stage I and 88 percent ten-year survival, with the unsourced figures removed; five source links added; Now reads "atezolizumab if PD-L1-positive (IMpower010) or pembrolizumab at any PD-L1 level (KEYNOTE-091)", with the keynote-091 record added to the row's refs
- 2026-11-03 · Extensive-stage small-cell lung cancer: Said 70 percent are extensive stage; the source says about two thirds. Put three-year survival at one in eight, which is the five-year figure; three-year survival is 16 to 18 percent. Put first-line response at 60 to 70 percent (source: 50 to 80) and topotecan response at around 20 percent (pivotal trial: 24.3). None of these, nor the thoracic radiotherapy dose, had a source on the record (Accuracy round 2 full sweep; NCI PDQ Small Cell Lung Cancer Treatment (updated 14 May 2025), IMpower133/IMbrella A (Lung Cancer 2024), CASPIAN 3-year (ESMO Open 2022), von Pawel JCO 1999, Evans JCO 1985 and CREST Lancet 2015 read in raw text) · Now "about two thirds", "about one in six alive at three years", "response rates of 50 to 80 percent", "a response rate of about 24 percent in its pivotal trial"; PDQ, Evans and von Pawel links added; CREST trial record added to the thoracic consolidation row's refs
- 2026-11-03 · Small-cell lung cancer: The burden line said there were "roughly 250,000 cases a year worldwide", but no source on the page gives that count. The very-limited-stage treatment row said such cases were "~5%" of the total, which no cited source states either (Accuracy round 2 full sweep; NCI PDQ small-cell lung cancer treatment (health professional) read in raw text) · Removed the worldwide count and kept "about 15% of lung cancers", which PDQ supports. Removed "~5%" from the very-limited-stage row
- 2026-11-03 · Mesothelioma: The GLOBOCAN 2022 case counts were presented without a date, as if they were this year's figures. The page said "almost all" cases follow asbestos exposure, but PDQ gives 70 to 80 percent. It gave a 20-50-year latency and a 40-50% MTAP-deletion share that no cited source states (Accuracy round 2 full sweep; GLOBOCAN 2022 (repo countries.json, code 18), NCI PDQ mesothelioma treatment and Drugs@FDA read in raw text) · Dated the counts to GLOBOCAN 2022 (about 30,600 worldwide, about 3,100 in the US). Changed "almost all" to "most" and "20-50 years" to "decades". Removed the MTAP percentage
- 2026-11-03 · Lung cancer: The highest female rate was given as "Hungary and Denmark at 36.0". The fact sheet's female maximum is Denmark; Hungary's 36.0 is its both-sexes death rate (Accuracy round 2 full sweep; GLOBOCAN 2024 lung fact sheet read in raw text (pdftotext with word positions)) · Women: "Denmark at 36.0"
- 2026-11-03 · Lung cancer: Adenocarcinoma was called the commonest type "everywhere the data allow"; the paper supports worldwide only (Accuracy round 2 full sweep; Lancet Respir Med 2025 abstract read in raw text) · "worldwide"
- 2026-11-03 · Lung cancer: The US mortality fall was called "the fastest fall of any common cancer", which SEER does not say (Accuracy round 2 full sweep; SEER Cancer Stat Facts read in raw text) · Clause removed; the figures stand
- 2026-11-03 · Lung cancer: Survival by age (32.7 and 22.2 against 9.2 and 5.2 percent) was not labelled; these are ten-year figures, and they sat between five-year figures (Accuracy round 2 full sweep; Cancer Research UK survival statistics read in raw text) · Labelled as ten-year survival
- 2026-11-03 · Lung cancer: Three unsupported claims: "of the ten European countries surveyed in 2026 only three had a formal programme" (no source on the record), the 0 to 67 percent overdiagnosis range called "the widest for any screened cancer", and "15 to 25 percent worldwide" for never-smokers, when the linked BJC Reports paper says 10 to 25 percent (Accuracy round 2 full sweep; GLOBOCAN fact sheet, USPSTF evidence report (JAMA 2021), BJC Reports 2023 and Health Sci Rep 2026 read in raw text) · European survey clause and "widest range" clause removed; Health Sci Rep 2026 (the source of 15 to 25 percent) added to the record's links
- 2026-11-03 · Lung cancer: The deprivation meta-analysis was stated as holding "at the same stage" for all treatment; the paper says the stage-adjusted gap holds for surgery (Accuracy round 2 full sweep; Forrest, PLoS Med 2013 abstract read in raw text) · Stage adjustment now applies to surgery only; "universal and other systems" kept
- 2026-11-03 · Lung cancer: Four treatment-row figures were wrongly framed. GEMSTONE-301's 9.0 against 5.8 months was presented as a sequential-chemoradiotherapy result but covers the whole trial. LUME-Lung 1's 3.4 against 2.7 months was placed under adenocarcinoma but covers all patients. ADRIATIC was called "the largest single gain recorded". PCI after Takahashi was not marked as extensive-stage (Accuracy round 2 full sweep; Lancet Oncol 2022, Lancet Oncol 2014, NEJM 2024 and Lancet Oncol 2017 abstracts read in raw text) · Each figure now carries its own cohort; adenocarcinoma OS 12.6 against 10.3 months added; the superlative removed; "in extensive-stage disease" added
- 2026-11-03 · Lung cancer: JROSG 99-1 was said to have "halved" twelve-month brain recurrence (76.4 to 46.8 percent, a 39 percent relative fall) (Accuracy round 2 full sweep; Aoyama, JAMA 2006 abstract read in raw text) · "reduced" (same fix in the palliation record that repeats the sentence)
- 2026-11-03 · Thyroid cancer: The papillary ten-year survival (about 97 percent) was applied to all differentiated cancer. HiLo was counted among trials showing low-risk patients gain nothing from radioiodine, but it compared a low dose with a high one. The HiLo ablation doses were called the adjuvant dose for intermediate and high risk. "About 60 percent" of anaplastic cancers were said to lack BRAF V600E with no source; ROAR says V600E is in 10 to 50 percent (Accuracy round 2 full sweep; Wikipedia (raw), HiLo NEJM 2012, ESTIMABL2 NEJM 2022, IoN Lancet 2025 and ROAR Ann Oncol 2022 (full text) read in raw text) · Survival attributed to papillary cancer; HiLo described correctly; dose relabelled; "half or more" without the mutation
- 2026-11-03 · Thyroid cancer: The burden line gave "~820,000 cases per year" undated (the GLOBOCAN 2022 figure) and ">98% survival", with only Wikipedia cited (Accuracy round 2 full sweep; GLOBOCAN 2022 world data (GCO, repo dataset) and Wikipedia read in raw text) · "In 2022, GLOBOCAN estimated about 821,000 new cases worldwide"; five-year survival 98% in the US; GCO link added
- 2026-11-03 · Head and neck cancer: The burden line gave "~900,000 cases per year" undated; the cited Wikipedia figure is 890,000 for 2018, and GLOBOCAN 2022 sums to 947,211 for the six sites (Accuracy round 2 full sweep; GLOBOCAN 2022 world data (GCO, repo dataset) and Wikipedia read in raw text) · "In 2022, GLOBOCAN estimated about 947,000 new cases across the lip and oral cavity, salivary glands, pharynx and larynx"; GCO link added
- 2026-11-03 · Head and neck cancer: Two unsourced figures: bispecifics with pembrolizumab "two to three times" pembrolizumab's response rate, and "5-year survival around 50%" for HPV-negative disease (Accuracy round 2 full sweep; ficerafusp alfa JCO 2026, RTOG 0129 NEJM 2010 and Wikipedia read in raw text) · Ratio removed ("high response rates in early single-arm trials"); HPV-negative survival given as RTOG 0129's three-year 57.1 against 82.4 percent
- 2026-11-03 · Colorectal cancer: The opening said "about 1.9 million cases a year" and "900,000 a year" undated, a GLOBOCAN 2022 figure presented as current; the epidemiology paragraph said the 1,984,605 colon-plus-rectum sum is "where the familiar round figures of about 1.9 million" come from, when it rounds to 2 million and the 1.9 million is GLOBOCAN 2022 (1,926,425) (Accuracy round 2 full sweep; GLOBOCAN 2024 colon, rectum and colorectum fact sheets and the GLOBOCAN 2022 dataset read in raw text) · Dated the opening figures to 2022; the sum now reads "close to 2 million cases and 900,000 deaths; the older round figure of about 1.9 million cases is GLOBOCAN's 2022 estimate (1,926,425 colorectal cancers)"
- 2026-11-03 · Colorectal cancer: The NordICC "35 to 41 percent reduction in incidence among those screened" was cited to Bretthauer 2022; it comes from the later instrumental-variable analysis (Shi, Eur J Epidemiol 2025) (Accuracy round 2 full sweep; Bretthauer 2022 and Shi 2025 abstracts read through Europe PMC) · Citation now "(Bretthauer 2022; Shi 2025)" and Shi 2025 (doi 10.1007/s10654-025-01209-w) added to the record's links
- 2026-11-03 · Colorectal cancer: The England survival sentence put the ten-year figure (almost 55 percent) under "people diagnosed in 2016 to 2020"; Cancer Research UK gives it for people diagnosed in 2013 to 2017 (Accuracy round 2 full sweep; Cancer Research UK survival page read in raw text) · Ten-year figure now labelled "for people diagnosed in 2013 to 2017"
- 2026-11-03 · Colorectal cancer: State of the art said dostarlimab gives "complete organ preservation in rectal cancer (AZUR-1)"; the first AZUR-1 report gives sustained clinical complete response at 12 months in 68 percent (Accuracy round 2 full sweep; AZUR-1 first results (Ann Oncol 2026) read through Europe PMC) · Now "lets most rectal cancers avoid surgery (dostarlimab; sustained clinical complete response at 12 months in 68% in the first AZUR-1 report)"; the paper added to the record's links
- 2026-11-03 · Colorectal cancer: Molecular state of the art: the odds ratio of 203 was attached to MLH1 silencing with BRAF, when Weisenberger 2006 reports it for the CpG island methylator phenotype with BRAF; residual-disease line gave post-chemotherapy hazard ratios "17 to 51" (Tie 2016 gives 11) and lead times "about 10 to 16 months" (a mean of 8.7 and median of 9.8, maximum 16.5); and called DYNAMIC "the only randomised trial in any solid tumour to change treatment on the result", which DYNAMIC-III on the same record contradicts (Accuracy round 2 full sweep; Weisenberger 2006, Tie 2016, Reinert 2019, Henriksen 2022, DYNAMIC and DYNAMIC-III abstracts read through Europe PMC) · Odds ratio reattributed to CIMP; range now "11 to 51" with lead time "a mean or median of about 9 to 10 months before imaging and up to 16.5 months"; DYNAMIC sentence now states its result and that DYNAMIC-III could not show the same in stage III
- 2026-11-03 · Colorectal cancer: IDEA's 83.1 against 83.3 percent was given as if for CAPOX alone; it is the combined FOLFOX and CAPOX exploratory analysis (Accuracy round 2 full sweep; IDEA (NEJM 2018) abstract read through Europe PMC) · Added "FOLFOX and CAPOX combined", in the standard-of-care row and the adjuvant decision tool
- 2026-11-03 · Colorectal cancer: CHRONOS was said to have rechallenged "the rest" after excluding 31 percent (36 patients); 27 were enrolled and treated (Accuracy round 2 full sweep; CHRONOS (Nat Med 2022) abstract read through Europe PMC) · Now "rechallenged 27 patients with panitumumab alone: 30 percent of them responded and 63 percent had disease control"
- 2026-11-03 · Colorectal cancer: Open problems gave the European early-onset rise (1.6 to 7.9 percent a year, Vuik 2019) as applying "across Europe and the United States"; and said MOUNTAINEER-03 and CodeBreaK 301 "complete" in December 2027 and September 2028, which are primary-completion dates (study completion 2030 and 2032) (Accuracy round 2 full sweep; Vuik 2019 and ACS 2026 abstracts and the ClinicalTrials.gov API read in raw text) · Now "1.6 to 7.9 percent a year across Europe, depending on age, and by 3 percent a year at 20 to 49 in the United States"; dates now "reaches primary completion"
- 2026-11-03 · Colon cancer: Said "GLOBOCAN counts colon and rectum together" and, in the summary, that there is "no separate GLOBOCAN figure"; GLOBOCAN publishes colon and rectum separately as well as the colorectum total (Accuracy round 2 full sweep; GLOBOCAN colon and rectum fact sheets read in raw text) · Now "GLOBOCAN reports the colon and the rectum separately as well as together (1,926,425 new colorectal cancers in 2022)"; summary points to the colorectal page for the separate colon figures
- 2026-11-03 · Rectal cancer: Said Heald's total mesorectal excision "cut local recurrence from a quarter of patients to well under a tenth", which no linked source states; said PROSPECT reserved radiotherapy for "the 9 percent who do not respond" when the 9 percent included those who stopped FOLFOX for side effects; gave the rectum's share as "about a third" and its length as "the last 15 cm" with no source on the record (Accuracy round 2 full sweep; Heald 1982, PROSPECT (NEJM 2023) and ACS 2026 read through Europe PMC) · Heald sentence now gives what the 1982 paper reports (no pelvic or staple-line recurrence in the first 50 curative operations at two years); PROSPECT now "needed by only 9 percent, those whose tumour shrank too little or who had to stop FOLFOX"; burden now cites 32 percent in the US in 2022 (American Cancer Society) and drops "15 cm"; Heald 1982 and ACS 2026 added to links
- 2026-11-03 · Mismatch-repair deficient (MSI-high) colorectal cancer: Lynch surveillance row said colonoscopy "from age 25 (earlier for MLH1 and MSH2)"; the UK guideline starts MLH1 and MSH2 carriers at 25 and MSH6 and PMS2 carriers at 35, so the page had it inverted (Accuracy round 2 full sweep; BSG/ACPGBI/UKCGG 2020 guideline full text read through Europe PMC (NCCN, the cited guideline, cannot be read by script)) · Now "from age 25 for MLH1 and MSH2 carriers and from 35 for MSH6 and PMS2 carriers in the UK guideline"; the guideline added to the record's links
- 2026-11-03 · Pancreatic ductal adenocarcinoma: The summary said only ~20% present resectable, with no source on the record, and that five-year survival was ~13% when SEER gives 13.7%. It also gave the PRODIGE 24 five-year figure (43.2%) as applying to patients "who complete" mFOLFIRINOX, when it is for everyone randomised. The KRAS allele and wild-type shares had no source on the record. A later standard-of-care row cited "the OnCo record" for the one-in-five figure. (Accuracy round 2 full sweep; SEER Cancer Stat Facts, Conroy JAMA Oncol 2022, cBioPortal pdac_msk_2024 (API) and Singhi 2019 read in raw text) · "~20%" became "a minority" (also in the treatment-order row, now citing Pancreatic Cancer UK only); "~13%" became "~14%"; reworded to "fit resected patients given adjuvant mFOLFIRINOX (43.2% in PRODIGE 24)"; added cBioPortal pdac_msk_2024, Singhi 2019 and Conroy 2022 as record links
- 2026-11-03 · Pancreatic ductal adenocarcinoma: Epidemiology and risk lines were slightly off. Huang 2021's country trends were dated "the decade to 2017", but the windows end between 2012 and 2017. Cancer Research UK's 50-fold risk for hereditary pancreatitis was given as if it were for PRSS1 carriers only. Klein 2004's figures were written as "rising to 6.4 times" from 9.0. Bachmann 2008's 48.9 against 77.8 percent resection rate was called "halved". NG12 1.2.5 "Consider" was written as "asks for". (Accuracy round 2 full sweep; Huang 2021, Klein 2004 and Bachmann 2008 abstracts (Europe PMC), Cancer Research UK risk factors page and NICE NG12 read in raw text) · Dated the trend as "ending between 2012 and 2017"; removed "with a PRSS1 mutation"; now reads "(4.6 times with one, 6.4 times with two and 32 times with three ...)"; "halved" became "lowered"; now reads "asks clinicians to consider"
- 2026-11-03 · Pancreatic ductal adenocarcinoma: State-of-art lines overstated or mislabelled their sources. "~3 in 4" cancers at stage I "in carriers" was the 9-case CAPS5 series of all high-risk people. Vaccine responders were said to "remain recurrence-free for years", though 2 of 8 recurred. CA 19-9's 79% and 82% are medians across studies, not pooled estimates. The 16.8% stage I methylation-test sensitivity is for all cancers, not pancreatic. (Accuracy round 2 full sweep; Dbouk JCO 2022, Sethna Nature 2025, Goonetilleke 2007 and Klein Ann Oncol 2021 abstracts read in raw text) · "found 7 of 9 cancers at stage I in the CAPS5 cohort (57.9% across all CAPS studies)"; "mostly remain recurrence-free at a median 3.2 years of follow-up (... 2 of 8 responders recurred)"; "a median sensitivity of 79% and specificity of 82% across studies"; "16.8% sensitivity at stage I across all cancers" (cards and matching notes)
- 2026-11-03 · Pancreatic ductal adenocarcinoma: Two open problems said the cachexia drug ponsegromab was "in phase 2 but no phase 3". A phase 2b/3 ponsegromab trial in metastatic pancreatic cancer (NCT06989437) has been recruiting since October 2025 and is on the record's own trial list. A third open problem said "four in five" present unresectable, with no source on the record. (Accuracy round 2 full sweep; ClinicalTrials.gov API for NCT06989437 read in raw text) · Both now read "only in a phase 2/3 trial that has not reported (NCT06989437)"; "four in five patients" became "most patients"
- 2026-11-03 · Pancreatic ductal adenocarcinoma: Basics said stage 4 spread is "most often liver, peritoneum or lung", citing Cancer Research UK, which says "such as the liver or lungs". (Accuracy round 2 full sweep; Cancer Research UK stage 4 page read in raw text) · "spread to other parts of the body, such as the liver or lungs"
- 2026-11-03 · Pancreatic ductal adenocarcinoma: Patient-side treatment rows. PREOPANC's benefit was said to be "most clearly for borderline disease", but the long-term report found it consistent across resectable and borderline patients. "Scans about every three months" during chemotherapy had no source. Temel 2010 was cited without saying it was a lung cancer trial, and was not linked. The 6 to 8 weeks before surgery was on an unlinked Pancreatic Cancer UK page. (Accuracy round 2 full sweep; Versteijne JCO 2022, Temel NEJM 2010 and Pancreatic Cancer UK chemotherapy and "who can have surgery" pages read in raw text) · "with the same effect in resectable and borderline disease"; "scans before, during and at the end of treatment"; "a randomised trial in advanced lung cancer (Temel 2010)"; Temel 2010 and the Pancreatic Cancer UK "who can have surgery" page added to the record links
- 2026-11-03 · Pancreatic ductal adenocarcinoma: Treatment rows called two superiority trials that found no difference "equivalent": PREOPANC-2 (21.9 against 21.3 months) and CROSSFIRE (stopped for futility). PANFIRE-2's "major complications in 42 percent" divided 21 complications by 50 people; 29 of 50 people had any complication. (Accuracy round 2 full sweep; PREOPANC-2 (Lancet Oncol 2025), CROSSFIRE (Lancet Gastroenterol Hepatol 2024) and PANFIRE-2 (Radiology 2020) abstracts read in raw text) · "found no survival difference between ..." for both; "21 major complications among the 50 participants"
- 2026-11-03 · Metastatic pancreatic ductal adenocarcinoma: The summary listed MRTX1133 among G12D inhibitors "in phase 3 first line". Its only trial (NCT05737706) was a phase 1 study, terminated in 2025 for formulation challenges. (Accuracy round 2 full sweep; ClinicalTrials.gov API for NCT05737706, NCT07621718 and NCT07805954 read in raw text) · "The G12D-selective inhibitor zoldonrasib is in phase 3 first line (MRTX1133 was stopped in phase 1)"
- 2026-11-03 · Prostate cancer: Burden gave GLOBOCAN 2022 cases and deaths undated as "per year", said lifetime risk was 1 in 8 across high-income countries (UK is 17%), put the median age at 67 (SEER: 68), and said most deaths come from disease metastatic at diagnosis, which no cited source states (Accuracy round 2 full sweep; GLOBOCAN 2022, SEER Stat Facts and Cancer Research UK read in raw text) · Dated both GLOBOCAN figures to 2022, gave lifetime risk as about 13% in the US and 17% in the UK, corrected median age to 68, removed the unsourced clause
- 2026-11-03 · Prostate cancer: Summary called prostate cancer the second commonest cause of cancer death in men with no geography; that holds for the UK, not worldwide (Accuracy round 2 full sweep; Cancer Research UK mortality page read in raw text) · Scoped to "in the UK"
- 2026-11-03 · Prostate cancer: Summary said 225Ac-PSMA agents were in phase 3 in AlphaBreak and AcTION; AlphaBreak is phase 2 and AcTION phase 1 (Accuracy round 2 full sweep; ClinicalTrials.gov records NCT06402331, NCT04597411 and NCT06780670 read in raw text) · Now phase 2 (AlphaBreak) and phase 2/3 (PSMAcTION) after phase 1 work (AcTION)
- 2026-11-03 · Prostate cancer: Screening row put BRCA carriers at 45 with no source on the row; the EAU guideline says 40 for BRCA2 carriers (Accuracy round 2 full sweep; EAU prostate cancer guideline read in raw text) · Ages corrected (50; 45 for African descent or family history; 40 for BRCA2) and the EAU chapter added as the row's guideline
- 2026-11-03 · Prostate cancer: VISION's PSMA screen-out given as "about a tenth"; it was 12.6% of men scanned (Accuracy round 2 full sweep; VISION full text (PMC8446332) read in raw text) · Now "about one in eight (12.6 percent)", in the open problem and the subtypes line
- 2026-11-03 · Prostate cancer: Black men's incidence excess given as ~70% with no country; SEER shows 64% higher incidence in the US (Accuracy round 2 full sweep; SEER Stat Facts read in raw text) · Now "in the United States ... about 64% higher incidence and double the mortality (SEER)"
- 2026-11-03 · Prostate cancer: Living-page bridge said CPG 1 is low risk and CPG 4-5 high risk; NICE says CPG 1 also takes some former intermediate-risk men and most, not all, CPG 4-5 men were high risk (Accuracy round 2 full sweep; NICE NG131 read in raw text) · Bridge restated as NICE gives it
- 2026-11-03 · Prostate cancer: Stage-at-diagnosis line gave Northern Ireland and Wales as if single recent years; they are 2015-2019 and 2017-2019 averages (Accuracy round 2 full sweep; Cancer Research UK statistics page read in raw text) · Averaging periods added
- 2026-11-03 · Prostate cancer: Treatment rows overstated four trial results: RTOG 94-08 benefit "confined to" intermediate risk (post hoc, "mainly"), RTOG 92-02 "better on every endpoint" (not overall survival), PROSPER and ARAMIS "the same size of effect" (HR 0.29 and 0.41), bevacizumab "quadrupled" deaths (4.0 vs 1.2%) (Accuracy round 2 full sweep; trial abstracts read on Europe PMC) · Each restated to the paper's wording or numbers
- 2026-11-03 · Prostate cancer: Science overview applied TheraP's 31% screen-out to radioligand therapy in general, and said PROfound's eleven rarer genes each supplied men when two had none and talazoparib's label says no test exists, which the current label no longer says (Accuracy round 2 full sweep; TheraP and VISION papers and the Lynparza and Talzenna labels on DailyMed read in raw text) · Attributed the 31% to TheraP, corrected the gene count, removed the outdated label statement in the overview and in science note 4
- 2026-11-03 · Metastatic castration-resistant prostate cancer: Burden gave GLOBOCAN 2022 deaths undated and a median survival of "around three years" that no cited source states (Accuracy round 2 full sweep; GLOBOCAN 2022 and the record's sources read in raw text) · Deaths dated to 2022; unsourced median removed
- 2026-11-03 · Renal cell carcinoma: Burden said ~180,000 deaths a year (GLOBOCAN 2022: about 156,000), 20-30% metastatic at diagnosis (SEER: 15%) and ~15% five-year survival for metastatic disease (SEER: 20.3%), with the case count undated (Accuracy round 2 full sweep; GLOBOCAN 2022 and SEER Stat Facts read in raw text) · Rewritten with dated GLOBOCAN 2022 counts for all kidney cancers and the SEER figures
- 2026-11-03 · Renal cell carcinoma: CheckMate 214's 22.8% progression-free at 90 months was called "durable remissions", "off treatment" in one place and given to the intermediate/poor-risk group, which was 25.4%; "three quarters clear-cell" not stated by any cited source (Accuracy round 2 full sweep; CheckMate 214 8-year paper (Annals of Oncology 2024) read on Europe PMC) · Restated as progression-free fractions with the right group, in summary, burden, state of the art and open problems; "three quarters" changed to "most"
- 2026-11-03 · Bladder cancer: Burden gave GLOBOCAN 2022 cases and deaths undated (Accuracy round 2 full sweep; GLOBOCAN 2022 read in raw text) · Both dated to 2022
- 2026-11-03 · Bladder cancer: CheckMate 274 described as having an overall survival benefit; the 5-year report gives a longer median at an interim analysis with no significance stated (Accuracy round 2 full sweep; Urology Times ESMO 2025 report read in raw text) · Now "longer median overall survival at an interim analysis (75 against 50.1 months)"
- 2026-11-03 · Bladder cancer: "Safer Nectin-4 conjugates stalled" generalised from one programme; surveillance cystoscopy interval row cited nothing that states it (Accuracy round 2 full sweep; ApexOnco report and EAU NMIBC guideline read in raw text) · Named zelenectide pevedotin and its March 2026 deprioritisation; added the intravesical-therapy record, which links the EAU guideline, to the cystoscopy row
- 2026-11-03 · Triple-negative breast cancer: The US triple-negative share (10.8 percent) was labelled as a share of cases "with a known subtype"; SEER's 10.8 percent includes the 5.5 percent of unknown subtype (Accuracy round 2 full sweep; SEER Cancer Stat Facts, female breast cancer subtypes, read in raw text) · Label corrected in the summary, the burden line and the "how common is it" note
- 2026-11-03 · Triple-negative breast cancer: "Residual disease after KEYNOTE-522 (RCB II-III) still carries ~40-50% relapse risk" had no source; the record's Symmans 2017 gives ten-year relapse-free survival of 55 percent (RCB-II) and 23 percent (RCB-III), before immunotherapy (Accuracy round 2 full sweep; Symmans 2017 (JCO) abstract read in raw text via Europe PMC) · Now "a high relapse risk (before immunotherapy, ten-year relapse-free survival was 55% for RCB-II and 23% for RCB-III, Symmans 2017)"
- 2026-11-03 · Triple-negative breast cancer: Anastrozole's 49 percent reduction in IBIS-II was attributed to ER-positive disease; 49 percent is all breast cancer, ER-positive invasive cancer fell 54 percent and ER-negative cancer did not fall significantly (Accuracy round 2 full sweep; Cuzick 2020 (Lancet) abstract and PMC full text read in raw text) · Now "came from ER-positive disease (54 percent fewer invasive ER-positive cancers, no significant effect on ER-negative cancer; Cuzick 2020)"
- 2026-11-03 · Triple-negative breast cancer: The stage I row said TIL-high tumours have ">90% 5-year RFS even without chemotherapy (OPTimal, ETNA, TIL-CHOICE cohorts)"; no source on the record, and the named cohorts could not be traced (Accuracy round 2 full sweep; Leon-Ferre 2024 (JAMA) abstract read in raw text via Europe PMC) · Now "stage I tumours with TILs of 50% or more had 94% 5-year distant relapse-free survival without chemotherapy in a pooled 1,966-patient analysis (Leon-Ferre 2024)"; Leon-Ferre added as a link
- 2026-11-03 · Triple-negative breast cancer: First-line median survival was said to be "roughly double the 2015 figure", a figure no source on the record gives (Accuracy round 2 full sweep; KEYNOTE-355 (NEJM 2022) and Lin 2008 (Cancer) abstracts read in raw text) · Now "(23.0 months with pembrolizumab and chemotherapy at CPS 10 or more in KEYNOTE-355), against 13.3 months in a 2000 to 2006 series"
- 2026-11-03 · Triple-negative breast cancer: The HER2-low row said trastuzumab deruxtecan is not recommended by NICE (TA992) and not commissioned in England; TA992 was replaced on 7 October 2026 by TA1197, which recommends it (Accuracy round 2 full sweep; NICE TA992 and TA1197 pages read in raw text) · Row now gives TA992 (July 2024, no) then TA1197 (7 October 2026, recommended, Cancer Drugs Fund until routine commissioning); guideline link points to TA1197; the matching open problem updated
- 2026-11-03 · Triple-negative breast cancer: African ancestry line read Huo 2017's heritability of basal versus non-basal subtype (0.436) as "44% of the subtype difference heritable" (Accuracy round 2 full sweep; Huo 2017 (JAMA Oncology) abstract read in raw text) · Now "an estimated heritability of 0.44 for basal versus non-basal subtype", in the state-of-the-art line and the ancestry table row
- 2026-11-03 · Triple-negative breast cancer: PD-L1 assays were said to disagree on "about a quarter" of tumours, beside a cited concordance of 69 percent (disagreement about 31 percent) (Accuracy round 2 full sweep; Rugo 2021 (JNCI) abstract read in raw text) · Now "about a third"
- 2026-11-03 · Triple-negative breast cancer: Special-type figures (metaplastic 70.3 percent triple-negative, adenoid cystic 95 percent localised and 91.4 percent 15-year survival, secretory 92 percent ETV6-NTRK3) cited papers that were not links on the record (Accuracy round 2 full sweep; Ong 2018, Ghabach 2010, Tognon 2002, Vranic 2013 and Cserni 2020 abstracts read in raw text) · Figures unchanged (verified); the five papers added to the record's links
- 2026-11-03 · Early triple-negative breast cancer: OlympiA overall survival was given as hazard ratio 0.72, which no source on the record gives; the record's OlympiA papers give 0.68 (Accuracy round 2 full sweep; OlympiA NEJM 2021 and Annals of Oncology 2022 abstracts read in raw text) · Now "at the 3.5-year analysis, overall survival (hazard ratio 0.68)"; OlympiA overall survival paper added as a link
- 2026-11-03 · Early triple-negative breast cancer: The burden line's "roughly 200,000 triple-negative breast cancers diagnosed each year" had no source and sits below 10 to 15 percent of GLOBOCAN's 2.43 million; the 1 cm chemotherapy threshold in the summary and stage I row had no source on the record (Accuracy round 2 full sweep; GLOBOCAN 2024 breast fact sheet read in raw text; NCCN and ESMO guidelines not readable by script) · Count removed; thresholds reworded to "the smallest tumours"; Dent 2007 added for the three-year relapse peak
- 2026-11-03 · Early triple-negative breast cancer: The KEYNOTE-522 seven-year survival (85.1 against 77.2 percent), the July 2021 FDA approval and IMpassion031's 58 against 41 percent had no source on the record (Accuracy round 2 full sweep; OncLive ASCO 2026 report, ASCO Post FDA report and IMpassion031 (Lancet 2020) abstract read in raw text) · Figures unchanged (verified); the three sources added as links
- 2026-11-03 · Metastatic triple-negative breast cancer: ASCENT's 12.1 against 6.7 months (hazard ratio 0.48) was attached to all 529 patients; it is the result in the 468 without brain metastases; all 529 had 11.8 against 6.9 months (hazard ratio 0.51) (Accuracy round 2 full sweep; Bardia 2021 (NEJM) abstract and the Trodelvy US label read in raw text) · Both populations now stated
- 2026-11-03 · Metastatic triple-negative breast cancer: EMBRACA, TROPION-Breast02, the 2026 first-line approvals and the 2021 atezolizumab withdrawal had no source on the record (Accuracy round 2 full sweep; EMBRACA (NEJM 2018) and TROPION-Breast02 (Annals of Oncology 2026) abstracts, Trodelvy and Datroway US labels and the Roche 27 August 2021 release read in raw text) · Figures unchanged (verified); the sources added as links
- 2026-11-03 · Breast cancer: The state-of-the-art line claimed five-year survival above 90 percent in early disease "across high-income countries"; the only source on the record is the American SEER figure (Accuracy round 2 full sweep; SEER Cancer Stat Facts, female breast cancer subtypes, read in raw text) · Now "five-year relative survival above 92 percent for localised disease in the United States, whatever the receptor subtype (SEER 21, 2016 to 2022)"
- 2026-11-03 · Breast cancer: The 70.1 percent hormone receptor-positive HER2-negative share was labelled as a share of cases "with a known subtype"; SEER's 70.1 percent includes the 5.5 percent with no known subtype (Accuracy round 2 full sweep; SEER Cancer Stat Facts, female breast cancer subtypes, read in raw text) · Label corrected in the subtypes line and the "which page is mine" note, and in the HER2-positive page's note
- 2026-11-03 · Breast cancer: PREDICT was said to be less accurate "in women under 30"; NICE says women under 30 with ER-positive breast cancer (Accuracy round 2 full sweep; NICE NG101 recommendation 1.6.5 read in raw text) · Now "women under 30 with oestrogen receptor-positive disease, women aged 70 and over"
- 2026-11-03 · Breast cancer: NSABP B-32 survival figures were given for all 5,611 randomised women; they come from the 3,986 whose sentinel nodes were clear (Accuracy round 2 full sweep; NSABP B-32 (Lancet Oncology 2010) abstract read in raw text) · Added "in the 3,986 whose sentinel nodes were clear"
- 2026-11-03 · Breast cancer: The 16 Gy boost dose was attributed to NICE recommendation 1.13.17, which sets no dose; 16 Gy is the EORTC trial's dose (Accuracy round 2 full sweep; NICE NG101 and EORTC 22881-10882 (Lancet Oncology 2015) read in raw text) · The dose now belongs to the trial: "EORTC 22881-10882, which gave 16 Gy, found ..."
- 2026-11-03 · Breast cancer: Implant failure "7.1 against 1.3 percent" compared implants with autologous reconstruction generally; 1.3 percent is the DIEP flap figure only (Accuracy round 2 full sweep; MROC two-year complication rates (JAMA Surgery 2018) abstract read in raw text) · Now "7.1 percent against 1.3 percent for deep inferior epigastric perforator flaps"
- 2026-11-03 · Breast cancer: The Danish pain survey was said to be answered "a median of 26 months" after surgery; the paper says an average (Accuracy round 2 full sweep; Gartner et al. (JAMA 2009) abstract read in raw text) · "a median" changed to "an average"
- 2026-11-03 · HR-positive / HER2-negative breast cancer: Genomic assays were said to spare "roughly 70%" of node-negative patients chemotherapy; 69 percent was TAILORx's midrange-score share, and the paper says up to 85 percent can be spared (Accuracy round 2 full sweep; TAILORx (NEJM 2018) abstract and PMC full text read in raw text) · Summary and state of the art now say "up to 85% of node-negative patients (TAILORx)"; TAILORx link added
- 2026-11-03 · HR-positive / HER2-negative breast cancer: Unsourced or mis-sized shares: ESR1 mutation "30-40%" (no source), PIK3CA/AKT1/PTEN "about 50%" (CAPItello-291 found 40.8 percent), HER2-low or ultralow "~60%" (no source, summary and ADC row), lobular "10-15%" (no source) (Accuracy round 2 full sweep; Brett et al. (Breast Cancer Research 2021) full text, CAPItello-291 (NEJM 2023) abstract and Cancer Research UK's invasive lobular page read in raw text) · ESR1 now "about 20-40% after aromatase inhibitors for metastatic disease"; pathway alterations "40.8% of patients in CAPItello-291"; the ~60% removed in both places; lobular "about 15% of breast cancers (Cancer Research UK)"; three sources added to the record
- 2026-11-03 · HR-positive / HER2-negative breast cancer: The burden said 70.1 percent of cases "with a known receptor subtype" and that this subtype accounts for "the majority of the 693,660 annual breast cancer deaths", which no source on the record states (Accuracy round 2 full sweep; SEER subtypes page and GLOBOCAN 2024 breast fact sheet read in raw text) · Label corrected to "American female breast cancer cases"; the deaths clause removed
- 2026-11-03 · HR-positive / HER2-negative breast cancer: Open problems said "half of relapses occur after year 5" and that HER2-low scoring decides eligibility "for millions of patients", neither sourced (Accuracy round 2 full sweep; EBCTCG Pan et al. (NEJM 2017) abstract and full text read in raw text) · Late recurrence now "recurrences continue at a steady rate from year 5 to year 20 (EBCTCG, Pan 2017)", Pan 2017 linked; "for millions of patients" removed
- 2026-11-03 · HER2-positive breast cancer: "roughly 400,000 cases per year worldwide" was a GLOBOCAN-derived figure given undated (Accuracy round 2 full sweep; GLOBOCAN 2024 breast fact sheet read in raw text) · Now "roughly 400,000 of the 2,434,087 new breast cancers GLOBOCAN estimated worldwide for 2024"
- 2026-11-03 · Cholangiocarcinoma: Five-year survival "under 20%", "about 210,000 cases a year", "incidence roughly doubled over 30 years" and "roughly 40% actionable" were not in the record's only source (Wikipedia); "a doubling of two-year survival" was attributed to KEYNOTE-966 as well as TOPAZ-1 (Accuracy round 2 full sweep; Wikipedia, TOPAZ-1 (NEJM Evidence 2022), KEYNOTE-966 (Lancet 2023), Lowery 2018 (Clin Cancer Res), FIGHT-202 and FOENIX-CCA2 read in raw text) · Survival now "under 5%" without resection, burden now the rates the source gives (0.5 to 2 per 100,000 in the West, up to 60 in parts of Thailand), the doubling attributed to TOPAZ-1 only (24.9% versus 10.4%), actionability now 47% in a 195-patient series; Lowery, TOPAZ-1, FIGHT-202 and FOENIX-CCA2 added as links
- 2026-11-03 · Biliary tract cancer (all types): "Around 200,000 cases a year" and "five-year survival under 20 percent overall" were in neither cited source (Accuracy round 2 full sweep; Wikipedia and NCI bile duct cancer page read in raw text) · Figures removed; now "for bile duct cancer that cannot be removed five-year survival is under 5 percent", as the source states
- 2026-11-03 · Intrahepatic cholangiocarcinoma: IDH1 mutations given as about 15 percent; ClarIDHy, cited on the record, says about 13 percent (Accuracy round 2 full sweep; ClarIDHy (Lancet Oncol 2020) and FIGHT-202 full text read in raw text) · Now "FGFR2 fusions in about 10 to 16 percent, IDH1 mutations in about 13 percent"
- 2026-11-03 · Extrahepatic cholangiocarcinoma: The Mayo transplant criterion read as "in primary sclerosing cholangitis or under 3 cm"; the 3 cm limit applies to every candidate, and no source on the record stated it (Accuracy round 2 full sweep; Darwish Murad 2012 (Gastroenterology) read in raw text) · Now "perihilar tumours no larger than 3 cm that are unresectable or arise in primary sclerosing cholangitis"; Gastroenterology 2012 link added
- 2026-11-03 · Hepatocellular carcinoma: "~75-85%" of primary liver cancer, the US death-rate claim, "surveillance uptake below 25%" and the 3-6 month imaging interval had no source on the record; GLOBOCAN burden undated; the third FDA letter dated 23 July instead of 10 July (Accuracy round 2 full sweep; Wikipedia, GLOBOCAN 2022 dataset, Wolf 2021 (Hepatology), OncLive 13 July 2026 and ClinicalTrials.gov NCT04102098 read in raw text) · 75-85% removed; burden dated (about 866,000 cases and 759,000 deaths in 2022); US claim replaced with the source's statement on rising incidence; uptake now "24% in a pooled analysis of 29 studies (Wolf 2021)"; imaging interval removed; history date corrected; Wolf 2021, OncLive and the IMbrave150 update added as links
- 2026-11-03 · Gastric cancer: "Five-year survival outside screened populations is under 30%" and "under 30% in most of the West" were contradicted by the record's own SEER source (39.8%); "two-thirds present with advanced disease" unsourced; GLOBOCAN figures undated; sonesitatug vedotin presented as a second-line option "from 2026" (Accuracy round 2 full sweep; SEER Stat Facts, GLOBOCAN 2022 dataset and OncLive (CLARITY-Gastric 01, 27 July 2026) read in raw text) · GLOBOCAN figures dated to 2022; replaced with SEER: 58% spread beyond the stomach at diagnosis, five-year relative survival 39.8% (2016 to 2022); CLARITY-Gastric 01 now described as an overall survival result; SEER and OncLive links added
- 2026-11-03 · Oesophageal cancer: Ranked "seventh most common" and "sixth" for deaths, which are older-edition ranks (GLOBOCAN 2022: eleventh and seventh); figures undated; ">80%" survival after endoscopic treatment and the 85% squamous share had no source on the record (Accuracy round 2 full sweep; GLOBOCAN 2022 dataset, NCI PDQ and Arnold 2020 (Gut) read in raw text) · Ranks corrected and figures dated to 2022; survival now 21.6% overall and 48.1% at the local stage (US); squamous share sourced to Arnold 2020 (84% in 2018), link added
- 2026-11-03 · Gallbladder cancer: Aloia 2015 was cited for "T4 disease and N2 nodes rarely benefit from resection"; the consensus says spread to the 7th-edition N2 nodal stations gains nothing and T3 or T4 node-positive disease should go to neoadjuvant trials. The HER2 testing row gave "about one in ten" HER2-positive on staining, the lowest of three series (9 to 31 percent) (Accuracy round 2 full sweep; Aloia 2015 (HPB), Angerilli 2026, Roa 2014 and Hiraoka 2020 abstracts read in raw text) · Staging sentence rewritten to what the consensus says; HER2 row now "between about one in ten and one in three ... depending on the series and the scoring rule"
- 2026-11-03 · Diffuse large B-cell lymphoma: Summary and burden gave "about 30% of all non-Hodgkin lymphoma", "median age around 65", "~150,000 new cases a year worldwide" and "~25,000 in the US", none from a source on the page (Wikipedia gives a median of about 70); open problem gave an unsourced "~10-15%" primary refractory rate (Accuracy round 2 full sweep; Wikipedia and Lymphoma Action DLBCL pages read in raw text) · Summary now says most people diagnosed are 65 or over; burden now gives the cited incidence (7 to 8 per 100,000 in the US and UK; just under 5,500 UK diagnoses a year); refractory percentage removed
- 2026-11-03 · Diffuse large B-cell lymphoma: Treatment rows: FLYER said "randomised 588" (592 were randomised, 588 analysed); EPCORE DLBCL-1 said "randomised 552" (the company release and registry give 483 enrolled); unsourced 30 to 40 Gy dose, R-mini-CHOP "50 per cent ... over about 80" and pre-phase schedule; MYC/BCL2 rearrangement rates and the 2016 WHO entity had no source on the page; "CD79b on more than 95%" unsourced (Accuracy round 2 full sweep; FLYER (Lancet 2019), Genmab topline release, ClinicalTrials.gov NCT04628494, Horn (Blood 2013), Johnson (JCO 2012) and Swerdlow (Blood 2016) read in raw text) · 592 (588 analysed); 483 enrolled; unsourced doses and schedules removed; Horn 2013, Johnson 2012 and the WHO 2016 revision added as links; CD79b now "almost every case"
- 2026-11-03 · Non-Hodgkin lymphoma: "Adult T-cell leukaemia/lymphoma has had exactly one controlled trial": a randomised phase 2 trial of chemotherapy with or without mogamulizumab was published in 2015; genetics figures (97% of 108, 20 of 23, 5 of 19, about 180-fold) had no source on the page (Accuracy round 2 full sweep; JCOG9801 (JCO 2007), ClinicalTrials.gov NCT00145002, Ishida (Br J Haematol 2015), Roemer 2016, Ansell 2015, Hiraga 2009 and Blombery 2019 read in raw text) · Now "one phase 3 trial, opened in 1998 with 118 patients"; the five papers added as links
- 2026-11-03 · Hodgkin lymphoma: HD21 described as matching escalated BEACOPP's ~94% PFS and as "~94% 5-year PFS with 40% less morbidity" (BrECADD 94.3% against 90.9% at four years; morbidity 42% against 59%); age peaks "20-30" (sources give 15 to 35); "cured in more than 85%" and "over 90% of early-stage" stated survival as cure; HD16 described as omitting radiotherapy after 3 cycles at "~5%" cost (2 cycles, 7.3 points); unsourced "about 1% of the mass", "8 years after chest RT", "half the cure rate and double the toxicity", "~10-15%" refractory and the EORTC risk-factor list; genetics figures had no source on the page (Accuracy round 2 full sweep; HD21 (Lancet 2024), HD16 (JCO 2019), SEER Hodgkin stat facts, Wikipedia, Lymphoma Action, gov.uk breast screening protocol, NCI PDQ, Roemer 2016 and 2018, Ansell 2015, Steidl 2010 and 2011 read in raw text) · Figures corrected to the trial reports; cure lines now "most are cured" with SEER's 89% five-year relative survival; unsourced figures removed or softened; five genetics papers added as links
- 2026-11-03 · Follicular lymphoma: GALLIUM given as "randomised 1,401" beside the follicular-only results (1,202); RELEVANCE median PFS "120.2 against 123.8 months (HR 0.92)" in no source read (cited paper: three-year PFS 77 against 78%); ZUMA-5 92%/74% presented as follicular when pooled with marginal zone; unsourced "~85%" t(14;18), "median survival exceeds 15-20 years", "3-4 per 100,000", "median age ~65" and "ZUMA-5 ~50% progression-free at 4 years"; chromatin mutation rates had no source on the page (Accuracy round 2 full sweep; GALLIUM and RELEVANCE (NEJM), RELEVANCE six-year update (JCO 2022), ZUMA-5 (Lancet Oncol 2022), HMRN (Br J Cancer 2015), Lymphoma Action, Morin 2010 and 2011, Pasqualucci 2011 read in raw text) · 1,202 patients with follicular lymphoma; three-year PFS 77 against 78 per cent; pooled label added; burden now from HMRN (3.2 per 100,000, median 65) with HMRN added as a link; unsourced figures removed; four genetics papers added as links
- 2026-11-03 · Mantle cell lymphoma: Burden said median age ~68 and 3:1 male with no source (HMRN: median 73.5, rate ratio 2.57); SYMPATICO "randomised 366" (267 randomised; 366 is total registry enrolment); ZUMA-2 "105 patients" (the cited report enrolled 74); TP53 and Ki-67 figures had no source on the page (Accuracy round 2 full sweep; HMRN (Br J Cancer 2015), SYMPATICO (Lancet Oncol 2025) and ClinicalTrials.gov NCT03112174 results, ZUMA-2 (NEJM 2020), Eskelund (Blood 2017) read in raw text) · Burden rewritten to HMRN with the link added; 267 randomised; 74 patients; Eskelund 2017 added as a link
- 2026-11-03 · Peripheral T-cell lymphomas: "Five-year survival with CHOP is 30-40%", "under 40% for PTCL-NOS" and "10-15% of NHL ... more in Asia ... over 30 WHO subtypes" had no source (HMRN: 19.7% PTCL-NOS, 26.2% AITL; T-cell 308 of 5,796 lymphomas); romidepsin dated 2009 for PTCL (2009 was the skin lymphoma approval; PTCL 2011); CHOEP row said the German analysis was "not confined to T-cell lymphoma" and "under 60" (it analysed 343 T-cell patients; subgroup 60 or under) (Accuracy round 2 full sweep; HMRN (Br J Cancer 2015), Drugs@FDA ISTODAX history, Schmitz (Blood 2010) and Kataoka (Nat Genet 2015) read in raw text) · Survival and burden lines now give HMRN figures; romidepsin "US PTCL approval 2011, withdrawn 2021"; CHOEP sentence corrected; HMRN, Schmitz 2010 and Kataoka 2015 added as links
- 2026-11-03 · Myelodysplastic syndromes / neoplasms (MDS): Median age at diagnosis given as ~70 "according to SEER" with no SEER source; SEER data give 76. VERONA (venetoclax) dated as failing in 2023-24, but it missed its survival endpoint in June 2025 (summary, state of the art and history) (Accuracy round 2 full sweep; Ma et al. Cancer 2007 and J Registry Manag 2021 (SEER) abstracts and AbbVie's 16 June 2025 release read in raw text) · Burden now "around 4-5 per 100,000 ... (4.7 in SEER 2001-2016) ... median age at diagnosis in SEER data was 76"; "2023-24" changed to "2023-25" and VERONA to 2025; SEER papers, BMT CTN 1102 and AbbVie release added as links
- 2026-11-03 · Myeloproliferative neoplasms: Mutation frequencies, the 10-20% leukaemic transformation rate and the 2-3 per 100,000 incidence had no source on the record; rusfertide was called "the first drug to control PV erythrocytosis without phlebotomy", which FDA does not say (Accuracy round 2 full sweep; Blood 2023, JAMA 2025, Am J Hematol 2014, Int J Mol Sci 2019 abstracts and FDA 28 August 2026 release read in raw text) · Mutation line rewritten to the sources (JAK2 V617F >95% of PV and about half of ET/PMF; in ET JAK2 ~64%, CALR ~23%, MPL ~4%); rusfertide now "the first approved hepcidin mimetic, freed most patients from phlebotomy in VERIFY (77% versus 33%)"; five source links added
- 2026-11-03 · Relapsed or refractory multiple myeloma: Survival before 2021 once refractory stated as "about a year" (MAMMOTH: 8.6 months); LINKER-MM1 response rate 70% (paper: 71%); bispecific response range "60 to 70 percent" left out talquetamab and linvoseltamab (Accuracy round 2 full sweep; MAMMOTH, LINKER-MM1, MagnetisMM-3, MonumenTAL-1, CARTITUDE-1/4 and IMWG 2011 read in raw text) · Burden now "a median of under nine months (8.6 months in the MAMMOTH study)"; 70 changed to 71 percent; range changed to "about 60 to 75 percent"; IMWG, MAMMOTH, CARTITUDE-1, CARTITUDE-4 OS, LINKER-MM1, MagnetisMM-3 and DREAMM-7 links added
- 2026-11-03 · Multiple myeloma: GLOBOCAN 2022 case and death counts given undated as "a year"; median survival "more than 10 years" and "~5-7 years" had no source; quadruplet MRD-negativity "60-75%" left out IMROZ (55.5%); the record cited only Wikipedia for trial and regulatory figures (Accuracy round 2 full sweep; GLOBOCAN 2022 (repo dataset), SEER Stat Facts, PERSEUS, IMROZ, CARTITUDE-1/4, J Cancer Policy 2025, FDA and Arcellx 10-K read in raw text) · Burden dated to GLOBOCAN 2022 (~188,000 cases, ~121,000 deaths) and SEER 2026 (~36,000 US), survival figures removed; MRD range now "about 55-75% (IMROZ 55.5%; PERSEUS 75.2%)"; nine source links added to the record
- 2026-11-03 · Leukaemia (all types): GLOBOCAN 2022 counts (490,000 cases, 300,000 deaths) given undated as current and with no source on the record (Accuracy round 2 full sweep; GLOBOCAN 2022 World row (487,294 cases, 305,405 deaths) read from the repo's GCO dataset) · Now "In 2022, GLOBOCAN estimated about 487,000 new cases and 305,000 deaths worldwide"; GLOBOCAN 2022 link added
- 2026-11-03 · Acute myeloid leukaemia: US cases given as about 20,000 and median age as 68, and 5-year survival as roughly 30%; SEER now gives 22,720 expected in 2026, median age 70 and 33.4% (2016-2022). APL standard-of-care row said "cure >95%" with no source bearing on it; APL0406 reports a 2-year event-free survival of 97%. Open problems said eprenetapopt failed in phase 3 in AML, but its phase 3 was in TP53-mutated MDS (Accuracy round 2 full sweep; SEER Cancer Stat Facts AML, Lo-Coco NEJM 2013 abstract (Europe PMC) and ClinicalTrials.gov NCT03745716 read in raw text) · Burden and summary updated to SEER figures with SEER link; APL row now cites APL0406 and its 2-year EFS; open problem reworded to place each failure in the right disease, with registry links
- 2026-11-03 · Acute lymphoblastic leukaemia: Said T-ALL had its own options "since 2023" naming nelarabine, which was first approved in 2005; burden said about 6,500 US cases a year, 60% in children, where SEER gives 6,250 expected in 2026 and 52.1% under 20 (Accuracy round 2 full sweep; DailyMed nelarabine label and SEER Cancer Stat Facts ALL read in raw text) · "Since 2023" removed and approval year 2005 given; burden changed to about 6,250 expected in 2026, about half under 20; SEER and DailyMed links added
- 2026-11-03 · Chronic lymphocytic leukaemia: Burden said about 20,000 US cases a year; SEER gives 22,760 expected in 2026 (Accuracy round 2 full sweep; SEER Cancer Stat Facts CLL and EHA CLL guidelines 2026 (PMC full text) read in raw text) · US figure changed to about 22,800 expected in 2026; SEER and EHA guideline links added (EHA supports the median age of 70)
- 2026-11-03 · Neuroblastoma (paediatric): GD2-CART01 credited with remissions "lasting more than a decade" that belong to a first-generation GD2 CAR-T trial (2004-2009); anti-GD2 gain described as overall survival when it was two-year event-free survival; ~800 US cases a year, median age ~18 months and 7-8% of childhood cancers did not match the sources; high-risk cure and survival overstated; "children who will live 70 years" unsourced (Accuracy round 2 full sweep; NCI PDQ Neuroblastoma Treatment, NEJM 2023 (GD2-CART01), Nature Medicine 2025, FDA eflornithine notice and ClinicalTrials.gov NCT00499616 read in raw text) · Decade-long remissions re-attributed to the first-generation trial; "two-year event-free survival"; more than 650 US cases, median age 17 months, 6-10%; high-risk "about half" cured and ~60% 5-year survival; rhetorical figure removed; ANBL0531 added to the intermediate-risk row; PDQ, FDA, NEJM and Nature Medicine added as record links
- 2026-11-03 · Glioma & glioblastoma: GLOBOCAN 2022 brain/CNS count undated and "most of them not glioblastoma" contradicted by registry data; "~50% of gliomas" and median age 65 unsourced or off by a year; vorasidenib said to delay treatment "by years"; MGMT-unmethylated share given as ~60% (Accuracy round 2 full sweep; GLOBOCAN 2022, CBTRUS 2018-2022, NEJM 2005 (Stupp, Hegi), NEJM 2023 (INDIGO) and FDA notices read in raw text) · Dated GLOBOCAN 2022 figure (about 322,000) with glioblastoma about half of malignant primary brain tumours; median age 64; INDIGO stated as progression-free survival 27.7 against 11.1 months; MGMT-unmethylated 55% in the Stupp trial; CBTRUS, Hegi, Stupp, NCI PDQ, FDA and GLOBOCAN added as record links
- 2026-11-03 · Sarcomas (soft tissue, bone, GIST): US case counts out of date; ">70 subtypes" and "70+ subtypes" unsourced; metastatic survival range "~15-30%" not in the cited source; "unchanged for three decades" and "a few hundred cases a year" unsourced; ISG-STS 1001 high-risk size given as >5 cm (trial: 5 cm or more); EORTC 62012 cited in a row without its record (Accuracy round 2 full sweep; SEER Cancer Stat Facts, NCI PDQ osteosarcoma and Ewing sarcoma, Lancet Oncology 2017 (ISG-STS 1001) and 2014 (EORTC 62012) read in raw text) · SEER 2026 estimates (about 13,900 soft-tissue and 4,100 bone and joint); "dozens of subtypes"; ~16% for distant soft-tissue sarcoma; unsourced clauses removed; "5 cm or more"; eortc-62012 added to row refs; SEER and PDQ added as record links
- 2026-11-03 · Melanoma: GLOBOCAN case count undated. "10-year survival ~50%" did not say it was melanoma-specific survival (overall survival was 43%). Non-response to PD-1 alone was understated. Relatlimab grade 3-4 toxicity was given as 21% where the sources say 18.9% and 22.0%. CheckMate 204 intracranial response was given as ~50% where the trial reported 56%. The rates after PD-1 failure were rounded down. Summary figures cited only Wikipedia. (Accuracy round 2 full sweep; CheckMate 067 10-year NEJM 2025, the RELATIVITY-047 paper (JCO 2025), the KEYNOTE-006 paper (Annals of Oncology 2024), CheckMate 204 NEJM 2018, FDA lifileucel review, IGNYTE JCO 2025, Drugs 2026 and the 2014 Keytruda label read in raw text) · Dated the burden line (GLOBOCAN 2022). Labelled the 10-year figure as melanoma-specific, with OS 43%. Non-response now "about 40% even with nivolumab-ipilimumab, over half on PD-1 alone". "~22%" for relatlimab. "56% intracranial response", with checkmate-204 added to refs. "About a third (31.5% and 32.9%)" after PD-1 failure. Seven primary sources added to the record links
- 2026-11-03 · Skin cancer: Said every alternative to the 4 mm excision "won on appearance", but radiotherapy lost on appearance in the Avril trial. A dermoscopy figure ("one tumour in six") had no source. The 3% lower bound for incomplete excision had no source. A "20 to 40 percentage points" patient-versus-doctor rating gap had no source. (Accuracy round 2 full sweep; Avril BJC 1997, Dermatol Surg 2015, J Surg Oncol 2026, Cochrane CD003412.pub3 read in raw text) · Appearance clause corrected. Dermoscopy clause removed. Incomplete excision now "up to about 15 per cent (14.9 per cent in one series)". The percentage-point figure removed
- 2026-11-03 · Basal cell carcinoma: "Several million cases per year in the US" overstated the cited ERIVANCE figure (2.1 million NMSC patients in 2006, ~80% BCC). The "<0.1%" metastasis figure had no source. Hedgehog-inhibitor response was "~45-60%" where ERIVANCE's independent review gave 43% and 30%. PTCH1/SMO frequencies were unsourced and SMO was given as 10-20% rather than ~20%. (Accuracy round 2 full sweep; ERIVANCE NEJM 2012 full text and Bonilla Nature Genetics 2016 read in raw text) · Burden rewritten to the dated 2006 figure, with the <0.1% removed. Response rates set to ERIVANCE's 43% and 30%. SMO set to ~20%, with Bonilla 2016 added to the links
- 2026-11-03 · Ovarian cancer: GLOBOCAN cases and deaths undated. "Under 30% for stage IV" had no source. "OS benefit" for SOLO-1 omitted that the 7-year OS result missed its significance threshold. "BEP with >90% cure" for germ-cell tumours had no source. PRIMA's lack of OS gain was not covered by any cited source. (Accuracy round 2 full sweep; GLOBOCAN 2022, SEER ovary, SOLO-1 JCO 2023, PRIMA final OS Annals 2024, ROSELLA Lancet 2026, ASCO Post (KEYNOTE-B96 approval) read in raw text) · Dated to 2022 (about 325,000 cases, 207,000 deaths). Distant-stage SEER figure (about 32%) now used. SOLO-1 now "67% vs 47% alive at 7 years, clinically meaningful, missed its strict significance threshold". "High cure rates" for BEP. GLOBOCAN 2022, SOLO-1 and PRIMA OS papers added to the links
- 2026-11-03 · Cervical cancer: Vaccine effect given as a typical 90% where the source says "up to 90%". GLOBOCAN figures undated. Sweden was called "near-zero" when the reduction was ~88%. The Australia elimination year was 2035 where the model projects ~2028 (range 2021-35). KEN SHE's 97.5% (persistent infection) read as cancer prevention. Test of cure was "6-12 months" where ASCCP says 6. HPV vaccine coverage of 27% was outdated (WHO: 33% in 2025). LMIC screening coverage and the GOG-240 comparator had no source. Two trial records linked identifiers that do not resolve. (Accuracy round 2 full sweep; Lei NEJM 2020, Palmer JNCI 2024, Hall Lancet Public Health 2019, KEN SHE NEJM Evidence 2022, ASCCP 2019, WHO immunization coverage fact sheet (July 2026), Bruni Lancet Glob Health 2022, Tewari NEJM 2014, KEYNOTE-826 JCO 2023, BEATcc Lancet 2024 read in raw text) · Each figure corrected and dated to its source; eight sources added to the record links. KEYNOTE-826 link and outcome sources changed from the non-resolving 10.1200/JCO.23.00810 to 10.1200/JCO.23.00914. BEATcc link and outcome sources changed from the non-resolving Lancet PII S0140-6736(23)02517-3 to 10.1016/S0140-6736(23)02405-4
- 2026-11-03 · Endometrial cancer: GLOBOCAN cases and deaths undated. Incidence was "rising ~1-2% a year" where SEER gives 0.7% (deaths 1.3%). The 18-month lenvatinib-pembrolizumab median was the all-comer figure, not pMMR (17.4 months). The 30% fertility-sparing relapse figure had no source; the systematic review gives 35% in carcinoma. (Accuracy round 2 full sweep; GLOBOCAN 2022, SEER uterine, KEYNOTE-775 NEJM 2022, Jemperli label (RUBY), Gunderson Gynecol Oncol 2012 read in raw text) · Dated to 2022 (about 420,000 cases, 98,000 deaths). SEER trend figures now used. pMMR now "17 months (17.4 vs 12.0)". Relapse now "about 35% of responders with carcinoma". GLOBOCAN, SEER and Gunderson added to the links
- 2026-11-03 · Neuroendocrine tumours: Incidence, trend and prevalence (7 per 100,000, six-fold, >170,000) were unsourced and undated. The cause of the rise was stated more firmly than the paper does. An FDA decision that fell due in August 2026 was still described as pending. The AlphaMedix 54% response rate is not in the cited Sanofi release. "Therapy-related leukaemia 2-3%" was mostly myelodysplasia. (Accuracy round 2 full sweep; Dasari JAMA Oncol 2017, Sanofi press release 8 Oct 2025, Lutathera US label section 5.3, CancerNetwork COMPETE report read in raw text) · Dated to 2012/2014 and sourced to Dasari 2017. "Probably in large part from earlier detection". "The FDA set a decision date of 28 August 2026". The 54% figure removed. "Myelodysplasia or leukaemia". Dasari 2017 and the Lutathera label added to the links
- 2026-11-03 · Metastatic cancer: SABR-COMET survival figures were given without saying it was a 99-patient randomised phase 2 trial, and phase 3 trials were said to be "confirming" it. Pembrolizumab's TMB-high approval was dated 2017 when it was 2020. Neither claim had a source on the record. (Accuracy round 2 full sweep; SABR-COMET JCO 2020 and FDA approval summaries (Clin Cancer Res 2019 and 2021) read in raw text) · Phase 2 context added and "testing" replaces "confirming". Approval years now 2017 (MSI-H) and 2020 (TMB-high). Three sources added to the links
- 2026-11-03 · Four paper records: Aparicio 2016, Shah 2021 dosing perspective, Kloor 2020, Unger 2019: Each PubMed id was a real paper, the wrong one: a photocatalysis study, a hip-anaesthesia trial, a dendritic-cell review and a nanopore paper. (
scripts/paper-ids.tsasked PubMed what all 2,504 PubMed ids on paper records are and compared the DOI PubMed holds) · Corrected to 26546618, 34623789, 32540851 and 30856272, each resolved by DOI through Europe PMC; Unger's ineligibility interval corrected to 10.9 to 34.6 and an unsourced "55% of those offered enrolled" replaced by what the paper says - 2026-11-03 · prevention-detection-biology key papers: The file holding three of the four wrong PubMed ids: 28 of its 102 records had figures that disagree with the paper's own abstract (cohorts swapped, conclusions overstated) (Every record's numbers read against Europe PMC abstracts and open full text) · Corrected from the abstracts; figures the abstract and open text do not contain were rewritten or removed
- 2026-11-03 · HORRAD, POP-RT, Euro Ewing 2012: Registry ids for other studies: a Bayer bioequivalence study, PEACE2 and EWING2008, so the pages carried those studies' status, start dates and sites. Euro Ewing 2012 also cited a DOI that does not exist and an overall-survival hazard ratio its paper does not report (ClinicalTrials.gov titles read against the record; the factcheck warning for HORRAD had stood since September) · POP-RT to NCT02302105 (registry acronym POP-RT, Tata Memorial); Euro Ewing 2012 to ISRCTN54540667 and the Lancet 2022 paper; HORRAD's id removed (no ClinicalTrials.gov record); registry captures for the wrong studies removed
- 2026-11-03 · Drug toxicity rows in eight cancer spike files: 122 of 188 side-effect rates without a source of their own were wrong: figures from another trial or arm, any-grade entered as grade 3 or worse, superseded labels, numbers in no source (Sample drew ten drug numbers and found five wrong; widened to every such row) · Corrected from FDA label tables and pivotal papers, each row now names its source and population; six rows removed. The other 143 unsourced rows on 46 drugs were then read too: 50 confirmed, 83 corrected, 10 figures removed. Lurbinectedin's summary no longer presents its second-line accelerated approval as current: the US label lists that indication as removed in September 2026
- 2026-11-03 · Hulscher ivermectin cohort: Described only an expression of concern; the journal retracted the paper in October 2026 (PubMed 42823188) (PubMed record now titled "RETRACTED") · Record renamed and the retraction added to the paper and both drug pages
- 2026-11-03 · Cancer and country figures: Oral cavity and Hodgkin burden on GLOBOCAN 2022 (2024 fact sheets now published); TROP2 ADCs placed before chemotherapy in HR-positive breast cancer against their labels; EFPIA oncology wait times attributed to Romania and Portugal that belong to Estonia and Lithuania; a Public Health Scotland quotation altered; Israeli investment figures not in the cited release; an extragonadal seminoma survival figure applied to all patients (Sample, sources read in raw text) · Corrected from the fact sheets, labels, PDF and workbook; unsourced figures removed
- 2026-11-03 · Companies and people: CSL founded 1994 (privatised then; founded 1916); RA Capital 2002 (the firm says 2004); T-MAXIMUM placed in Beijing (a press-release dateline); Freenome in South San Francisco (Brisbane, CA per SEC); Alligator Bioscience's 42.1% response (paper: 23 of 57, 40%) and its sale of mitazalimab; James Yao no longer department chair; Usha Menon's title (Sample; company sites, SEC EDGAR, institution pages) · Corrected
- 2026-11-03 · Trials and tests: EV-304 result still "topline"; CROSS hazard ratio 0.68 (paper 0.657); NATALEE paper year; EsPhALL p-value; WINTHER phase; VITAL omega-3 DOI that does not resolve; SeekInCare's $143 belongs to a two-step strategy; Adela's AACR figure was a retrospective biobank study; BREAKWATER toxicity attribution; RESTORE denominator; an unsourced cemiplimab metastatic response (Sample and its incidental findings) · Corrected from the papers and labels
- 2026-11-03 · Omega Funds, taletrectinib, talimogene laherparepvec: The investor listed both medicines as its own products, so each page showed a venture fund among its makers (Link-sense review list) · Products removed from the investor; the makers already credited match the labels (Ibtrozi "Distributed by: Nuvation Bio Inc."; Imlygic "Manufactured by: BioVex LLC, a subsidiary of Amgen Inc.", DailyMed)
- 2026-11-03 · CAPTEM, ECOG-ACRIN E2211: The regimen was credited to ECOG-ACRIN as if the trials group had developed it (Link-sense review list) · ECOG-ACRIN moved to a new record for the trial it ran, E2211 (NCT01824875, lead sponsor ECOG-ACRIN with NCI; Kunz et al., J Clin Oncol 2023, PFS 22.7 vs 14.4 months, HR 0.58), linked from the regimen
- 2026-11-03 · Degarelix, leuprolide, triptorelin, goserelin: Target given as the androgen or oestrogen receptor, which none binds (Link-sense review list) · Target set to the GnRH receptor; labels: Firmagon "a GnRH receptor antagonist", Lupron Depot "a GnRH agonist", Trelstar "agonist analog of GnRH", Zoladex "a synthetic decapeptide analogue of GnRH"
- 2026-11-03 · Exemestane, progestins, mevrometostat: Linked to the oestrogen receptor (exemestane, progestins) and the androgen receptor (mevrometostat) (Link-sense review list) · Aromatase (Aromasin label: "an irreversible, steroidal aromatase inactivator"), progesterone receptor (megestrol label: "progestational drug") and EZH2 alone; the record text already names the hormone each lowers or the enzalutamide combination
- 2026-11-03 · Omacetaxine: Linked to BCR::ABL1 as its target (Link-sense review list) · Target removed: Synribo label says the action "is independent of direct Bcr-Abl binding" and it binds the ribosome, which has no target record; the mechanism text already says so
- 2026-11-03 · CAVE: Target PD-1; avelumab is anti-PD-L1 (Link-sense review list) · Target set to PD-L1
- 2026-11-03 · NCT02960022: Linked the breast-cancer ovarian suppression record (goserelin) (Link-sense review list; registry interventions) · Linked to leuprolide, the registry's listed intervention (for patients from EMBARK); the goserelin record no longer lists the trial
- 2026-11-03 · FDA018-ADC, FUSCC: The hospital was credited as the drug's developer (Link-sense review list; ClinicalTrials.gov) · Developer link removed; the drug text now names the registry sponsor of NCT05174637 and NCT06519370, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical. The trial keeps the hospital as its only listed site
- 2026-11-03 · Pancreatoblastoma: Listed vincristine, which no regimen in its text uses (Link-sense review list) · Removed; the record's treatment is PLADO (cisplatin and doxorubicin)
- 2026-11-03 · Envafolimab: Linked to cancer of unknown primary (Link-sense review list) · Removed: none of its six trials (ClinicalTrials.gov) nor its NMPA approval names it
- 2026-11-03 · E1910: Linked to adolescent and young adult cancers (Link-sense review list) · Removed: the registry's age range is 30 to 70
- 2026-11-03 · KEN SHE: Linked to head and neck cancer (Link-sense review list) · Removed: the registry lists women aged 15 to 20 and persistent HPV infection only
- 2026-11-03 · Sponsor names: Coherus counted for Junshi; the NCT sites in Dresden, Würzburg (NCT WERA), Essen (NCT West) and Tübingen (NCT SouthWest) for Heidelberg; CRUK-named centres in Oxford, Southampton, Birmingham, Manchester, Cambridge, Glasgow and London, and the Bowelbabe Fund, for the charity; "NCT number" for Heidelberg (Link-sense review list) ·
src/data/sponsor-aliases.ts: each resolves to its own record; 30 of 46,779 names change, all checked - 2026-11-03 · SPEARHEAD-1 paper: Linked to lete-cel (Link-sense review list) · Linked to afami-cel (Crossref: "Afamitresgene autoleucel for advanced synovial sarcoma ... (SPEARHEAD-1)")
- 2026-11-03 · Shenzhen Ionova, Georgiamune, Treadwell, Ascentawits: Called "late-stage" with "phase 2 and phase 3" trials; every one of their ten trials is phase 1/2 (Company-products audit; ClinicalTrials.gov) · Text and translations corrected to phase 1/2 with each trial's status
- 2026-11-03 · Bellicum: Said BPX-501 reached phase 3 and the company ceased operations in 2023 (Company-products audit; SEC filings) · BP-004 was phase 1/2; delisted July 2023, assets sold to MD Anderson and dissolution approved in February 2024
- 2026-11-03 · Argos: Said ADAPT was stopped for futility in 2017 and the company filed for bankruptcy in 2019 (Company-products audit; SEC filings) · The monitoring committee recommended stopping in February 2017, Argos continued and ended the trial in April 2018, and filed for chapter 11 on 30 November 2018
- 2026-11-03 · Angiocrine, Delta-Fly: Described phase 3 trials as running (Company-products audit; ClinicalTrials.gov) · NCT05181540 terminated for lack of efficacy at interim; NCT03926624 terminated for futility
- 2026-11-03 · Century, Recursion: CNTY-308 called a cancer product; Recursion's ENPP1 programme listed as cancer and linked to cGAS-STING (Company-products audit; SEC filings) · CNTY-308 is "for B-cell-mediated diseases" (Q2 2026 release); REC-102 (ENPP1) is for hypophosphatasia (2025 results deck), pathway link removed
- 2026-11-03 · Instil Bio, Amunix, Kainova (Domain) Therapeutics: Called ITIL-168 a CoStAR product; Amunix's HER2 engager not traced to Vir; Domain's January 2026 renaming missing (Company-products audit; SEC filings; the former website's notice) · ITIL-168 was unmodified TIL and ITIL-306 the CoStAR product (10-K 2022); Vir's licence (8-K, September 2024) and VIR-5818 added; renamed Kainova Therapeutics with the old names kept as aliases
- 2026-11-03 · NCT07310173: The English and Chinese summaries named regorafenib as the drug under test (Company-products audit; registry arms) · Regorafenib is the active comparator; AST-3424 is tested
- 2026-11-03 · GFH375 and VS-7375; GC012F and AZD0120: Each pair is one product held as two records (Duplicate survey) · Each record now says so, with the source (Verastem's January 2026 presentation; AstraZeneca's first-quarter 2024 results). The merge needs a redirect, a product change, so it is proposed in
docs/proposals/merge-plan-2026-11.md - 2026-10-29 · DETECT-A (Science 2020): Linked ClinicalTrials.gov NCT03934866 as the study's registration; that record is the UCL SUMMIT lung screening study. The paper's full text cites no registry number. The record also said 12 blood-detected cancers were treated with surgery; the paper says 15 of the 26 underwent PET-CT and nine of those (60%) were surgically excised. (Multi-cancer early detection census; registry record and paper full text read) · Link removed and figures corrected (this commit)
- 2026-10-29 · CancerSEEK (Science 2018): Linked the CancerSEEK paper to Caris Life Sciences' MI Cancer Seek, an unrelated tumour profiling test with a similar name. (Multi-cancer early detection census) · Linked to the new CancerSEEK and Cancerguard records instead (this commit)
- 2026-10-29 · nhs-galleri: Said no peer-reviewed primary-endpoint paper existed; Sasieni et al. published it in NEJM (DOI 10.1056/NEJMoa2505723): incidence rate ratio for stage III or IV cancer 1.03 (95% CI 0.92 to 1.14). (Multi-cancer early detection census; Europe PMC) · Summary updated and paper record added (this commit)